[
  {
    "element_id": "page_1_seq_0",
    "page_number": 1,
    "type": "text",
    "raw_text": "Suspected cancer:\nrecognition and referral\nNICE guideline\nPublished: 23 June 2015\nLast updated: 12 January 2026\nwww.nice.org.uk/guidance/ng12\n© NICE 2026. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\nconditions#notice-of-rights).\n\nThis chunk serves as the title page and header information for the NICE guideline on suspected cancer, providing essential details such as the guideline's name, publication and update dates, website address, copyright information, and terms of use, establishing the document's authority and source. It essentially identifies the document and its ownership."
  },
  {
    "element_id": "page_2_seq_0",
    "page_number": 2,
    "type": "text",
    "raw_text": "Your responsibility\nThe recommendations in this guideline represent the view of NICE, arrived at after careful\nconsideration of the evidence available. When exercising their judgement, professionals\nand practitioners are expected to take this guideline fully into account, alongside the\nindividual needs, preferences and values of their patients or the people using their service.\nIt is not mandatory to apply the recommendations, and the guideline does not override the\nresponsibility to make decisions appropriate to the circumstances of the individual, in\nconsultation with them and their families and carers or guardian.\nAll problems (adverse events) related to a medicine or medical device used for treatment\nor in a procedure should be reported to the Medicines and Healthcare products Regulatory\nAgency using the Yellow Card Scheme.\nLocal commissioners and providers of healthcare have a responsibility to enable the\n\nThis section clarifies that while the NICE guideline offers evidence-based recommendations for suspected cancer recognition and referral, healthcare professionals must use their own judgment, considering individual patient needs and circumstances, and are responsible for reporting adverse events related to medical products. It emphasizes that the guideline is not mandatory but should inform decision-making within the context of local resources and priorities."
  },
  {
    "element_id": "page_2_seq_0",
    "page_number": 2,
    "type": "text",
    "raw_text": "Local commissioners and providers of healthcare have a responsibility to enable the\nguideline to be applied when individual professionals and people using services wish to\nuse it. They should do so in the context of local and national priorities for funding and\ndeveloping services, and in light of their duties to have due regard to the need to eliminate\nunlawful discrimination, to advance equality of opportunity and to reduce health\ninequalities. Nothing in this guideline should be interpreted in a way that would be\ninconsistent with complying with those duties.\nCommissioners and providers have a responsibility to promote an environmentally\nsustainable health and care system and should assess and reduce the environmental\nimpact of implementing NICE recommendations wherever possible.\n\nThis section clarifies the responsibilities of local healthcare commissioners and providers, emphasizing that while the guideline isn't mandatory, they should facilitate its application while considering local priorities, equality duties, and environmental sustainability. This ensures the guideline's recommendations are implemented in a way that is practical, equitable, and environmentally responsible within the local healthcare system."
  },
  {
    "element_id": "page_3_seq_0",
    "page_number": 3,
    "type": "text",
    "raw_text": "Contents\nOverview ...................................................................................................................................... 6\nWho is it for? .......................................................................................................................................... 6\nIntroduction .................................................................................................................................. 7\nSafeguarding children ........................................................................................................................... 7\nHow the guideline is organised ............................................................................................................ 7\nRecommendation wording in guideline updates ................................................................................ 8\nRecommendations organised by site of cancer ....................................................................... 9\n\nThis \"Contents\" section acts as a roadmap for the NICE guideline document, providing a hierarchical overview of the guideline's structure and enabling readers to quickly locate specific information regarding suspected cancer recognition and referral advice. It highlights key areas, such as recommendations based on cancer site or symptom, and introductory elements relating to safeguarding and how the guideline is organised."
  },
  {
    "element_id": "page_3_seq_0",
    "page_number": 3,
    "type": "text",
    "raw_text": "1.1 Lung and pleural cancers ................................................................................................................ 9\n1.2 Upper gastrointestinal tract cancers ............................................................................................. 11\n1.3 Lower gastrointestinal tract cancers ............................................................................................. 14\n1.4 Breast cancer ................................................................................................................................... 16\n1.5 Gynaecological cancers .................................................................................................................. 17\n1.6 Urological cancers ........................................................................................................................... 19\n\nThis chunk of the document's table of contents outlines the sections dedicated to specific types of cancer based on their anatomical site, which is a key organizational principle of the guideline for facilitating quick access to relevant recommendations. These sections guide healthcare professionals on appropriate investigations and referrals based on the location of suspected cancer."
  },
  {
    "element_id": "page_3_seq_0",
    "page_number": 3,
    "type": "text",
    "raw_text": "1.7 Skin cancers ..................................................................................................................................... 22\n1.8 Head and neck cancers .................................................................................................................. 24\n1.9 Brain and central nervous system cancers ................................................................................... 25\n1.10 Haematological cancers ................................................................................................................ 26\n1.11 Sarcomas ......................................................................................................................................... 29\n1.12 Childhood cancers ......................................................................................................................... 30\n\nThis chunk of the document represents a section of the table of contents. It indicates the guideline covers specific types of cancer based on their location in the body, including skin, head and neck, brain, blood, bone, and cancers found in children."
  },
  {
    "element_id": "page_3_seq_0",
    "page_number": 3,
    "type": "text",
    "raw_text": "1.13 Non-site-specific symptoms ........................................................................................................ 31\nRecommendations on patient support, safety netting and the diagnostic process .............33\n1.14 Patient information and support ................................................................................................... 33\n1.15 Safety netting ................................................................................................................................. 35\n1.16 The diagnostic process ................................................................................................................. 35\nRecommendations organised by symptom and findings of primary care investigations .....37\nAbdominal symptoms ........................................................................................................................... 37\n\nThis chunk outlines the structure of the document, indicating a transition from general recommendations regarding non-site-specific symptoms, patient support, and diagnostic processes to specific guidance based on symptoms and primary care investigation findings, starting with abdominal symptoms. This shift allows healthcare professionals to quickly access relevant recommendations based on a patient's presentation or the results of initial tests."
  },
  {
    "element_id": "page_3_seq_0",
    "page_number": 3,
    "type": "text",
    "raw_text": "Bleeding ................................................................................................................................................. 43\n\nThis chunk indicates the start of a section within the NICE guideline dedicated to recommendations regarding referral and investigation of suspected cancers based on the symptom of bleeding. This section is important because bleeding can be a symptom of various cancers, and the guideline provides specific advice for healthcare professionals to assess and manage patients presenting with this symptom."
  },
  {
    "element_id": "page_4_seq_0",
    "page_number": 4,
    "type": "text",
    "raw_text": "Gynaecological symptoms ................................................................................................................... 44\nLumps or masses .................................................................................................................................. 45\nNeurological symptoms in adults ......................................................................................................... 48\nPain ......................................................................................................................................................... 49\nRespiratory symptoms .......................................................................................................................... 51\nSkeletal symptoms ................................................................................................................................ 53\n\nThis chunk represents a section of the NICE guideline that categorizes recommendations for suspected cancer referrals based on specific symptoms. It serves as a quick reference guide for healthcare professionals to identify potential cancer indicators and determine appropriate actions based on the patient's presented symptoms."
  },
  {
    "element_id": "page_4_seq_0",
    "page_number": 4,
    "type": "text",
    "raw_text": "Skin or surface symptoms .................................................................................................................... 55\nUrological symptoms ............................................................................................................................ 58\nNon-specific features of cancer .......................................................................................................... 61\nPrimary care investigations .................................................................................................................. 68\nSymptoms in children and young people ............................................................................................ 73\nTerms used in this guideline .......................................................................................................83\n\nThis chunk of the document represents the sections that provide specific guidance on recognizing potential cancer symptoms and signs related to skin/surface issues, urological problems, and non-specific indicators, in addition to guidance related to primary care investigations, symptoms in children and young people, and a glossary of key terms used within the guideline. These sections aim to equip healthcare professionals with the knowledge to identify and appropriately respond to varied presentations of potential cancer, considering both site-specific and non-specific indicators across different age groups."
  },
  {
    "element_id": "page_4_seq_0",
    "page_number": 4,
    "type": "text",
    "raw_text": "Children .................................................................................................................................................. 83\nChildren and young people .................................................................................................................. 83\nConsistent with ...................................................................................................................................... 83\nDirect access ......................................................................................................................................... 83\nImmediate .............................................................................................................................................. 83\nNon-urgent ............................................................................................................................................ 83\n\nThis chunk defines key terms used throughout the NICE guideline document on suspected cancer recognition and referral, ensuring clarity and consistency in understanding the recommendations for healthcare professionals. These definitions are crucial for accurate interpretation and application of the guideline's advice on referrals, investigations, and urgency levels."
  },
  {
    "element_id": "page_4_seq_0",
    "page_number": 4,
    "type": "text",
    "raw_text": "Persistent ............................................................................................................................................... 83\nRaises the suspicion of ......................................................................................................................... 84\nSafety netting ........................................................................................................................................ 84\nSuspected cancer pathway referral .................................................................................................... 84\nUnexplained ........................................................................................................................................... 84\nUrgent ..................................................................................................................................................... 84\n\nThis chunk defines key terms used throughout the NICE guideline on suspected cancer, ensuring consistent understanding of concepts like \"urgent referral,\" \"safety netting,\" and \"unexplained symptoms\" for healthcare professionals using the document to assess and refer patients. These definitions are crucial for accurate interpretation and application of the guideline's recommendations."
  },
  {
    "element_id": "page_4_seq_0",
    "page_number": 4,
    "type": "text",
    "raw_text": "Very urgent ............................................................................................................................................ 84\nYoung people ......................................................................................................................................... 85\nRecommendations for research .................................................................................................86\nKey recommendations for research .................................................................................................... 86\n\nThis chunk defines the term \"Very urgent\" for the purposes of this guideline (as \"to happen within 48 hours\"), distinguishes \"Young people\" as those aged 16-24, and introduces the section outlining key recommendations for future research related to suspected cancer recognition and referral. This research section is crucial for improving the evidence base and ultimately refining the guideline's recommendations in the future."
  },
  {
    "element_id": "page_5_seq_0",
    "page_number": 5,
    "type": "text",
    "raw_text": "Rationale and impact ...................................................................................................................88\nProstate-specific antigen testing for prostate cancer ...................................................................... 88\nContext .........................................................................................................................................90\nFinding more information and committee details .....................................................................92\nUpdate information .....................................................................................................................93\n\nThis chunk provides essential supplementary information for the guideline: it explains the reasoning behind specific recommendations (like PSA testing), offers context for the guideline's development, directs readers to additional resources, and details the document's update history, ensuring transparency and facilitating proper application of the guidance. It allows the user to understand not just \"what\" the guideline recommends but \"why\" and how it was developed."
  },
  {
    "element_id": "page_6_seq_0",
    "page_number": 6,
    "type": "text",
    "raw_text": "This guideline replaces CG27.\nThis guideline partially replaces CG122.\nThis guideline is partially replaced by HTG690.\nThis guideline is the basis of QS96, QS124, QS130, QS203 and QS90.\nThis guideline should be read in conjunction with QS155.\nOverview\nThis guideline covers identifying children, young people and adults with symptoms that\ncould be caused by cancer. It outlines appropriate investigations in primary care, and\nselection of people to refer for a specialist opinion. It aims to help people understand what\nto expect if they have symptoms that may suggest cancer.\nWho is it for?\n• Healthcare professionals\n• People involved in clinical governance in both primary and secondary care\n• People with suspected cancer and their families and/or carers.\n\nThis section clarifies the relationship of this guideline (NG12) to previous and related NICE guidelines and quality standards, outlining that it supersedes some, is superseded by others, builds the foundation for several quality standards and should be used alongside another guideline. Additionally, it outlines the scope and intended audience of this guideline, emphasizing its purpose in aiding the identification and management of potential cancer cases."
  },
  {
    "element_id": "page_7_seq_0",
    "page_number": 7,
    "type": "text",
    "raw_text": "Introduction\nSafeguarding children\nRemember that child maltreatment:\n• is common\n• can present anywhere\n• may co-exist with other health problems, including suspected cancer.\nSee NICE's guideline on child maltreatment for clinical features that may be associated\nwith maltreatment.\nPeople have the right to be involved in discussions and make informed decisions\nabout their care, as described in NICE's information on making decisions about your\ncare.\nWe have used the terms 'men' and 'women' in some recommendations on gender-\nrelated cancers, but they also apply to people who have changed or are in the\nprocess of changing gender, and who retain the relevant organs.\nMaking decisions using NICE guidelines explains how we use words to show the\nstrength (or certainty) of our recommendations (although this may not apply to\nrecommendations made before 2009; see the section on recommendation wording in\nguideline updates below). It also has information about prescribing medicines\n\nThis introductory chunk sets essential ethical and practical considerations for applying the guideline, emphasizing child safeguarding, patient involvement in decision-making, and inclusivity for transgender individuals, while also clarifying the interpretation of recommendation strength. It highlights the importance of considering individual needs and preferences alongside the guideline's recommendations."
  },
  {
    "element_id": "page_7_seq_0",
    "page_number": 7,
    "type": "text",
    "raw_text": "guideline updates below). It also has information about prescribing medicines\n(including off-label use), professional guidelines, standards and laws (including on\nconsent and mental capacity) and safeguarding.\nHow the guideline is organised\nThe recommendations in this guideline have been organised into 3 separate sections to\nhelp healthcare professionals find the relevant information easily. The recommendations\nfor investigation and referral organised by site of suspected cancer are also presented in\n\nThis section clarifies the legal and ethical considerations surrounding the guideline's recommendations, and describes how the guideline is structured into three sections to facilitate easy access to relevant information for healthcare professionals. It ensures responsible application of the recommendations while highlighting the organization for efficient navigation."
  },
  {
    "element_id": "page_8_seq_0",
    "page_number": 8,
    "type": "text",
    "raw_text": "tables of recommendations organised by symptoms and investigation findings. Either\nsection should be used in conjunction with the recommendations on patient support,\nsafety netting and the diagnostic process.\nRecommendation wording in guideline updates\nNICE began using standard wording to denote the strength of recommendations in\nguidelines that started development after January 2009. It does not apply to any\nrecommendations ending [2005] (see update information for details about how\nrecommendations are labelled). In particular, for recommendations labelled [2005] the\nword 'consider' may not necessarily be used to denote the strength of the\nrecommendation.\n\nThis chunk clarifies how to use the guideline's recommendations, emphasizing the importance of combining the symptom-based and cancer site-based recommendations with the overarching guidance on patient support, safety netting, and diagnosis. It also explains how the wording of recommendations made before 2009 should be interpreted, as the standard wording to denote the strength of recommendations may not apply to them."
  },
  {
    "element_id": "page_9_seq_0",
    "page_number": 9,
    "type": "text",
    "raw_text": "Recommendations organised by site of\ncancer\nUse this guideline to guide referrals. If still uncertain about whether a referral is\nneeded, consider contacting a specialist (see the recommendations on the diagnostic\nprocess). Consider a review for people with any symptom associated with increased\ncancer risk who do not meet the criteria for referral or investigative action (see the\nrecommendations on safety netting).\n1.1 Lung and pleural cancers\nLung cancer\n1.1.1 Refer people using a suspected cancer pathway referral for lung cancer if they:\n• have chest X-ray findings that suggest lung cancer or\n• are aged 40 and over with unexplained haemoptysis. [2015]\n1.1.2 Offer an urgent chest X-ray (to be done within 2 weeks) to assess for lung cancer\nin people aged 40 and over if they have 2 or more of the following unexplained\nsymptoms, or if they have ever smoked and have 1 or more of the following\nunexplained symptoms:\n• cough\n• fatigue\n• shortness of breath\n• chest pain\n• weight loss\n\nThis section of the NICE guideline provides specific recommendations for healthcare professionals on when to suspect and refer patients for lung and pleural cancers based on symptoms and findings, acting as a practical guide for early cancer detection and referral pathways. It emphasizes the importance of considering specialist consultation and safety netting for cases outside the defined referral criteria."
  },
  {
    "element_id": "page_9_seq_0",
    "page_number": 9,
    "type": "text",
    "raw_text": "unexplained symptoms:\n• cough\n• fatigue\n• shortness of breath\n• chest pain\n• weight loss\n• appetite loss. [2015]\n\nThis chunk provides a list of unexplained symptoms that, when present in certain combinations in people aged 40 and over, should prompt an urgent chest X-ray to assess for lung cancer or mesothelioma. It serves as a key decision-making tool for healthcare professionals in primary care to identify individuals who require further investigation for these cancers."
  },
  {
    "element_id": "page_10_seq_0",
    "page_number": 10,
    "type": "text",
    "raw_text": "1.1.3 Consider an urgent chest X-ray (to be done within 2 weeks) to assess for lung\ncancer in people aged 40 and over with any of the following:\n• persistent or recurrent chest infection\n• finger clubbing\n• supraclavicular lymphadenopathy or persistent cervical lymphadenopathy\n• chest signs consistent with lung cancer\n• thrombocytosis. [2015]\nMesothelioma\n1.1.4 Refer people using a suspected cancer pathway referral for mesothelioma if they\nhave chest X-ray findings that suggest mesothelioma. [2015]\n1.1.5 Offer an urgent chest X-ray (to be done within 2 weeks) to assess for\nmesothelioma in people aged 40 and over, if:\n• they have 2 or more of the following unexplained symptoms or\n• they have 1 or more of the following unexplained symptoms and have ever\nsmoked or\n• they have 1 or more of the following unexplained symptoms and have been\nexposed to asbestos:\n－ cough\n－ fatigue\n－ shortness of breath\n－ chest pain\n－ weight loss\n－ appetite loss. [2015]\n\nThis chunk provides specific NICE guidelines for recognizing and referring suspected lung cancer and mesothelioma cases. It outlines the criteria (symptoms and findings) that warrant urgent chest X-rays or suspected cancer pathway referrals, aiming to facilitate early detection and improve patient outcomes for these cancers."
  },
  {
    "element_id": "page_11_seq_0",
    "page_number": 11,
    "type": "text",
    "raw_text": "1.1.6 Consider an urgent chest X-ray (to be done within 2 weeks) to assess for\nmesothelioma in people aged 40 and over with either:\n• finger clubbing or\n• chest signs compatible with pleural disease. [2015]\n1.2 Upper gastrointestinal tract cancers\nOesophageal cancer\n1.2.1 Refer people using a suspected cancer pathway referral for oesophageal cancer\nif they:\n• have dysphagia or\n• are aged 55 and over, with weight loss, and they have any of the following:\n－ upper abdominal pain\n－ reflux\n－ dyspepsia. [2015, amended 2025]\n1.2.2 Consider non-urgent, direct access upper gastrointestinal endoscopy to assess\nfor oesophageal cancer in people with haematemesis. [2015]\n1.2.3 Consider non-urgent, direct access upper gastrointestinal endoscopy to assess\nfor oesophageal cancer in people aged 55 or over with:\n• treatment-resistant dyspepsia or\n• upper abdominal pain with low haemoglobin levels or\n• raised platelet count with any of the following:\n－ nausea\n－ vomiting\n\nThis chunk of the NICE guideline provides specific recommendations for urgent chest X-rays for potential mesothelioma and suspected cancer pathway referrals and non-urgent endoscopies for potential oesophageal cancer, focusing on specific symptoms and age groups to aid healthcare professionals in making appropriate referrals and investigations. It helps to ensure timely diagnosis and management of these cancers based on evidence-based criteria."
  },
  {
    "element_id": "page_12_seq_0",
    "page_number": 12,
    "type": "text",
    "raw_text": "－ weight loss\n－ reflux\n－ dyspepsia\n－ upper abdominal pain or\n• nausea or vomiting with any of the following:\n－ weight loss\n－ reflux\n－ dyspepsia\n－ upper abdominal pain. [2015]\nPancreatic cancer\n1.2.4 Refer people using a suspected cancer pathway referral for pancreatic cancer if\nthey are aged 40 and over and have jaundice. [2015]\n1.2.5 Consider an urgent, direct access CT scan (to be done within 2 weeks), or an\nurgent ultrasound scan if CT is not available, to assess for pancreatic cancer in\npeople aged 60 and over with weight loss and any of the following:\n• diarrhoea\n• back pain\n• abdominal pain\n• nausea\n• vomiting\n• constipation\n• new-onset diabetes. [2015]\n\nThis chunk provides specific NICE guideline recommendations for referral and investigation of suspected oesophageal, stomach, and pancreatic cancers, outlining criteria based on age, symptoms, and diagnostic findings to guide healthcare professionals in primary care. It aims to facilitate early detection and appropriate management of these cancers by specifying when urgent action, like a suspected cancer pathway referral or direct access imaging, is warranted."
  },
  {
    "element_id": "page_13_seq_0",
    "page_number": 13,
    "type": "text",
    "raw_text": "Stomach cancer\n1.2.6 Consider a suspected cancer pathway referral for people with an upper\nabdominal mass consistent with stomach cancer. [2015]\n1.2.7 Refer people using a suspected cancer pathway referral for stomach cancer if\nthey:\n• have dysphagia or\n• are aged 55 and over, with weight loss, and they have any of the following:\n－ upper abdominal pain\n－ reflux\n－ dyspepsia. [2015, amended 2025]\n1.2.8 Consider non-urgent, direct access upper gastrointestinal endoscopy to assess\nfor stomach cancer in people with haematemesis. [2015]\n1.2.9 Consider non-urgent, direct access upper gastrointestinal endoscopy to assess\nfor stomach cancer in people aged 55 or over with:\n• treatment-resistant dyspepsia or\n• upper abdominal pain with low haemoglobin levels or\n• raised platelet count with any of the following:\n－ nausea\n－ vomiting\n－ weight loss\n－ reflux\n－ dyspepsia\n－ upper abdominal pain or\n\nThis section of the NICE guideline provides specific recommendations for identifying and referring individuals suspected of having stomach cancer, outlining criteria based on symptoms, age, and examination findings to guide healthcare professionals in primary care. It aims to facilitate early diagnosis and appropriate referral to specialist services for timely investigation and management of potential stomach cancer cases."
  },
  {
    "element_id": "page_14_seq_0",
    "page_number": 14,
    "type": "text",
    "raw_text": "• nausea or vomiting with any of the following:\n－ weight loss\n－ reflux\n－ dyspepsia\n－ upper abdominal pain. [2015]\nGall bladder cancer\n1.2.10 Consider an urgent, direct access ultrasound scan (to be done within 2 weeks) to\nassess for gall bladder cancer in people with an upper abdominal mass\nconsistent with an enlarged gall bladder. [2015]\nLiver cancer\n1.2.11 Consider an urgent, direct access ultrasound scan (to be done within 2 weeks) to\nassess for liver cancer in people with an upper abdominal mass consistent with\nan enlarged liver. [2015]\n1.3 Lower gastrointestinal tract cancers\nColorectal cancer\nRecommendations 1.3.1 to 1.3.4 are adapted from NICE's diagnostics guidance on\nquantitative faecal immunochemical testing to guide colorectal cancer pathway\nreferral in primary care.\n1.3.1 Offer quantitative faecal immunochemical testing (FIT) using HM-JACKarc or\nOC-Sensor to guide referral for suspected colorectal cancer in adults:\n\nThis chunk provides specific recommendations for investigating suspected upper gastrointestinal, gall bladder, and liver cancers, as well as initiating faecal immunochemical testing (FIT) for suspected colorectal cancer, outlining the symptoms that should prompt these actions. These recommendations aim to guide healthcare professionals in primary care to identify potential cancers early and determine the appropriate course of action, whether further investigation or referral."
  },
  {
    "element_id": "page_15_seq_0",
    "page_number": 15,
    "type": "text",
    "raw_text": "• with an abdominal mass or\n• with a change in bowel habit or\n• with iron-deficiency anaemia or\n• aged 40 and over with unexplained weight loss and abdominal pain or\n• aged under 50 with rectal bleeding and either of the following unexplained\nsymptoms:\n－ abdominal pain\n－ weight loss or\n• aged 50 and over with any of the following unexplained symptoms:\n－ rectal bleeding\n－ abdominal pain\n－ weight loss or\n• aged 60 and over with anaemia even in the absence of iron deficiency.\nFIT should be offered even if the person has previously had a negative FIT\nresult through the NHS bowel cancer screening programme. People with a\nrectal mass, an unexplained anal mass or unexplained anal ulceration do not\nneed to be offered FIT before referral is considered. [2023]\n1.3.2 Refer adults using a suspected cancer pathway referral for colorectal cancer if\nthey have a FIT result of at least 10 micrograms of haemoglobin per gram of\nfaeces. [2023]\n\nThis section of the NICE guideline outlines the criteria for offering a quantitative faecal immunochemical test (FIT) to adults suspected of having colorectal cancer based on various symptoms and age groups, and specifies that a positive FIT result (at least 10 micrograms of haemoglobin per gram of faeces) warrants a suspected cancer pathway referral. Its purpose is to guide primary care physicians in identifying patients who require further investigation for colorectal cancer, using FIT as a tool to triage referrals."
  },
  {
    "element_id": "page_15_seq_0",
    "page_number": 15,
    "type": "text",
    "raw_text": "they have a FIT result of at least 10 micrograms of haemoglobin per gram of\nfaeces. [2023]\n1.3.3 For people who have not returned a faecal sample or who have a FIT result below\n10 micrograms of haemoglobin per gram of faeces:\n• safety netting processes should be in place\n• referral to an appropriate secondary care pathway should not be delayed if\nthere is strong clinical concern of cancer because of ongoing unexplained\n\nThis section specifies the FIT (Faecal Immunochemical Test) result threshold (10 micrograms of haemoglobin per gram of faeces) that warrants a suspected cancer pathway referral for colorectal cancer, while also emphasizing the importance of safety netting and not delaying referral based on strong clinical suspicion, even with low or absent FIT results. It provides guidance for primary care physicians to determine when to refer patients for further investigation of colorectal cancer."
  },
  {
    "element_id": "page_16_seq_0",
    "page_number": 16,
    "type": "text",
    "raw_text": "symptoms (for example, abdominal mass). [2023]\n1.3.4 Clinicians should consider if people need additional help, information or support\nto return their sample. [2023]\n1.3.5 Consider a suspected cancer pathway referral for colorectal cancer in adults with\na rectal mass. [2015, amended 2023]\nAnal cancer\n1.3.6 Consider a suspected cancer pathway referral for anal cancer in people with an\nunexplained anal mass or unexplained anal ulceration. [2015]\n1.4 Breast cancer\n1.4.1 Refer people using a suspected cancer pathway referral for breast cancer if they\nare:\n• aged 30 and over and have an unexplained breast lump with or without pain\nor\n• aged 50 and over with any of the following symptoms in one nipple only:\n－ discharge\n－ retraction\n－ other changes of concern. [2015]\n1.4.2 Consider a suspected cancer pathway referral for breast cancer in people:\n• with skin changes that suggest breast cancer or\n• aged 30 and over with an unexplained lump in the axilla. [2015]\n\nThis section provides specific recommendations for suspected colorectal, anal, and breast cancers, outlining when to offer FIT testing, consider referral to a specialist, or directly refer using a suspected cancer pathway based on specific symptoms and age criteria. It guides healthcare professionals in primary care to appropriately assess and refer patients with potential signs of these cancers for further investigation."
  },
  {
    "element_id": "page_16_seq_0",
    "page_number": 16,
    "type": "text",
    "raw_text": "• aged 30 and over with an unexplained lump in the axilla. [2015]\n1.4.3 Consider non-urgent referral in people aged under 30 with an unexplained breast\nlump with or without pain. See also recommendations 1.16.2 and 1.16.3 for\n\nThis section of the NICE guideline provides recommendations for referrals related to suspected breast cancer based on age and symptoms. It advises a suspected cancer pathway referral for those 30 and over with an unexplained axillary lump, and a non-urgent referral for those under 30 with an unexplained breast lump, while also directing users to further guidance on specialist advice."
  },
  {
    "element_id": "page_17_seq_0",
    "page_number": 17,
    "type": "text",
    "raw_text": "information about seeking specialist advice. [2015]\n1.5 Gynaecological cancers\nOvarian cancer\nThe recommendations in this section have been incorporated from NICE's guideline on\novarian cancer and have not been updated. The recommendations for ovarian cancer\napply to women aged 18 and over.\n1.5.1 Make a referral to a gynaecological cancer service using a suspected cancer\npathway referral if physical examination identifies ascites and/or a pelvic or\nabdominal mass (which is not obviously uterine fibroids). [2011, amended 2020]\n1.5.2 Carry out tests in primary care (see recommendations 1.5.6 to 1.5.9) if a woman\n(especially if aged 50 or over) reports having any of the following symptoms on a\npersistent or frequent basis – particularly more than 12 times per month:\n• persistent abdominal distension (women often refer to this as 'bloating')\n• feeling full (early satiety) and/or loss of appetite\n• pelvic or abdominal pain\n• increased urinary urgency and/or frequency. [2011]\n\nThis chunk focuses on guidelines for suspected gynaecological cancers, specifically ovarian cancer, outlining referral criteria based on physical examination findings (ascites/pelvic mass) and prompting further primary care investigation for women exhibiting specific persistent symptoms like abdominal distension or pelvic pain. The document emphasizes that these ovarian cancer recommendations apply to women aged 18 and over, and were incorporated from another NICE guideline without updates."
  },
  {
    "element_id": "page_17_seq_0",
    "page_number": 17,
    "type": "text",
    "raw_text": "• pelvic or abdominal pain\n• increased urinary urgency and/or frequency. [2011]\n1.5.3 Consider carrying out tests in primary care (see recommendations 1.5.6 to 1.5.9) if\na woman reports unexplained weight loss, fatigue or changes in bowel habit.\n[2011]\n1.5.4 Advise any woman who is not suspected of having ovarian cancer to return to her\nGP if her symptoms become more frequent and/or persistent. [2011]\n1.5.5 Carry out appropriate tests for ovarian cancer (see recommendations 1.5.6 to\n1.5.9) in any woman aged 50 or over who has experienced symptoms within the\nlast 12 months that suggest irritable bowel syndrome (IBS), because IBS rarely\npresents for the first time in women of this age. (See NICE's guideline on irritable\n\nThis section of the NICE guideline focuses on the recognition and referral of suspected ovarian cancer. It provides guidance for healthcare professionals on when to consider testing for ovarian cancer in women presenting with certain symptoms, especially those that overlap with IBS, and advises on managing patients not initially suspected of having ovarian cancer."
  },
  {
    "element_id": "page_18_seq_0",
    "page_number": 18,
    "type": "text",
    "raw_text": "bowel syndrome in adults). [2011]\n1.5.6 Measure serum CA125 in primary care in women with symptoms that suggest\novarian cancer (see recommendations 1.5.1 to 1.5.5). [2011]\n1.5.7 If serum CA125 is 35 IU/ml or greater, arrange an ultrasound scan of the abdomen\nand pelvis. [2011]\n1.5.8 If the ultrasound suggests ovarian cancer, make a referral to a gynaecological\ncancer service using a suspected cancer pathway referral. [2011, amended\n2020]\n1.5.9 For any woman who has normal serum CA125 (less than 35 IU/ml), or CA125 of\n35 IU/ml or greater but a normal ultrasound:\n• assess her carefully for other clinical causes of her symptoms and investigate\nif appropriate\n• if no other clinical cause is apparent, advise her to return to her GP if her\nsymptoms become more frequent and/or persistent. [2011]\nEndometrial cancer\n1.5.10 Refer women using a suspected cancer pathway referral for endometrial cancer if\nthey are aged 55 and over with post-menopausal bleeding (unexplained vaginal\n\nThis chunk of the NICE guideline provides specific recommendations for identifying and managing suspected ovarian and endometrial cancers, guiding healthcare professionals in primary care through investigations and referral pathways based on symptoms, serum CA125 levels, and ultrasound findings. These recommendations aim to facilitate early detection and appropriate referral, ultimately improving outcomes for women with these cancers."
  },
  {
    "element_id": "page_18_seq_0",
    "page_number": 18,
    "type": "text",
    "raw_text": "they are aged 55 and over with post-menopausal bleeding (unexplained vaginal\nbleeding more than 12 months after menstruation has stopped because of the\nmenopause). [2015]\n1.5.11 Consider a suspected cancer pathway referral for endometrial cancer in women\naged under 55 with post-menopausal bleeding. [2015]\n1.5.12 Consider a direct access ultrasound scan to assess for endometrial cancer in\nwomen aged 55 and over with:\n• unexplained symptoms of vaginal discharge who:\n－ are presenting with these symptoms for the first time or\n\nThis section outlines the recommendations for suspected endometrial cancer referrals based on post-menopausal bleeding and vaginal discharge, differentiating actions based on the patient's age. It aims to guide healthcare professionals in determining the appropriate pathway (suspected cancer referral or direct access ultrasound) for women presenting with these symptoms, considering the varying risk levels associated with age."
  },
  {
    "element_id": "page_19_seq_0",
    "page_number": 19,
    "type": "text",
    "raw_text": "－ have thrombocytosis or\n－ report haematuria or\n• visible haematuria and:\n－ low haemoglobin levels or\n－ thrombocytosis or\n－ high blood glucose levels. [2015]\nCervical cancer\n1.5.13 Consider a suspected cancer pathway referral for women if, on examination, the\nappearance of their cervix is consistent with cervical cancer. [2015]\nVulval cancer\n1.5.14 Consider a suspected cancer pathway referral for vulval cancer in women with an\nunexplained vulval lump, ulceration or bleeding. [2015]\nVaginal cancer\n1.5.15 Consider a suspected cancer pathway referral for vaginal cancer in women with\nan unexplained palpable mass in or at the entrance to the vagina. [2015]\n1.6 Urological cancers\nProstate cancer\n1.6.1 Refer people using a suspected cancer pathway referral for prostate cancer if\ntheir prostate feels malignant on digital rectal examination. [2015]\n\nThis chunk of the NICE guideline provides specific recommendations for referrals related to suspected endometrial, cervical, vulval, vaginal, and prostate cancers, outlining symptoms and examination findings that should prompt consideration of a suspected cancer pathway referral. Its purpose is to guide healthcare professionals in identifying and appropriately referring individuals who may have these cancers for further evaluation and timely diagnosis."
  },
  {
    "element_id": "page_20_seq_0",
    "page_number": 20,
    "type": "text",
    "raw_text": "1.6.2 Consider a prostate-specific antigen (PSA) test and digital rectal examination to\nassess for prostate cancer in people with:\n• any lower urinary tract symptoms, such as nocturia, urinary frequency,\nhesitancy, urgency or retention or\n• erectile dysfunction or\n• visible haematuria. [2015]\n1.6.3 Consider referring people with possible symptoms of prostate cancer, as\nspecified in recommendation 1.6.2, using a suspected cancer pathway referral for\nprostate cancer if their PSA levels are above the threshold for their age in table 1.\nTake into account the person's preferences and any comorbidities when making\nthe decision. [2021]\nTable 1 Age-specific PSA thresholds for people\nwith possible symptoms of prostate cancer\nAge (years) Prostate-specific antigen threshold (micrograms/litre)\nBelow 40 Use clinical judgement\n40 to 49 More than 2.5\n50 to 59 More than 3.5\n60 to 69 More than 4.5\n70 to 79 More than 6.5\nAbove 79 Use clinical judgement\n\nThis section of the NICE guideline provides recommendations for assessing and referring patients with suspected prostate cancer. It outlines when to consider a PSA test and digital rectal exam, and when to make a suspected cancer pathway referral based on age-specific PSA thresholds, while emphasizing the importance of considering individual patient factors."
  },
  {
    "element_id": "page_20_seq_0",
    "page_number": 20,
    "type": "text",
    "raw_text": "50 to 59 More than 3.5\n60 to 69 More than 4.5\n70 to 79 More than 6.5\nAbove 79 Use clinical judgement\nFor a short explanation of why the committee made the 2021 recommendation and\nhow it might affect practice, see the rationale and impact section on PSA testing for\nprostate cancer.\nFull details of the evidence and the committee's discussion are in evidence review A:\nPSA testing for prostate cancer.\n\nThis chunk provides age-specific PSA thresholds (Table 1) that, if exceeded in people with possible prostate cancer symptoms, should prompt consideration of a suspected cancer pathway referral, supplementing recommendation 1.6.3. It guides healthcare professionals in assessing the urgency of referral based on PSA levels in relation to the patient's age, aiding in the early detection of prostate cancer."
  },
  {
    "element_id": "page_20",
    "page_number": 20,
    "type": "table",
    "raw_text": "Table 1 on Page 20\n\n| Age (years)   | Prostate-specific antigen threshold (micrograms/litre)   |\n|:--------------|:---------------------------------------------------------|\n| Below 40      | Use clinical judgement                                   |\n| 40 to 49      | More than 2.5                                            |\n| 50 to 59      | More than 3.5                                            |\n| 60 to 69      | More than 4.5                                            |\n| 70 to 79      | More than 6.5                                            |\n| Above 79      | Use clinical judgement                                   |\n\nTitle: Age-Specific PSA Thresholds | Summary: The table presents prostate-specific antigen (PSA) thresholds in micrograms per litre, stratified by age ranges, for assessing potential prostate cancer in individuals presenting with related symptoms. Clinical judgement is advised for those under 40 and over 79.",
    "table_summary": "Title: Age-Specific PSA Thresholds | Summary: The table presents prostate-specific antigen (PSA) thresholds in micrograms per litre, stratified by age ranges, for assessing potential prostate cancer in individuals presenting with related symptoms. Clinical judgement is advised for those under 40 and over 79."
  },
  {
    "element_id": "page_21_seq_0",
    "page_number": 21,
    "type": "text",
    "raw_text": "Bladder cancer\n1.6.4 Refer people using a suspected cancer pathway referral for bladder cancer if they\nare:\n• aged 45 and over and have:\n－ unexplained visible haematuria without urinary tract infection or\n－ visible haematuria that persists or recurs after successful treatment of\nurinary tract infection or\n• aged 60 and over and have unexplained non-visible haematuria and either\ndysuria or a raised white cell count on a blood test. [2015]\n1.6.5 Consider non-urgent referral for bladder cancer in people aged 60 and over with\nrecurrent or persistent unexplained urinary tract infection. [2015]\nRenal cancer\n1.6.6 Refer people using a suspected cancer pathway referral for renal cancer if they\nare aged 45 and over and have:\n• unexplained visible haematuria without urinary tract infection or\n• visible haematuria that persists or recurs after successful treatment of\nurinary tract infection. [2015]\nTesticular cancer\n\nThis section of the NICE guideline provides specific recommendations for referral and investigation of suspected bladder and renal cancers based on age and presence of hematuria, dysuria, and urinary tract infections, guiding healthcare professionals in primary care to identify patients who require further evaluation. It also provides recommendations for testicular cancer referrals based on physical symptoms."
  },
  {
    "element_id": "page_21_seq_0",
    "page_number": 21,
    "type": "text",
    "raw_text": "urinary tract infection. [2015]\nTesticular cancer\n1.6.7 Consider a suspected cancer pathway referral for testicular cancer in men if they\nhave a non-painful enlargement or change in shape or texture of the testis.\n[2015]\n1.6.8 Consider a direct access ultrasound scan for testicular cancer in men with\nunexplained or persistent testicular symptoms. [2015]\n\nThis section focuses on the urological cancers, specifically providing guidance on when to suspect and refer patients for bladder and testicular cancer. It outlines specific criteria, such as age and presence of haematuria for bladder cancer, and testicular changes for testicular cancer, prompting either a suspected cancer pathway referral or a direct access ultrasound scan."
  },
  {
    "element_id": "page_22_seq_0",
    "page_number": 22,
    "type": "text",
    "raw_text": "Penile cancer\n1.6.9 Consider a suspected cancer pathway referral for penile cancer in men if they\nhave:\n• a penile mass or ulcerated lesion, when a sexually transmitted infection has\nbeen excluded as a cause or\n• a persistent penile lesion after treatment for a sexually transmitted infection\nhas been completed. [2015]\n1.6.10 Consider a suspected cancer pathway referral for penile cancer in men with\nunexplained or persistent symptoms affecting the foreskin or glans. [2015]\n1.7 Skin cancers\nMalignant melanoma of the skin\n1.7.1 Refer people using a suspected cancer pathway referral for melanoma if they\nhave a suspicious pigmented skin lesion with a weighted 7-point checklist score\nof 3 or more. [2015]\n\nThis section of the NICE guideline provides specific recommendations for healthcare professionals on when to suspect and refer patients for penile and skin cancers, focusing on observable symptoms and risk assessment to facilitate timely diagnosis and intervention. It outlines the criteria for suspected cancer pathway referrals, including specific findings like penile masses, ulcerated lesions, and suspicious skin lesions with a certain score on a weighted checklist."
  },
  {
    "element_id": "page_23_seq_0",
    "page_number": 23,
    "type": "text",
    "raw_text": "Weighted 7-point checklist\nMajor features of the lesions (scoring 2 points each):\n• change in size\n• irregular shape\n• irregular colour.\nMinor features of the lesions (scoring 1 point each):\n• largest diameter 7 mm or more\n• inflammation\n• oozing\n• change in sensation.\n1.7.2 Refer people using a suspected cancer pathway referral if dermoscopy suggests\nmelanoma of the skin. [2015]\n1.7.3 Consider a suspected cancer pathway referral for melanoma in people with a\npigmented or non-pigmented skin lesion that suggests nodular melanoma. [2015]\nSquamous cell carcinoma\n1.7.4 Consider a suspected cancer pathway referral for people with a skin lesion that\nraises the suspicion of squamous cell carcinoma. [2015]\nBasal cell carcinoma\n1.7.5 Consider routine referral for people if they have a skin lesion that raises the\nsuspicion of a basal cell carcinoma. (Typical features of basal cell carcinoma\n\nThis excerpt from the NICE guideline focuses on the recognition and referral of suspected skin cancers, providing specific criteria like the 7-point checklist for melanoma to guide healthcare professionals in making appropriate referral decisions. It outlines different referral pathways (suspected cancer pathway, routine referral) based on the type of suspected skin cancer (melanoma, squamous cell carcinoma, basal cell carcinoma) to ensure timely specialist assessment and management."
  },
  {
    "element_id": "page_24_seq_0",
    "page_number": 24,
    "type": "text",
    "raw_text": "include: an ulcer with a raised rolled edge; prominent fine blood vessels around a\nlesion; or a nodule on the skin [particularly pearly or waxy nodules].) [2015]\n1.7.6 Only consider a suspected cancer pathway referral for people with a skin lesion\nthat raises the suspicion of a basal cell carcinoma if there is particular concern\nthat a delay may have a significant impact, because of factors such as lesion site\nor size. [2015]\n1.7.7 Follow NICE's guidance on improving outcomes for people with skin tumours\nincluding melanoma for advice on who should excise suspected basal cell\ncarcinomas. [2015]\n1.8 Head and neck cancers\nLaryngeal cancer\n1.8.1 Consider a suspected cancer pathway referral for laryngeal cancer in people\naged 45 and over with:\n• persistentunexplained hoarseness or\n• an unexplained lump in the neck. [2015]\nOral cancer\n1.8.2 Consider a suspected cancer pathway referral for oral cancer in people with\neither:\n\nThis chunk of the NICE guideline focuses on the referral process for suspected skin cancers, particularly basal cell carcinoma, and then transitions to the referral criteria for suspected laryngeal and oral cancers, providing guidance for healthcare professionals to identify and manage potential head and neck cancers. It outlines when a specialist referral is necessary based on specific signs and symptoms."
  },
  {
    "element_id": "page_24_seq_0",
    "page_number": 24,
    "type": "text",
    "raw_text": "1.8.2 Consider a suspected cancer pathway referral for oral cancer in people with\neither:\n• unexplained ulceration in the oral cavity lasting for more than 3 weeks or\n• a persistent and unexplained lump in the neck. [2015]\n1.8.3 Consider an urgent referral (for an appointment within 2 weeks) for assessment\nfor possible oral cancer by a dentist in people who have either:\n• a lump on the lip or in the oral cavity or\n\nThis section of the guideline provides recommendations for healthcare professionals on when to suspect and refer patients for oral cancer, outlining specific symptoms like persistent oral ulceration or neck lumps that warrant further investigation, and emphasizing the importance of dental assessments for oral cavity abnormalities. It aims to facilitate early detection and referral for timely diagnosis and management of potential oral cancers."
  },
  {
    "element_id": "page_25_seq_0",
    "page_number": 25,
    "type": "text",
    "raw_text": "• a red or red and white patch in the oral cavity consistent with erythroplakia or\nerythroleukoplakia. [2015]\n1.8.4 Consider a suspected cancer pathway referral by the dentist for oral cancer in\npeople when assessed by a dentist as having either:\n• a lump on the lip or in the oral cavity consistent with oral cancer or\n• a red or red and white patch in the oral cavity consistent with erythroplakia or\nerythroleukoplakia. [2015]\nThyroid cancer\n1.8.5 Consider a suspected cancer pathway referral for thyroid cancer in people with\nan unexplained thyroid lump. [2015]\n1.9 Brain and central nervous system cancers\nAdults\n1.9.1 Consider an urgent, direct access, MRI scan of the brain (or CT scan if MRI is\ncontraindicated; to be done within 2 weeks) to assess for brain or central nervous\nsystem cancer in adults with progressive, sub-acute loss of central neurological\nfunction. [2015]\nChildren and young people\n1.9.2 Consider a very urgent referral (for an appointment within 48 hours) for\n\nThis chunk provides specific guidance on when to suspect and refer for oral and thyroid cancers, as well as brain and central nervous system cancers in both adults and children/young people, emphasizing the importance of timely action based on identified symptoms and age group. It is part of the broader document aiming to aid healthcare professionals in recognizing potential cancer symptoms and making appropriate referral decisions."
  },
  {
    "element_id": "page_25_seq_0",
    "page_number": 25,
    "type": "text",
    "raw_text": "1.9.2 Consider a very urgent referral (for an appointment within 48 hours) for\nsuspected brain or central nervous system cancer in children and young people\nwith newly abnormal cerebellar or other central neurological function. [2015]\n\nThis recommendation, found within the section on brain and central nervous system cancers, advises healthcare professionals to urgently (within 48 hours) refer children and young people showing new signs of cerebellar or other central neurological dysfunction for specialist assessment to rule out suspected brain or central nervous system cancer. It highlights the need for rapid action in this specific patient population due to the potential severity and time-sensitivity of childhood cancers."
  },
  {
    "element_id": "page_26_seq_0",
    "page_number": 26,
    "type": "text",
    "raw_text": "1.10 Haematological cancers\nLeukaemia in adults\n1.10.1 Consider a very urgent full blood count (within 48 hours) to assess for leukaemia\nin adults with any of the following:\n• pallor\n• persistent fatigue\n• unexplained fever\n• unexplained persistent or recurrent infection\n• generalised lymphadenopathy\n• unexplained bruising\n• unexplained bleeding\n• unexplained petechiae\n• hepatosplenomegaly. [2015]\nLeukaemia in children and young people\n1.10.2 Refer children and young people for immediate specialist assessment for\nleukaemia if they have unexplained petechiae or hepatosplenomegaly. [2015]\n1.10.3 Offer a very urgent full blood count (within 48 hours) to assess for leukaemia in\nchildren and young people with any of the following:\n• pallor\n• persistent fatigue\n• unexplained fever\n• unexplained persistent infection\n\nThis section of the NICE guideline provides recommendations for recognizing and referring suspected cases of hematological cancers, specifically leukemia, in both adults and children/young people, outlining specific symptoms that warrant urgent blood tests or immediate specialist assessment. This ensures timely investigation and referral for potential leukemia cases, contributing to earlier diagnosis and improved outcomes."
  },
  {
    "element_id": "page_27_seq_0",
    "page_number": 27,
    "type": "text",
    "raw_text": "• generalised lymphadenopathy\n• persistent or unexplained bone pain\n• unexplained bruising\n• unexplained bleeding. [2015]\nMyeloma\n1.10.4 Offer the following to assess for myeloma in people aged 60 and over with\npersistent bone pain, particularly back pain, or unexplained fracture:\n• a full blood count and\n• blood tests for:\n－ calcium\n－ plasma viscosity or erythrocyte sedimentation rate\n－ paraprotein, using serum protein electrophoresis\n－ free light chains contained in serum.\nIf serum free light chain testing is not available, use a Bence–Jones test\nto check for free light chains contained in urine. [2015, amended 2025]\n1.10.5 Refer people using a suspected cancer pathway referral if the results of the blood\ntests outlined in recommendation 1.10.4 suggest myeloma. [2015, amended\n2025]\nNon-Hodgkin's lymphoma\nSeparate recommendations have been made for adults and for children and young people\nto reflect that there are different referral pathways. In practice young people (aged 16 to\n\nThis excerpt from the NICE guideline on suspected cancer outlines the recommended actions for healthcare professionals when assessing patients for potential haematological cancers, specifically leukaemia and myeloma, including urgent blood tests and referral pathways based on specific symptoms and age groups. Its purpose is to guide clinicians in the early detection and appropriate management of these cancers to improve patient outcomes."
  },
  {
    "element_id": "page_27_seq_0",
    "page_number": 27,
    "type": "text",
    "raw_text": "to reflect that there are different referral pathways. In practice young people (aged 16 to\n24) may be referred using either pathway depending on their age and local arrangements.\n\nThis chunk clarifies that referral pathways for suspected lymphomas and sarcomas differ between adults and children/young people, but allows flexibility in applying either pathway to those aged 16-24 based on local protocols. Its purpose is to acknowledge varying regional practices and age-related considerations in managing suspected cancers in young people."
  },
  {
    "element_id": "page_28_seq_0",
    "page_number": 28,
    "type": "text",
    "raw_text": "Adults\n1.10.6 Consider a suspected cancer pathway referral for non-Hodgkin's lymphoma in\nadults presenting with unexplained lymphadenopathy or splenomegaly. When\nconsidering referral, take into account any associated symptoms, particularly\nfever, night sweats, shortness of breath, pruritus or weight loss. [2015]\nChildren and young people\n1.10.7 Consider a very urgent referral (for an appointment within 48 hours) for specialist\nassessment for non-Hodgkin's lymphoma in children and young people\npresenting with unexplained lymphadenopathy or splenomegaly. When\nconsidering referral, take into account any associated symptoms, particularly\nfever, night sweats, shortness of breath, pruritus or weight loss. [2015]\nHodgkin's lymphoma\nSeparate recommendations have been made for adults and for children and young people\nto reflect that there are different referral pathways. In practice young people (aged 16 to\n24) may be referred using either pathway depending on their age and local arrangements.\n\nThis chunk provides specific referral guidance for suspected Non-Hodgkin's lymphoma in both adults and children/young people, emphasizing the importance of considering associated symptoms like fever and weight loss. It highlights differing referral pathways based on age, acknowledging that young adults may be referred using either the adult or pediatric pathway depending on local practices."
  },
  {
    "element_id": "page_28_seq_0",
    "page_number": 28,
    "type": "text",
    "raw_text": "24) may be referred using either pathway depending on their age and local arrangements.\nAdults\n1.10.8 Consider a suspected cancer pathway referral for Hodgkin's lymphoma in adults\npresenting with unexplained lymphadenopathy. When considering referral, take\ninto account any associated symptoms, particularly fever, night sweats,\nshortness of breath, pruritus, weight loss or alcohol-induced lymph node pain.\n[2015]\nChildren and young people\n1.10.9 Consider a very urgent referral (for an appointment within 48 hours) for specialist\nassessment for Hodgkin's lymphoma in children and young people presenting\nwith unexplained lymphadenopathy. When considering referral, take into account\n\nThis chunk provides specific guidance on when to refer patients with suspected Hodgkin's lymphoma, differentiating the urgency and pathway (suspected cancer pathway referral vs. very urgent referral) based on whether the patient is an adult or a child/young person. It emphasizes considering associated symptoms to inform the referral decision, reflecting the guideline's overall aim of aiding healthcare professionals in recognizing and appropriately referring individuals with potential cancer."
  },
  {
    "element_id": "page_29_seq_0",
    "page_number": 29,
    "type": "text",
    "raw_text": "any associated symptoms, particularly fever, night sweats, shortness of breath,\npruritus or weight loss. [2015]\n1.11 Sarcomas\nSeparate recommendations have been made for adults and for children and young people\nto reflect that there are different referral pathways. In practice young people (aged 16 to\n24) may be referred using either pathway depending on their age and local arrangements.\nBone sarcoma in adults\n1.11.1 Consider a suspected cancer pathway referral for adults if an X-ray suggests the\npossibility of bone sarcoma. [2015]\nBone sarcoma in children and young people\n1.11.2 Consider a very urgent referral (for an appointment within 48 hours) for specialist\nassessment for children and young people if an X-ray suggests the possibility of\nbone sarcoma. [2015]\n1.11.3 Consider a very urgent direct access X-ray (to be done within 48 hours) to assess\nfor bone sarcoma in children and young people with unexplained bone swelling or\npain. [2015]\nSoft tissue sarcoma in adults\n\nThis chunk focuses on bone sarcoma referrals, differentiating between adults (suspected cancer pathway referral based on X-ray findings) and children/young people (very urgent referral/X-ray for specialist assessment), and highlights the importance of considering associated symptoms (fever, night sweats, shortness of breath, pruritus or weight loss). This is crucial for timely diagnosis and appropriate referral pathways based on age and specific symptoms."
  },
  {
    "element_id": "page_29_seq_0",
    "page_number": 29,
    "type": "text",
    "raw_text": "pain. [2015]\nSoft tissue sarcoma in adults\n1.11.4 Consider an urgent, direct access ultrasound scan (to be done within 2 weeks) to\nassess for soft tissue sarcoma in adults with an unexplained lump that is\nincreasing in size. [2015]\n1.11.5 Consider a suspected cancer pathway referral for adults if they have ultrasound\nscan findings that are suggestive of soft tissue sarcoma or if ultrasound findings\nare uncertain and clinical concern persists. [2015]\n\nThis section provides guidance on recognizing and referring suspected cases of soft tissue sarcoma in adults, emphasizing the importance of ultrasound scans for unexplained and growing lumps, followed by a potential suspected cancer pathway referral based on the scan results and clinical judgment. It aims to facilitate early detection and appropriate management of this type of cancer."
  },
  {
    "element_id": "page_30_seq_0",
    "page_number": 30,
    "type": "text",
    "raw_text": "Soft tissue sarcoma in children and young people\n1.11.6 Consider a very urgent, direct access ultrasound scan (to be done within\n48 hours) to assess for soft tissue sarcoma in children and young people with an\nunexplained lump that is increasing in size. [2015]\n1.11.7 Consider a very urgent referral (for an appointment within 48 hours) for children\nand young people if they have ultrasound scan findings that are suggestive of\nsoft tissue sarcoma or if ultrasound findings are uncertain and clinical concern\npersists. [2015]\n1.12 Childhood cancers\nNICE has published a guideline on babies, children and young people's experience of\nhealthcare.\nNeuroblastoma\n1.12.1 Consider very urgent referral (for an appointment within 48 hours) for specialist\nassessment for neuroblastoma in children with a palpable abdominal mass or\nunexplained enlarged abdominal organ. [2015]\nRetinoblastoma\n1.12.2 Consider referral for ophthalmological assessment using a suspected cancer\n\nThis chunk provides specific guidance on when to urgently investigate or refer children and young people for suspected soft tissue sarcoma, neuroblastoma, and retinoblastoma, all serious childhood cancers, emphasizing the need for rapid assessment and specialist input due to the aggressive nature of these diseases in this age group. These recommendations aim to facilitate early detection and intervention, improving outcomes for affected children and young people."
  },
  {
    "element_id": "page_30_seq_0",
    "page_number": 30,
    "type": "text",
    "raw_text": "Retinoblastoma\n1.12.2 Consider referral for ophthalmological assessment using a suspected cancer\npathway referral for retinoblastoma in children with an absent fundal ('red') reflex.\nIf there is new-onset squint that occurs together with an absent fundal ('red')\nreflex, see the recommendation on new-onset squint with loss of fundal 'red'\nreflex in NICE's guideline on suspected neurological conditions. [2015]\nWilms' tumour\n1.12.3 Consider very urgent referral (for an appointment within 48 hours) for specialist\n\nThis chunk provides specific guidance on when to suspect and refer children for retinoblastoma (eye cancer) or Wilms' tumour (kidney cancer), both of which are childhood cancers, ensuring prompt specialist assessment. It emphasizes urgent action for potentially serious conditions in young patients."
  },
  {
    "element_id": "page_31_seq_0",
    "page_number": 31,
    "type": "text",
    "raw_text": "assessment for Wilms' tumour in children with any of the following:\n• a palpable abdominal mass\n• an unexplained enlarged abdominal organ\n• unexplained visible haematuria. [2015]\n1.13 Non-site-specific symptoms\nSome symptoms or symptom combinations may be features of several different cancers.\nFor some of these symptoms, the risk for each individual cancer may be low but the total\nrisk of cancer of any type may be higher. This section includes recommendations for these\nsymptoms.\nSymptoms of concern in children and young people\n1.13.1 Take into account the insight and knowledge of parents and carers when\nconsidering making a referral for suspected cancer in a child or young person.\nConsider referral for children if their parent or carer has persistent concern or\nanxiety about the child's symptoms, even if the symptoms are most likely to have\na benign cause. [2015]\nSymptoms of concern in adults\n1.13.2 For people with unexplained weight loss, which is a symptom of several cancers\n\nThis excerpt from the NICE guideline provides specific recommendations for the assessment and referral of children with suspected Wilms' tumor, and highlights the importance of considering parental concerns when evaluating children and young people for potential cancer. It also transitions into a broader discussion of non-site-specific symptoms that may indicate cancer in adults."
  },
  {
    "element_id": "page_31_seq_0",
    "page_number": 31,
    "type": "text",
    "raw_text": "1.13.2 For people with unexplained weight loss, which is a symptom of several cancers\nincluding colorectal, gastro-oesophageal, lung, prostate, pancreatic and\nurological cancer:\n• carry out an assessment for additional symptoms, signs or findings that may\nhelp to clarify which cancer is most likely and\n• offer urgent investigation or a suspected cancer pathway referral. [2015]\n1.13.3 For people with unexplained appetite loss, which is a symptom of several cancers\nincluding lung, oesophageal, stomach, colorectal, pancreatic, bladder and renal\n\nThis section provides guidance on managing patients with non-site-specific symptoms like unexplained weight loss or appetite loss, which can be indicative of several different cancers. It emphasizes the importance of assessing for other clues to identify the most likely cancer and offering urgent investigation or referral, reflecting that while individual cancer risks might be low, the overall risk of cancer warrants prompt attention."
  },
  {
    "element_id": "page_32_seq_0",
    "page_number": 32,
    "type": "text",
    "raw_text": "cancer:\n• carry out an assessment for additional symptoms, signs or findings that may\nhelp to clarify which cancer is most likely and\n• offer urgent investigation or a suspected cancer pathway referral. [2015]\n1.13.4 For people with deep vein thrombosis, which is associated with several cancers\nincluding urogenital, breast, colorectal and lung cancer:\n• carry out an assessment for additional symptoms, signs or findings that may\nhelp to clarify which cancer is most likely and\n• consider urgent investigation or a suspected cancer pathway referral. [2015]\n\nThis chunk of the NICE guideline addresses the management of patients presenting with deep vein thrombosis (DVT), emphasizing the importance of assessing for underlying cancers and considering urgent investigations or referral due to the association between DVT and various malignancies. It aims to guide healthcare professionals in identifying potential cancer cases presenting with DVT, ensuring timely evaluation and intervention."
  },
  {
    "element_id": "page_33_seq_0",
    "page_number": 33,
    "type": "text",
    "raw_text": "Recommendations on patient support,\nsafety netting and the diagnostic process\nUse this guideline to guide referrals. If still uncertain about whether a referral is\nneeded, consider contacting a specialist (see the recommendations on the diagnostic\nprocess). Consider a review for people with any symptom associated with increased\ncancer risk who do not meet the criteria for referral or investigative action (see the\nrecommendations on safety netting).\n1.14 Patient information and support\n1.14.1 Discuss with people with suspected cancer (and their carers, as appropriate,\ntaking account of the need for confidentiality) their preferences for being\ninvolved in decision-making about referral options and further investigations\nincluding their potential risks and benefits. [2015]\n1.14.2 When cancer is suspected in a child, discuss the referral decision and information\nto be given to the child with the parents or carers (and the child if appropriate).\n[2015]\n\nThis section emphasizes the importance of patient-centered care, highlighting the need for healthcare professionals to involve patients and their carers in decision-making regarding referrals and investigations for suspected cancer while respecting confidentiality and individual preferences. It stresses the need to provide tailored information and support throughout the diagnostic process."
  },
  {
    "element_id": "page_33_seq_0",
    "page_number": 33,
    "type": "text",
    "raw_text": "to be given to the child with the parents or carers (and the child if appropriate).\n[2015]\n1.14.3 Explain to people who are being referred with suspected cancer that they are\nbeing referred to a cancer service. Reassure them, as appropriate, that most\npeople referred will not have a diagnosis of cancer, and discuss alternative\ndiagnoses with them. [2015]\n1.14.4 Give the person information on the possible diagnosis (both benign and\nmalignant) in accordance with their wishes for information (see also NICE's\nguideline on patient experience in adult NHS services). [2015]\n1.14.5 The information given to people with suspected cancer and their families and/or\ncarers should cover, among other issues:\n• where the person is being referred to\n\nThis section of the NICE guideline focuses on providing information and support to patients (and their families/carers) who are suspected of having cancer, emphasizing clear communication about the referral process, potential diagnoses, and available resources to alleviate anxiety and facilitate informed decision-making. It highlights the importance of tailoring information to the individual's needs, preferences, and cultural background."
  },
  {
    "element_id": "page_34_seq_0",
    "page_number": 34,
    "type": "text",
    "raw_text": "• how long they will have to wait for the appointment\n• how to obtain further information about the type of cancer suspected or help\nbefore the specialist appointment\n• what to expect from the service the person will be attending\n• what type of tests may be carried out, and what will happen during\ndiagnostic procedures\n• how long it will take to get a diagnosis or test results\n• whether they can take someone with them to the appointment\n• who to contact if they do not receive confirmation of an appointment\n• other sources of support. [2015]\n1.14.6 Provide information that is appropriate for the person in terms of language, ability\nand culture, recognising the potential for different cultural meanings associated\nwith the possibility of cancer. [2015]\n1.14.7 Have information available in a variety of formats on both local and national\nsources of information and support for people who are being referred with\nsuspected cancer. For more information on information sharing, see the section\n\nThis chunk, specifically recommendations 1.14.5 through 1.14.7, details the essential information and support that healthcare professionals should provide to individuals suspected of having cancer and their families, emphasizing clarity, accessibility, and cultural sensitivity in communication to reduce anxiety and empower informed decision-making. This is part of a larger section that gives recommendations on patient support, safety netting and the diagnostic process."
  },
  {
    "element_id": "page_34_seq_0",
    "page_number": 34,
    "type": "text",
    "raw_text": "suspected cancer. For more information on information sharing, see the section\non enabling patients to actively participate in their care in NICE's guideline on\npatient experience in adult NHS services. [2015]\n1.14.8 Reassure people in the safety netting group (see recommendation 1.15.2) who are\nconcerned that they may have cancer that with their current symptoms their risk\nof having cancer is low. [2015]\n1.14.9 Explain to people who are being offered safety netting (see\nrecommendation 1.15.2) which symptoms to look out for and when they should\nreturn for re-evaluation. It may be appropriate to provide written information.\n[2015]\n1.14.10 When referring a person with suspected cancer to a specialist service, assess\ntheir need for continuing support while waiting for their referral appointment. This\n\nThis chunk focuses on providing appropriate information and reassurance to patients throughout the cancer referral process, particularly those undergoing safety netting, ensuring they understand their risk, what to watch for, and available support. This aims to empower patients and manage their expectations while awaiting specialist appointments or undergoing active monitoring for potential cancer symptoms."
  },
  {
    "element_id": "page_35_seq_0",
    "page_number": 35,
    "type": "text",
    "raw_text": "should include inviting the person to contact their healthcare professional again if\nthey have more concerns or questions before they see a specialist. [2005]\n1.14.11 If the person has additional support needs because of their personal\ncircumstances, inform the specialist (with the person's agreement). [2005]\n1.15 Safety netting\n1.15.1 Ensure that the results of investigations are reviewed and acted upon\nappropriately, with the healthcare professional who ordered the investigation\ntaking or explicitly passing on responsibility for this. Be aware of the possibility of\nfalse-negative results for chest X-rays and tests for occult blood in faeces.\n[2015]\n1.15.2 Consider a review for people with any symptom that is associated with an\nincreased risk of cancer, but who do not meet the criteria for referral or other\ninvestigative action. The review may be:\n• planned within a time frame agreed with the person or\n• patient-initiated if new symptoms develop, the person continues to be\n\nThis chunk focuses on patient support and safety netting, emphasizing the importance of ongoing communication, addressing individual support needs, and proactive monitoring of patients who don't immediately qualify for referral to ensure timely intervention if their condition changes. It aims to improve the patient experience, ensure that important information is not missed, and prevent delays in diagnosis."
  },
  {
    "element_id": "page_35_seq_0",
    "page_number": 35,
    "type": "text",
    "raw_text": "• patient-initiated if new symptoms develop, the person continues to be\nconcerned, or their symptoms recur, persist or worsen. [2015]\n1.16 The diagnostic process\n1.16.1 Take part in continuing education, peer review and other activities to improve and\nmaintain clinical consulting, reasoning and diagnostic skills, in order to identify at\nan early stage people who may have cancer, and to communicate the possibility\nof cancer to the person. [2005]\n1.16.2 Discussion with a specialist (for example, by telephone or email) should be\nconsidered if there is uncertainty about the interpretation of symptoms and signs,\nand whether a referral is needed. This may also enable the primary healthcare\nprofessional to communicate their concerns and a sense of urgency to secondary\nhealthcare professionals when symptoms are not classical. [2005]\n\nThis chunk focuses on safety netting and the diagnostic process, emphasizing the importance of ongoing monitoring of patients who don't initially meet referral criteria but have concerning symptoms, as well as continuous professional development and specialist consultation to improve diagnostic accuracy and ensure timely referrals when needed. It aims to provide guidance to healthcare professionals to ensure that patients with potential cancer symptoms are not missed and receive appropriate care."
  },
  {
    "element_id": "page_36_seq_0",
    "page_number": 36,
    "type": "text",
    "raw_text": "1.16.3 Put in place local arrangements to ensure that letters about non-urgent referrals\nare assessed by the specialist, so that the person can be seen more urgently if\nnecessary. [2005]\n1.16.4 Put in place local arrangements to ensure that there is a maximum waiting period\nfor non-urgent referrals, in accordance with national targets and local\narrangements. [2005]\n1.16.5 Ensure local arrangements are in place to identify people who miss their\nappointments so that they can be followed up. [2005]\n1.16.6 Include all appropriate information in referral correspondence, including whether\nthe referral is urgent or non-urgent. [2005]\n1.16.7 Use local referral proformas if these are in use. [2005]\n1.16.8 Once the decision to refer has been made, make sure that the referral is made\nwithin 1 working day. [2005]\n\nThis chunk outlines crucial local arrangements and responsibilities for healthcare providers to ensure timely and appropriate management of suspected cancer referrals, emphasizing efficient processing, monitoring, and communication within the diagnostic process, particularly for non-urgent cases. These recommendations aim to expedite specialist review when necessary and prevent patients from being lost in the system, supporting earlier diagnosis and improved patient care."
  },
  {
    "element_id": "page_37_seq_0",
    "page_number": 37,
    "type": "text",
    "raw_text": "Recommendations organised by symptom\nand findings of primary care\ninvestigations\nThe recommendations in this section are displayed alphabetically by symptom then in\norder of urgency of the action needed, to make sure that the most urgent actions are not\nmissed. Where there are several recommendations relating to the same cancer these have\nbeen grouped for ease of reference. Occasionally the same symptom may suggest more\nthan 1 cancer site. In such instances, the recommendations are displayed together and the\nGP should use their clinical judgement to decide on the most appropriate action.\nUse this guideline to guide referrals. If still uncertain about whether a referral is\nneeded, consider contacting a specialist (see the recommendations on the diagnostic\nprocess). Consider a review for people with any symptom associated with increased\ncancer risk who do not meet the criteria for referral or investigative action (see the\nrecommendations on safety netting).\nAbdominal symptoms\n\nThis section provides a structured guide for healthcare professionals, specifically GPs, on how to assess and manage patients presenting with symptoms potentially indicative of cancer, focusing on recommendations organized by symptom and primary care investigation findings. It emphasizes a symptom-based approach to referral decisions, with consideration of the urgency of the situation, the potential for multiple cancer sites, and the need for clinical judgment."
  },
  {
    "element_id": "page_37_seq_0",
    "page_number": 37,
    "type": "text",
    "raw_text": "recommendations on safety netting).\nAbdominal symptoms\nSee also the section on bleeding for recommendations on rectal bleeding.\n\nThis chunk introduces the section on abdominal symptoms, emphasizing that the guideline provides recommendations based on specific symptoms. It also directs the reader to another section for information about rectal bleeding, a symptom potentially related to abdominal issues but addressed separately."
  },
  {
    "element_id": "page_38_seq_0",
    "page_number": 38,
    "type": "text",
    "raw_text": "Abdominal distension\nPossible\nSymptom and specific features Recommendation\ncancer\nCarry out tests in primary care\n[1.5.2]\nMeasure serum CA125 in primary\nAbdominal distension (persistent or care [1.5.6]\nfrequent – particularly more than 12 times See the section on primary care\nOvarian\nper month) in women, especially if 50 and investigations for more\nover information on tests for ovarian\ncancer\nThese recommendations apply\nto women aged 18 and over\nAbdominal examination findings\nPossible\nSymptoms and signs Recommendation\ncancer\nRefer women using a\nsuspected cancer\nAscites and/or a pelvic or abdominal mass\npathway referral [1.5.1]\nidentified by physical examination (which is not Ovarian\nThese recommendations\nobviously uterine fibroids) in women\napply to women aged\n18 and over\nAbdominal, pelvic or rectal mass or enlarged abdominal organ\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nAbdominal or pelvic\nmass identified by Refer women using a suspected cancer\n\nThis chunk of the NICE guideline provides recommendations for suspected cancer referrals based on abdominal symptoms and examination findings, specifically focusing on ovarian cancer in women and colorectal cancer based on physical examination. It guides healthcare professionals on appropriate actions, including primary care tests, suspected cancer pathway referrals, and quantitative faecal immunochemical testing (FIT), based on specific symptoms and examination findings, aiding in early cancer detection."
  },
  {
    "element_id": "page_38_seq_0",
    "page_number": 38,
    "type": "text",
    "raw_text": "features\nAbdominal or pelvic\nmass identified by Refer women using a suspected cancer\nphysical examination pathway referral [1.5.1]\nOvarian\n(which is not These recommendations apply to women aged\nobviously uterine 18 and over\nfibroids) in women\nOffer quantitative faecal immunochemical\nAbdominal mass Colorectal\ntesting [1.3.1]\nConsider a suspected cancer pathway referral\nRectal mass Colorectal\n[1.3.5]\n\nThis excerpt from the NICE guideline provides specific recommendations for when to refer patients with abdominal, pelvic, or rectal masses for suspected ovarian or colorectal cancer. It emphasizes the importance of physical examination and quantitative fecal immunochemical testing (FIT) in guiding referral decisions, and clarifies that women with ascites and/or a pelvic or abdominal mass (which is not obviously uterine fibroids) should be referred using a suspected cancer pathway."
  },
  {
    "element_id": "page_38",
    "page_number": 38,
    "type": "table",
    "raw_text": "Table 1 on Page 38\n\n| Symptom and specific features              | Possible   | Recommendation                   |\n|                                            | cancer     |                                  |\n|:-------------------------------------------|:-----------|:---------------------------------|\n| Abdominal distension (persistent or        | Ovarian    | Carry out tests in primary care  |\n| frequent – particularly more than 12 times |            | [1.5.2]                          |\n| per month) in women, especially if 50 and  |            | Measure serum CA125 in primary   |\n| over                                       |            | care [1.5.6]                     |\n|                                            |            | See the section on primary care  |\n|                                            |            | investigations for more          |\n|                                            |            | information on tests for ovarian |\n|                                            |            | cancer                           |\n|                                            |            | These recommendations apply      |\n|                                            |            | to women aged 18 and over        |\n\nTitle: Ovarian Cancer - Abdominal Distension | Summary: This table provides recommendations for primary care physicians regarding further action if a woman, particularly if over 50, presents with persistent or frequent abdominal distension (more than 12 times a month), a symptom that may indicate ovarian cancer. The recommendations include carrying out tests in primary care and measuring serum CA125 levels.",
    "table_summary": "Title: Ovarian Cancer - Abdominal Distension | Summary: This table provides recommendations for primary care physicians regarding further action if a woman, particularly if over 50, presents with persistent or frequent abdominal distension (more than 12 times a month), a symptom that may indicate ovarian cancer. The recommendations include carrying out tests in primary care and measuring serum CA125 levels."
  },
  {
    "element_id": "page_38",
    "page_number": 38,
    "type": "table",
    "raw_text": "Table 2 on Page 38\n\n| Symptoms and signs                               | Possible   | Recommendation           |\n|                                                  | cancer     |                          |\n|:-------------------------------------------------|:-----------|:-------------------------|\n| Ascites and/or a pelvic or abdominal mass        | Ovarian    | Refer women using a      |\n| identified by physical examination (which is not |            | suspected cancer         |\n| obviously uterine fibroids) in women             |            | pathway referral [1.5.1] |\n|                                                  |            | These recommendations    |\n|                                                  |            | apply to women aged      |\n|                                                  |            | 18 and over              |\n\nTitle: Ovarian Cancer Referral Criteria Based on Abdominal Examination Findings | Summary: This table outlines the criteria for referring women with suspected ovarian cancer based on the presence of ascites and/or a pelvic or abdominal mass identified during physical examination. It specifies that the recommendations apply to women aged 18 and over.",
    "table_summary": "Title: Ovarian Cancer Referral Criteria Based on Abdominal Examination Findings | Summary: This table outlines the criteria for referring women with suspected ovarian cancer based on the presence of ascites and/or a pelvic or abdominal mass identified during physical examination. It specifies that the recommendations apply to women aged 18 and over."
  },
  {
    "element_id": "page_38",
    "page_number": 38,
    "type": "table",
    "raw_text": "Table 3 on Page 38\n\n| Symptom and specific   | Possible cancer   | Recommendation                               |\n| features               |                   |                                              |\n|:-----------------------|:------------------|:---------------------------------------------|\n| Abdominal or pelvic    | Ovarian           | Refer women using a suspected cancer         |\n| mass identified by     |                   | pathway referral [1.5.1]                     |\n| physical examination   |                   | These recommendations apply to women aged    |\n| (which is not          |                   | 18 and over                                  |\n| obviously uterine      |                   |                                              |\n| fibroids) in women     |                   |                                              |\n| Abdominal mass         | Colorectal        | Offer quantitative faecal immunochemical     |\n|                        |                   | testing [1.3.1]                              |\n| Rectal mass            | Colorectal        | Consider a suspected cancer pathway referral |\n|                        |                   | [1.3.5]                                      |\n\nTitle: Abdominal, Pelvic, or Rectal Masses and Suspected Cancers | Summary: This table lists recommendations for suspected cancers (Ovarian and Colorectal) based on abdominal, pelvic, or rectal masses identified during physical examination, including whether to offer a suspected cancer pathway referral or quantitative faecal immunochemical testing.",
    "table_summary": "Title: Abdominal, Pelvic, or Rectal Masses and Suspected Cancers | Summary: This table lists recommendations for suspected cancers (Ovarian and Colorectal) based on abdominal, pelvic, or rectal masses identified during physical examination, including whether to offer a suspected cancer pathway referral or quantitative faecal immunochemical testing."
  },
  {
    "element_id": "page_39_seq_0",
    "page_number": 39,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account\nany associated symptoms, particularly fever,\nnight sweats, shortness of breath, pruritus or\nSplenomegaly weight loss [1.10.6]\nNon-Hodgkin's\n(unexplained) in Separate recommendations have been made for\nlymphoma\nadults adults and for children and young people to\nreflect that there are different referral\npathways. In practice young people (aged 16 to\n24) may be referred using either pathway\ndepending on their age and local arrangements\nUpper abdominal\nConsider a suspected cancer pathway referral\nmassconsistent with Stomach\n[1.2.6]\nstomach cancer\nUpper abdominal\nmassconsistent with Consider an urgent direct access ultrasound\nGall bladder\nan enlarged gall scan (to be done within 2 weeks) [1.2.10]\nbladder\nUpper abdominal\nConsider an urgent direct access ultrasound\nmassconsistent with Liver\nscan (to be done within 2 weeks) [1.2.11]\n\nThis excerpt from the NICE guideline provides specific recommendations for referral actions based on different abdominal symptoms, helping healthcare professionals determine the appropriate pathway (suspected cancer pathway referral, urgent scan, etc.) for adults presenting with these symptoms in order to assess the possibility of underlying cancers like Non-Hodgkin's lymphoma, stomach, gall bladder, or liver cancer. It emphasizes considering associated symptoms and age-related factors for a more comprehensive assessment."
  },
  {
    "element_id": "page_39_seq_0",
    "page_number": 39,
    "type": "text",
    "raw_text": "massconsistent with Liver\nscan (to be done within 2 weeks) [1.2.11]\nan enlarged liver\nConsider a very urgent full blood count (within\nHepatosplenomegaly Leukaemia\n48 hours) [1.10.1]\nAbdominal or pelvic pain\nSymptom and specific features Possible cancer Recommendation\nAbdominal pain with weight loss Offer quantitative faecal\nColorectal\n(unexplained), 40 and over immunochemical testing [1.3.1]\nAbdominal pain (unexplained)\nOffer quantitative faecal\nwith rectal bleeding in adults Colorectal\nimmunochemical testing [1.3.1]\nunder 50\nAbdominal pain (unexplained), Offer quantitative faecal\nColorectal\n50 and over immunochemical testing [1.3.1]\n\nThis section of the guideline provides recommendations for investigating potential cancers based on abdominal symptoms, specifically guiding healthcare professionals on appropriate actions like offering specific tests or considering urgent referrals based on the symptom and associated factors. It helps in the early identification of potential cancers, such as colorectal, liver, and leukemia, based on abdominal presentations."
  },
  {
    "element_id": "page_39",
    "page_number": 39,
    "type": "table",
    "raw_text": "Table 1 on Page 39\n\n| Symptom and specific   | Possible cancer   | Recommendation                                  |\n| features               |                   |                                                 |\n|:-----------------------|:------------------|:------------------------------------------------|\n| Splenomegaly           | Non-Hodgkin's     | Consider a suspected cancer pathway referral.   |\n| (unexplained) in       | lymphoma          | When considering referral, take into account    |\n| adults                 |                   | any associated symptoms, particularly fever,    |\n|                        |                   | night sweats, shortness of breath, pruritus or  |\n|                        |                   | weight loss [1.10.6]                            |\n|                        |                   | Separate recommendations have been made for     |\n|                        |                   | adults and for children and young people to     |\n|                        |                   | reflect that there are different referral       |\n|                        |                   | pathways. In practice young people (aged 16 to  |\n|                        |                   | 24) may be referred using either pathway        |\n|                        |                   | depending on their age and local arrangements   |\n| Upper abdominal        | Stomach           | Consider a suspected cancer pathway referral    |\n| massconsistent with    |                   | [1.2.6]                                         |\n| stomach cancer         |                   |                                                 |\n| Upper abdominal        | Gall bladder      | Consider an urgent direct access ultrasound     |\n| massconsistent with    |                   | scan (to be done within 2 weeks) [1.2.10]       |\n| an enlarged gall       |                   |                                                 |\n| bladder                |                   |                                                 |\n| Upper abdominal        | Liver             | Consider an urgent direct access ultrasound     |\n| massconsistent with    |                   | scan (to be done within 2 weeks) [1.2.11]       |\n| an enlarged liver      |                   |                                                 |\n| Hepatosplenomegaly     | Leukaemia         | Consider a very urgent full blood count (within |\n|                        |                   | 48 hours) [1.10.1]                              |\n\nTitle: Abdominal, Pelvic or Rectal Mass or Enlarged Abdominal Organ | Summary: This table lists abdominal symptoms, their specific features, and related recommendations for possible cancers, including ovarian, colorectal, stomach, gall bladder, liver, and leukemia. It outlines the recommended actions, such as quantitative faecal immunochemical testing, suspected cancer pathway referrals, urgent direct access ultrasound scans, and urgent full blood counts.",
    "table_summary": "Title: Abdominal, Pelvic or Rectal Mass or Enlarged Abdominal Organ | Summary: This table lists abdominal symptoms, their specific features, and related recommendations for possible cancers, including ovarian, colorectal, stomach, gall bladder, liver, and leukemia. It outlines the recommended actions, such as quantitative faecal immunochemical testing, suspected cancer pathway referrals, urgent direct access ultrasound scans, and urgent full blood counts."
  },
  {
    "element_id": "page_39",
    "page_number": 39,
    "type": "table",
    "raw_text": "Table 2 on Page 39\n\n| Symptom and specific features   | Possible cancer   | Recommendation                 |\n|:--------------------------------|:------------------|:-------------------------------|\n| Abdominal pain with weight loss | Colorectal        | Offer quantitative faecal      |\n| (unexplained), 40 and over      |                   | immunochemical testing [1.3.1] |\n| Abdominal pain (unexplained)    | Colorectal        | Offer quantitative faecal      |\n| with rectal bleeding in adults  |                   | immunochemical testing [1.3.1] |\n| under 50                        |                   |                                |\n| Abdominal pain (unexplained),   | Colorectal        | Offer quantitative faecal      |\n| 50 and over                     |                   | immunochemical testing [1.3.1] |\n\nTitle: Abdominal, Pelvic or Rectal Mass or Enlarged Abdominal Organ | Summary: This table outlines recommendations for quantitative faecal immunochemical testing (FIT) based on abdominal pain and weight loss in individuals over 40, abdominal pain with rectal bleeding in adults under 50, and abdominal pain in individuals over 50, all of which could indicate colorectal cancer.",
    "table_summary": "Title: Abdominal, Pelvic or Rectal Mass or Enlarged Abdominal Organ | Summary: This table outlines recommendations for quantitative faecal immunochemical testing (FIT) based on abdominal pain and weight loss in individuals over 40, abdominal pain with rectal bleeding in adults under 50, and abdominal pain in individuals over 50, all of which could indicate colorectal cancer."
  },
  {
    "element_id": "page_40_seq_0",
    "page_number": 40,
    "type": "text",
    "raw_text": "Symptom and specific features Possible cancer Recommendation\nUpper abdominal pain with Oesophageal Refer using a suspected cancer\nweight loss, 55 and over or stomach pathway referral [1.2.1] [1.2.7]\nUpper abdominal pain with low\nConsider non-urgent, direct access\nhaemoglobin levels or raised Oesophageal\nupper gastrointestinal endoscopy\nplatelet count or nausea or or stomach\n[1.2.3] [1.2.9]\nvomiting, 55 and over\nCarry out tests in primary care [1.5.2]\nMeasure serum CA125 in primary\nAbdominal or pelvic pain\ncare [1.5.6]\n(persistent or frequent –\nSee the section on primary care\nparticularly more than 12 times Ovarian\ninvestigations for more information\nper month) in women, especially if\non tests for ovarian cancer\n50 and over\nThese recommendations apply to\nwomen aged 18 and over\nConsider an urgent, direct access CT\nAbdominal pain with weight loss, scan (to be done within 2 weeks), or\nPancreatic\n60 and over an urgent ultrasound scan if CT is not\navailable [1.2.5]\n\nThis chunk from the NICE guideline provides specific recommendations for investigating abdominal pain based on accompanying symptoms and patient characteristics. It helps healthcare professionals determine the appropriate course of action, such as referral or further investigation, based on the likelihood of different cancers."
  },
  {
    "element_id": "page_40_seq_0",
    "page_number": 40,
    "type": "text",
    "raw_text": "Pancreatic\n60 and over an urgent ultrasound scan if CT is not\navailable [1.2.5]\nCarry out appropriate tests for\novarian cancer, because irritable\nbowel syndrome rarely presents for\nthe first time in women of this age\n[1.5.5]\nMeasure serum CA125 in primary\nIrritable bowel syndrome\ncare [1.5.6]\nsymptoms within the last Ovarian\nSee the section on primary care\n12 months in women 50 and over\ninvestigations for more information\non tests for ovarian cancer\nThese recommendations apply to\nwomen aged 18 and over\nAlso see the NICE guideline on\nirritable bowel syndrome in adults.\n\nThis excerpt, found in the \"Recommendations organised by symptom and findings of primary care investigations\" section, provides guidance on when to consider testing for pancreatic or ovarian cancer based on specific abdominal symptoms and age, emphasizing the importance of considering ovarian cancer even when symptoms resemble irritable bowel syndrome in older women. It aims to direct appropriate investigations based on specific symptoms and age groups."
  },
  {
    "element_id": "page_40",
    "page_number": 40,
    "type": "table",
    "raw_text": "Table 1 on Page 40\n\n| Symptom and specific features      | Possible cancer   | Recommendation                          |\n|:-----------------------------------|:------------------|:----------------------------------------|\n| Upper abdominal pain with          | Oesophageal       | Refer using a suspected cancer          |\n| weight loss, 55 and over           | or stomach        | pathway referral [1.2.1] [1.2.7]        |\n| Upper abdominal pain with low      | Oesophageal       | Consider non-urgent, direct access      |\n| haemoglobin levels or raised       | or stomach        | upper gastrointestinal endoscopy        |\n| platelet count or nausea or        |                   | [1.2.3] [1.2.9]                         |\n| vomiting, 55 and over              |                   |                                         |\n| Abdominal or pelvic pain           | Ovarian           | Carry out tests in primary care [1.5.2] |\n| (persistent or frequent –          |                   | Measure serum CA125 in primary          |\n| particularly more than 12 times    |                   | care [1.5.6]                            |\n| per month) in women, especially if |                   | See the section on primary care         |\n| 50 and over                        |                   | investigations for more information     |\n|                                    |                   | on tests for ovarian cancer             |\n|                                    |                   | These recommendations apply to          |\n|                                    |                   | women aged 18 and over                  |\n| Abdominal pain with weight loss,   | Pancreatic        | Consider an urgent, direct access CT    |\n| 60 and over                        |                   | scan (to be done within 2 weeks), or    |\n|                                    |                   | an urgent ultrasound scan if CT is not  |\n|                                    |                   | available [1.2.5]                       |\n| Irritable bowel syndrome           | Ovarian           | Carry out appropriate tests for         |\n| symptoms within the last           |                   | ovarian cancer, because irritable       |\n| 12 months in women 50 and over     |                   | bowel syndrome rarely presents for      |\n|                                    |                   | the first time in women of this age     |\n|                                    |                   | [1.5.5]                                 |\n|                                    |                   | Measure serum CA125 in primary          |\n|                                    |                   | care [1.5.6]                            |\n|                                    |                   | See the section on primary care         |\n|                                    |                   | investigations for more information     |\n|                                    |                   | on tests for ovarian cancer             |\n|                                    |                   | These recommendations apply to          |\n|                                    |                   | women aged 18 and over                  |\n|                                    |                   | Also see the NICE guideline on          |\n|                                    |                   | irritable bowel syndrome in adults.     |\n\nTitle: Table 1 - Abdominal or Pelvic Pain and Possible Cancer | Summary: This table provides recommendations for action based on upper abdominal, abdominal or pelvic pain in adults, in which cancer may be suspected. It lists specific features, possible cancers and the recommended action for each scenario, including referrals, blood tests and scans.",
    "table_summary": "Title: Table 1 - Abdominal or Pelvic Pain and Possible Cancer | Summary: This table provides recommendations for action based on upper abdominal, abdominal or pelvic pain in adults, in which cancer may be suspected. It lists specific features, possible cancers and the recommended action for each scenario, including referrals, blood tests and scans."
  },
  {
    "element_id": "page_41_seq_0",
    "page_number": 41,
    "type": "text",
    "raw_text": "Change in bowel habit\nPossible\nSymptom and specific features Recommendation\ncancer\nOffer quantitative faecal immunochemical\nChange in bowel habit Colorectal\ntesting [1.3.1]\nConsider carrying out tests in primary care\n[1.5.3]\nMeasure serum CA125 in primary care [1.5.6]\nChange in bowel habit\nOvarian See the section on primary care investigations\n(unexplained) in women\nfor information on tests for ovarian cancer\nThese recommendations apply to women\naged 18 and over\nDiarrhoea or constipation Consider an urgent, direct access CT scan (to\nwith weight loss, 60 and Pancreatic be done within 2 weeks), or an urgent\nover ultrasound scan if CT is not available [1.2.5]\nCarry out appropriate tests for ovarian cancer,\nbecause irritable bowel syndrome rarely\npresents for the first time in women of this\nage [1.5.5]\nMeasure serum CA125 in primary care [1.5.6]\nIrritable bowel syndrome\nsymptoms within the last See the section on primary care investigations\nOvarian\n\nThis section of the NICE guideline provides recommendations for investigating potential cancers based on the symptom of a change in bowel habit, including specific guidance for colorectal, ovarian, and pancreatic cancers, with a focus on appropriate testing and imaging referrals. It helps healthcare professionals determine the next steps in diagnosing cancer when a patient presents with this symptom."
  },
  {
    "element_id": "page_41_seq_0",
    "page_number": 41,
    "type": "text",
    "raw_text": "symptoms within the last See the section on primary care investigations\nOvarian\n12 months, in women for more information about tests for ovarian\n50 and over cancer\nThese recommendations apply to women\naged 18 and over\nAlso see the NICE guideline on irritable bowel\nsyndrome in adults\nDyspepsia\nSymptom and specific features Possible cancer Recommendation\nConsider non-urgent, direct access\nDyspepsia (treatment-resistant), Oesophageal\nupper gastrointestinal endoscopy\n55 and over or stomach\n[1.2.3] [1.2.9]\n\nThis excerpt from the NICE guideline provides specific recommendations for referral and investigation of potential ovarian, oesophageal, and stomach cancers based on patient symptoms and age, highlighting the importance of considering these cancers in individuals presenting with certain gastrointestinal issues, particularly older women and those with persistent dyspepsia. It guides healthcare professionals in primary care to determine appropriate next steps, which may include specific tests or referral for further evaluation."
  },
  {
    "element_id": "page_41",
    "page_number": 41,
    "type": "table",
    "raw_text": "Table 1 on Page 41\n\n| Symptom and specific features   | Possible   | Recommendation                                  |\n|                                 | cancer     |                                                 |\n|:--------------------------------|:-----------|:------------------------------------------------|\n| Change in bowel habit           | Colorectal | Offer quantitative faecal immunochemical        |\n|                                 |            | testing [1.3.1]                                 |\n| Change in bowel habit           | Ovarian    | Consider carrying out tests in primary care     |\n| (unexplained) in women          |            | [1.5.3]                                         |\n|                                 |            | Measure serum CA125 in primary care [1.5.6]     |\n|                                 |            | See the section on primary care investigations  |\n|                                 |            | for information on tests for ovarian cancer     |\n|                                 |            | These recommendations apply to women            |\n|                                 |            | aged 18 and over                                |\n| Diarrhoea or constipation       | Pancreatic | Consider an urgent, direct access CT scan (to   |\n| with weight loss, 60 and        |            | be done within 2 weeks), or an urgent           |\n| over                            |            | ultrasound scan if CT is not available [1.2.5]  |\n| Irritable bowel syndrome        | Ovarian    | Carry out appropriate tests for ovarian cancer, |\n| symptoms within the last        |            | because irritable bowel syndrome rarely         |\n| 12 months, in women             |            | presents for the first time in women of this    |\n| 50 and over                     |            | age [1.5.5]                                     |\n|                                 |            | Measure serum CA125 in primary care [1.5.6]     |\n|                                 |            | See the section on primary care investigations  |\n|                                 |            | for more information about tests for ovarian    |\n|                                 |            | cancer                                          |\n|                                 |            | These recommendations apply to women            |\n|                                 |            | aged 18 and over                                |\n|                                 |            | Also see the NICE guideline on irritable bowel  |\n|                                 |            | syndrome in adults                              |\n\nTitle: Change in Bowel Habit Recommendations | Summary: This table summarizes recommendations for investigating changes in bowel habits to detect potential colorectal or ovarian cancer. It includes offering faecal immunochemical testing for colorectal cancer and considering serum CA125 testing for ovarian cancer, particularly in older women presenting with IBS-like symptoms. It also suggests urgent CT or ultrasound scans for pancreatic cancer when diarrhoea or constipation is accompanied by weight loss in older adults.",
    "table_summary": "Title: Change in Bowel Habit Recommendations | Summary: This table summarizes recommendations for investigating changes in bowel habits to detect potential colorectal or ovarian cancer. It includes offering faecal immunochemical testing for colorectal cancer and considering serum CA125 testing for ovarian cancer, particularly in older women presenting with IBS-like symptoms. It also suggests urgent CT or ultrasound scans for pancreatic cancer when diarrhoea or constipation is accompanied by weight loss in older adults."
  },
  {
    "element_id": "page_41",
    "page_number": 41,
    "type": "table",
    "raw_text": "Table 2 on Page 41\n\n| Symptom and specific features    | Possible cancer   | Recommendation                     |\n|:---------------------------------|:------------------|:-----------------------------------|\n| Dyspepsia (treatment-resistant), | Oesophageal       | Consider non-urgent, direct access |\n| 55 and over                      | or stomach        | upper gastrointestinal endoscopy   |\n|                                  |                   | [1.2.3] [1.2.9]                    |\n\nTitle: Dyspepsia and Potential Upper GI Cancers | Summary: This table shows that treatment-resistant dyspepsia in individuals 55 and over could be indicative of oesophageal or stomach cancer, suggesting consideration of a non-urgent, direct access upper gastrointestinal endoscopy.",
    "table_summary": "Title: Dyspepsia and Potential Upper GI Cancers | Summary: This table shows that treatment-resistant dyspepsia in individuals 55 and over could be indicative of oesophageal or stomach cancer, suggesting consideration of a non-urgent, direct access upper gastrointestinal endoscopy."
  },
  {
    "element_id": "page_42_seq_0",
    "page_number": 42,
    "type": "text",
    "raw_text": "Symptom and specific features Possible cancer Recommendation\nDyspepsia\nOesophageal Refer using a suspected cancer\nDyspepsia with weight loss,\nor stomach pathway referral [1.2.1] [1.2.7]\n55 and over\nDyspepsia with raised platelet Consider non-urgent, direct access\nOesophageal\ncount or nausea or vomiting, upper gastrointestinal endoscopy\nor stomach\n55 and over [1.2.3] [1.2.9]\nDysphagia\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nOesophageal or Refer using a suspected cancer pathway\nDysphagia\nstomach referral [1.2.1] [1.2.7]\nNausea or vomiting\nSymptom and specific features Possible cancer Recommendation\nConsider an urgent, direct access\nNausea or vomiting with weight CT scan (to be done within\nPancreatic\nloss, 60 and over 2 weeks), or an urgent ultrasound\nscan if CT is not available [1.2.5]\nNausea or vomiting with raised\nConsider non-urgent, direct access\nplatelet count or weight loss or Oesophageal\nupper gastrointestinal endoscopy\nreflux or dyspepsia or upper or stomach\n\nThis chunk of the document provides specific guidance for healthcare professionals on when to suspect and refer patients for potential oesophageal, stomach, or pancreatic cancer based on symptoms like dyspepsia, dysphagia, nausea, and vomiting. It outlines scenarios that warrant either a suspected cancer pathway referral (urgent) or a non-urgent direct access upper gastrointestinal endoscopy, helping to facilitate timely diagnosis and intervention."
  },
  {
    "element_id": "page_42_seq_0",
    "page_number": 42,
    "type": "text",
    "raw_text": "upper gastrointestinal endoscopy\nreflux or dyspepsia or upper or stomach\n[1.2.3] [1.2.9]\nabdominal pain, 55 and over\nRectal examination findings\nPossible\nSymptom and signs Recommendation\ncancer\nProstate feels malignant on digital Refer men using a suspected cancer\nProstate\nrectal examination, in men pathway referral [1.6.1]\nAnal mass or anal ulceration Consider a suspected cancer\nAnal\n(unexplained) pathway referral [1.3.6]\nConsider a suspected cancer\nRectalmass Colorectal\npathway referral [1.3.5]\n\nThis excerpt provides referral guidance based on specific symptoms and age for potential oesophageal or stomach cancer, as well as referral guidance based on rectal examination findings for potential prostate, anal, or colorectal cancer. It instructs healthcare professionals on when to consider specific actions, such as endoscopy or suspected cancer pathway referrals, based on physical examination findings."
  },
  {
    "element_id": "page_42",
    "page_number": 42,
    "type": "table",
    "raw_text": "Table 1 on Page 42\n\n| Symptom and specific features   | Possible cancer   | Recommendation                     |\n|:--------------------------------|:------------------|:-----------------------------------|\n| Dyspepsia                       | Oesophageal       | Refer using a suspected cancer     |\n| Dyspepsia with weight loss,     | or stomach        | pathway referral [1.2.1] [1.2.7]   |\n| 55 and over                     |                   |                                    |\n| Dyspepsia with raised platelet  | Oesophageal       | Consider non-urgent, direct access |\n| count or nausea or vomiting,    | or stomach        | upper gastrointestinal endoscopy   |\n| 55 and over                     |                   | [1.2.3] [1.2.9]                    |\n\nTitle: Dyspepsia Recommendations | Summary: This table provides guidance on referrals and endoscopies for dyspepsia, considering factors such as age, weight loss, platelet count, nausea, and vomiting, to assess the possibility of oesophageal or stomach cancer.",
    "table_summary": "Title: Dyspepsia Recommendations | Summary: This table provides guidance on referrals and endoscopies for dyspepsia, considering factors such as age, weight loss, platelet count, nausea, and vomiting, to assess the possibility of oesophageal or stomach cancer."
  },
  {
    "element_id": "page_42",
    "page_number": 42,
    "type": "table",
    "raw_text": "Table 2 on Page 42\n\n| Symptom and specific   | Possible cancer   | Recommendation                         |\n| features               |                   |                                        |\n|:-----------------------|:------------------|:---------------------------------------|\n| Dysphagia              | Oesophageal or    | Refer using a suspected cancer pathway |\n|                        | stomach           | referral [1.2.1] [1.2.7]               |\n\nTitle: Table 2: Dysphagia Referral Recommendations | Summary: This table details the recommendation for referral based on the symptom of dysphagia, specifying the possible cancers (Oesophageal or stomach) and the type of referral required: a suspected cancer pathway referral.",
    "table_summary": "Title: Table 2: Dysphagia Referral Recommendations | Summary: This table details the recommendation for referral based on the symptom of dysphagia, specifying the possible cancers (Oesophageal or stomach) and the type of referral required: a suspected cancer pathway referral."
  },
  {
    "element_id": "page_42",
    "page_number": 42,
    "type": "table",
    "raw_text": "Table 3 on Page 42\n\n| Symptom and specific features    | Possible cancer   | Recommendation                      |\n|:---------------------------------|:------------------|:------------------------------------|\n| Nausea or vomiting with weight   | Pancreatic        | Consider an urgent, direct access   |\n| loss, 60 and over                |                   | CT scan (to be done within          |\n|                                  |                   | 2 weeks), or an urgent ultrasound   |\n|                                  |                   | scan if CT is not available [1.2.5] |\n| Nausea or vomiting with raised   | Oesophageal       | Consider non-urgent, direct access  |\n| platelet count or weight loss or | or stomach        | upper gastrointestinal endoscopy    |\n| reflux or dyspepsia or upper     |                   | [1.2.3] [1.2.9]                     |\n| abdominal pain, 55 and over      |                   |                                     |\n\nTitle: Abdominal Symptoms Table: Nausea or Vomiting | Summary: This table provides recommendations for referral or investigation of pancreatic, oesophageal, or stomach cancer based on nausea or vomiting combined with other specific symptoms, primarily in individuals over 55 or 60 years of age.",
    "table_summary": "Title: Abdominal Symptoms Table: Nausea or Vomiting | Summary: This table provides recommendations for referral or investigation of pancreatic, oesophageal, or stomach cancer based on nausea or vomiting combined with other specific symptoms, primarily in individuals over 55 or 60 years of age."
  },
  {
    "element_id": "page_42",
    "page_number": 42,
    "type": "table",
    "raw_text": "Table 4 on Page 42\n\n| Symptom and signs                   | Possible   | Recommendation                     |\n|                                     | cancer     |                                    |\n|:------------------------------------|:-----------|:-----------------------------------|\n| Prostate feels malignant on digital | Prostate   | Refer men using a suspected cancer |\n| rectal examination, in men          |            | pathway referral [1.6.1]           |\n| Anal mass or anal ulceration        | Anal       | Consider a suspected cancer        |\n| (unexplained)                       |            | pathway referral [1.3.6]           |\n| Rectalmass                          | Colorectal | Consider a suspected cancer        |\n|                                     |            | pathway referral [1.3.5]           |\n\nTitle: Rectal Examination Findings | Summary: The table outlines recommendations for suspected cancer pathway referrals based on findings during rectal examinations, specifically addressing malignant prostate feels, unexplained anal masses or ulcerations, and rectal masses.",
    "table_summary": "Title: Rectal Examination Findings | Summary: The table outlines recommendations for suspected cancer pathway referrals based on findings during rectal examinations, specifically addressing malignant prostate feels, unexplained anal masses or ulcerations, and rectal masses."
  },
  {
    "element_id": "page_43_seq_0",
    "page_number": 43,
    "type": "text",
    "raw_text": "Reflux\nSymptom and specific features Possible cancer Recommendation\nReflux with weight loss, 55 and Oesophageal Refer using a suspected cancer\nover or stomach pathway referral [1.2.1] [1.2.7]\nReflux with raised platelet Consider non-urgent, direct access\nOesophageal\ncount or nausea or vomiting, upper gastrointestinal endoscopy\nor stomach\n55 and over [1.2.3] [1.2.9]\nBleeding\nSee also:\n• the section on urological symptoms for haematuria\n• the section on primary care investigations for faecal occult blood.\nBleeding, bruising or petechiae\nPossible\nSymptom and specific features Recommendation\ncancer\nBleeding, bruising or Consider a very urgent full blood count\nLeukaemia\npetechiae (unexplained) (within 48 hours) [1.10.1]\nHaematemesis\nSymptom and\nPossible cancer Recommendation\nspecific features\nOesophageal or Consider non-urgent, direct access upper\nHaematemesis\nstomach gastrointestinal endoscopy [1.2.2] [1.2.8]\nHaemoptysis\nPossible\nSymptom and specific features Recommendation\ncancer\n\nThis chunk provides guidance on when to suspect cancer based on symptoms of reflux, bleeding, bruising, petechiae, haematemesis, and haemoptysis, and it directs healthcare professionals to the appropriate referrals or investigations based on the specific symptoms and patient characteristics. This section is crucial for early cancer detection and appropriate management in primary care."
  },
  {
    "element_id": "page_43_seq_0",
    "page_number": 43,
    "type": "text",
    "raw_text": "Haemoptysis\nPossible\nSymptom and specific features Recommendation\ncancer\nHaemoptysis (unexplained), Refer people using a suspected cancer\nLung\n40 and over pathway referral [1.1.1]\n\nThis section of the NICE guideline provides guidance for healthcare professionals on when to suspect lung cancer based on the symptom of haemoptysis (coughing up blood). It recommends that individuals aged 40 and over with unexplained haemoptysis should be referred using a suspected cancer pathway referral."
  },
  {
    "element_id": "page_43",
    "page_number": 43,
    "type": "table",
    "raw_text": "Table 1 on Page 43\n\n| Symptom and specific features   | Possible cancer   | Recommendation                     |\n|:--------------------------------|:------------------|:-----------------------------------|\n| Reflux with weight loss, 55 and | Oesophageal       | Refer using a suspected cancer     |\n| over                            | or stomach        | pathway referral [1.2.1] [1.2.7]   |\n| Reflux with raised platelet     | Oesophageal       | Consider non-urgent, direct access |\n| count or nausea or vomiting,    | or stomach        | upper gastrointestinal endoscopy   |\n| 55 and over                     |                   | [1.2.3] [1.2.9]                    |\n\nTitle: Reflux Symptoms and Cancer Referral | Summary: This table outlines recommendations for referral and investigation based on reflux symptoms, specifically in relation to potential oesophageal or stomach cancer, considering factors like age, weight loss, platelet count, nausea, and vomiting.",
    "table_summary": "Title: Reflux Symptoms and Cancer Referral | Summary: This table outlines recommendations for referral and investigation based on reflux symptoms, specifically in relation to potential oesophageal or stomach cancer, considering factors like age, weight loss, platelet count, nausea, and vomiting."
  },
  {
    "element_id": "page_43",
    "page_number": 43,
    "type": "table",
    "raw_text": "Table 2 on Page 43\n\n| Symptom and specific features   | Possible   | Recommendation                          |\n|                                 | cancer     |                                         |\n|:--------------------------------|:-----------|:----------------------------------------|\n| Bleeding, bruising or           | Leukaemia  | Consider a very urgent full blood count |\n| petechiae (unexplained)         |            | (within 48 hours) [1.10.1]              |\n\nTitle: Blood related symptoms for Leukaemia | Summary: The table shows that unexplained bleeding, bruising or petechiae may indicate leukaemia, in which case a very urgent full blood count (within 48 hours) should be considered.",
    "table_summary": "Title: Blood related symptoms for Leukaemia | Summary: The table shows that unexplained bleeding, bruising or petechiae may indicate leukaemia, in which case a very urgent full blood count (within 48 hours) should be considered."
  },
  {
    "element_id": "page_43",
    "page_number": 43,
    "type": "table",
    "raw_text": "Table 3 on Page 43\n\n| Symptom and         | Possible cancer   | Recommendation                             |\n| specific features   |                   |                                            |\n|:--------------------|:------------------|:-------------------------------------------|\n| Haematemesis        | Oesophageal or    | Consider non-urgent, direct access upper   |\n|                     | stomach           | gastrointestinal endoscopy [1.2.2] [1.2.8] |\n\nTitle: Haematemesis Recommendations | Summary: This table provides recommendations for managing patients presenting with haematemesis, focusing on the potential for oesophageal or stomach cancer and suggesting non-urgent, direct access upper gastrointestinal endoscopy.",
    "table_summary": "Title: Haematemesis Recommendations | Summary: This table provides recommendations for managing patients presenting with haematemesis, focusing on the potential for oesophageal or stomach cancer and suggesting non-urgent, direct access upper gastrointestinal endoscopy."
  },
  {
    "element_id": "page_43",
    "page_number": 43,
    "type": "table",
    "raw_text": "Table 4 on Page 43\n\n| Symptom and specific features   | Possible   | Recommendation                        |\n|                                 | cancer     |                                       |\n|:--------------------------------|:-----------|:--------------------------------------|\n| Haemoptysis (unexplained),      | Lung       | Refer people using a suspected cancer |\n| 40 and over                     |            | pathway referral [1.1.1]              |\n\nTitle: Haemoptysis Referral Guidelines | Summary: This table outlines the NICE guideline recommendation for referral of patients aged 40 and over with unexplained haemoptysis for suspected lung cancer using a suspected cancer pathway referral.",
    "table_summary": "Title: Haemoptysis Referral Guidelines | Summary: This table outlines the NICE guideline recommendation for referral of patients aged 40 and over with unexplained haemoptysis for suspected lung cancer using a suspected cancer pathway referral."
  },
  {
    "element_id": "page_44_seq_0",
    "page_number": 44,
    "type": "text",
    "raw_text": "Post-menopausal bleeding\nSymptom and specific features Possible cancer Recommendation\nPost-menopausal bleeding in Refer women using a suspected cancer\nEndometrial\nwomen 55 and over pathway referral [1.5.10]\nPost-menopausal bleeding in Consider a suspected cancer pathway\nEndometrial\nwomen under 55 referral [1.5.11]\nPost-menopausal bleeding is unexplained vaginal bleeding more than 12 months after\nmenstruation has stopped because of the menopause.\nRectal bleeding\nPossible\nSymptom and specific features Recommendation\ncancer\nOffer quantitative faecal\nRectal bleeding (unexplained), 50 and over Colorectal immunochemical testing\n[1.3.1]\nOffer quantitative faecal\nRectal bleeding with unexplained abdominal\nColorectal immunochemical testing\npain or weight loss in adults under 50\n[1.3.1]\nVulval bleeding\nPossible\nSymptom and specific features Recommendation\ncancer\nVulval bleeding (unexplained) in Consider a suspected cancer pathway\nVulval\nwomen referral [1.5.14]\nGynaecological symptoms\n\nThis chunk of the NICE guideline focuses on recommendations for suspected cancer pathway referrals and investigations based on bleeding symptoms, specifically post-menopausal, rectal, and vulval bleeding, to aid healthcare professionals in identifying potential endometrial, colorectal, and vulval cancers. It provides specific criteria, including age and associated symptoms, to guide appropriate and timely action."
  },
  {
    "element_id": "page_44_seq_0",
    "page_number": 44,
    "type": "text",
    "raw_text": "Vulval\nwomen referral [1.5.14]\nGynaecological symptoms\nSee also the section on bleeding for post-menopausal (vaginal) bleeding\nGynaecological examination findings\nPossible\nSymptom and signs Recommendation\ncancer\nAppearance of cervixconsistent with Consider a suspected cancer pathway\nCervical\ncervical cancer referral [1.5.13]\n\nThis chunk provides specific recommendations for suspected vulval and cervical cancers based on gynaecological symptoms and examination findings, guiding healthcare professionals on when to consider a suspected cancer pathway referral for further investigation. It emphasizes the importance of recognizing key signs during gynaecological examinations to ensure timely referral and potential diagnosis of these cancers."
  },
  {
    "element_id": "page_44",
    "page_number": 44,
    "type": "table",
    "raw_text": "Table 1 on Page 44\n\n| Symptom and specific features   | Possible cancer   | Recommendation                       |\n|:--------------------------------|:------------------|:-------------------------------------|\n| Post-menopausal bleeding in     | Endometrial       | Refer women using a suspected cancer |\n| women 55 and over               |                   | pathway referral [1.5.10]            |\n| Post-menopausal bleeding in     | Endometrial       | Consider a suspected cancer pathway  |\n| women under 55                  |                   | referral [1.5.11]                    |\n\nTitle: Post-Menopausal Bleeding Recommendations | Summary: This table provides referral guidance based on post-menopausal bleeding symptoms, differentiating recommendations based on the patient's age (55 and over versus under 55) and the associated risk of endometrial cancer.",
    "table_summary": "Title: Post-Menopausal Bleeding Recommendations | Summary: This table provides referral guidance based on post-menopausal bleeding symptoms, differentiating recommendations based on the patient's age (55 and over versus under 55) and the associated risk of endometrial cancer."
  },
  {
    "element_id": "page_44",
    "page_number": 44,
    "type": "table",
    "raw_text": "Table 2 on Page 44\n\n| Symptom and specific features              | Possible   | Recommendation            |\n|                                            | cancer     |                           |\n|:-------------------------------------------|:-----------|:--------------------------|\n| Rectal bleeding (unexplained), 50 and over | Colorectal | Offer quantitative faecal |\n|                                            |            | immunochemical testing    |\n|                                            |            | [1.3.1]                   |\n| Rectal bleeding with unexplained abdominal | Colorectal | Offer quantitative faecal |\n| pain or weight loss in adults under 50     |            | immunochemical testing    |\n|                                            |            | [1.3.1]                   |\n\nTitle: Rectal Bleeding Recommendations | Summary: This table provides recommendations for quantitative faecal immunochemical testing for colorectal cancer in adults presenting with rectal bleeding, with or without other symptoms, based on age.",
    "table_summary": "Title: Rectal Bleeding Recommendations | Summary: This table provides recommendations for quantitative faecal immunochemical testing for colorectal cancer in adults presenting with rectal bleeding, with or without other symptoms, based on age."
  },
  {
    "element_id": "page_44",
    "page_number": 44,
    "type": "table",
    "raw_text": "Table 3 on Page 44\n\n| Symptom and specific features    | Possible   | Recommendation                      |\n|                                  | cancer     |                                     |\n|:---------------------------------|:-----------|:------------------------------------|\n| Vulval bleeding (unexplained) in | Vulval     | Consider a suspected cancer pathway |\n| women                            |            | referral [1.5.14]                   |\n\nTitle: Vulval Bleeding Referral Guidance | Summary: This table provides guidance on when to consider a suspected cancer pathway referral for vulval cancer in women presenting with unexplained vulval bleeding.",
    "table_summary": "Title: Vulval Bleeding Referral Guidance | Summary: This table provides guidance on when to consider a suspected cancer pathway referral for vulval cancer in women presenting with unexplained vulval bleeding."
  },
  {
    "element_id": "page_44",
    "page_number": 44,
    "type": "table",
    "raw_text": "Table 4 on Page 44\n\n| Symptom and signs                   | Possible   | Recommendation                      |\n|                                     | cancer     |                                     |\n|:------------------------------------|:-----------|:------------------------------------|\n| Appearance of cervixconsistent with | Cervical   | Consider a suspected cancer pathway |\n| cervical cancer                     |            | referral [1.5.13]                   |\n\nTitle: Gynaecological Examination Findings | Summary: This table lists a symptom (appearance of cervix consistent with cervical cancer) and recommends a suspected cancer pathway referral to specialist services.",
    "table_summary": "Title: Gynaecological Examination Findings | Summary: This table lists a symptom (appearance of cervix consistent with cervical cancer) and recommends a suspected cancer pathway referral to specialist services."
  },
  {
    "element_id": "page_45_seq_0",
    "page_number": 45,
    "type": "text",
    "raw_text": "Vaginal symptoms\nSymptom and specific features Possible cancer Recommendation\nVaginal discharge (unexplained) either at first Consider a direct\npresentation or with thrombocytosis or with Endometrial access ultrasound\nhaematuria, in women 55 and over scan [1.5.12]\nConsider a\nVaginal mass (unexplained and palpable) in or at suspected cancer\nVaginal\nthe entrance to the vagina pathway referral\n[1.5.15]\nVulval symptoms\nPossible\nSymptom and specific features Recommendation\ncancer\nConsider a suspected cancer pathway\nVulval bleeding (unexplained) Vulval\nreferral [1.5.14]\nVulval lump or ulceration Consider a suspected cancer pathway\nVulval\n(unexplained) referral [1.5.14]\nLumps or masses\nLumps and masses\nSymptom and specific Possible\nRecommendation\nfeatures cancer\nAnal mass\nAnal Consider a suspected cancer pathway referral 1.3.6]\n(unexplained)\nAxillary lump\n(unexplained), Breast Consider a suspected cancer pathway referral [1.4.2]\n30 and over\nBreast lump\n\nThis chunk of the NICE guideline provides specific recommendations for referral and investigation of suspected gynecological cancers based on vaginal and vulval symptoms, as well as a broader section on lumps and masses throughout the body. It guides healthcare professionals in primary care to identify potential cancers early and determine the appropriate course of action, such as imaging or specialist referral."
  },
  {
    "element_id": "page_45_seq_0",
    "page_number": 45,
    "type": "text",
    "raw_text": "(unexplained), Breast Consider a suspected cancer pathway referral [1.4.2]\n30 and over\nBreast lump\n(unexplained) Refer people using a suspected cancer pathway referral\nBreast\nwith or without [1.4.1]\npain, 30 and over\n\nThis excerpt from the NICE guideline outlines referral recommendations for suspected breast cancer based on the presence of unexplained lumps, with or without pain, and unexplained axillary lumps in individuals aged 30 and over, guiding healthcare professionals in determining the appropriate course of action. It specifies that those with unexplained breast lumps should be referred using a suspected cancer pathway referral, while those with unexplained lumps in the axilla should be considered for the same pathway."
  },
  {
    "element_id": "page_45",
    "page_number": 45,
    "type": "table",
    "raw_text": "Table 1 on Page 45\n\n| Symptom and specific features                    | Possible cancer   | Recommendation    |\n|:-------------------------------------------------|:------------------|:------------------|\n| Vaginal discharge (unexplained) either at first  | Endometrial       | Consider a direct |\n| presentation or with thrombocytosis or with      |                   | access ultrasound |\n| haematuria, in women 55 and over                 |                   | scan [1.5.12]     |\n| Vaginal mass (unexplained and palpable) in or at | Vaginal           | Consider a        |\n| the entrance to the vagina                       |                   | suspected cancer  |\n|                                                  |                   | pathway referral  |\n|                                                  |                   | [1.5.15]          |\n\nTitle: Vaginal Symptoms Table | Summary: This table outlines the recommended actions, including direct access ultrasound scans or suspected cancer pathway referrals, for women presenting with unexplained vaginal discharge or masses, potentially indicating endometrial or vaginal cancer.",
    "table_summary": "Title: Vaginal Symptoms Table | Summary: This table outlines the recommended actions, including direct access ultrasound scans or suspected cancer pathway referrals, for women presenting with unexplained vaginal discharge or masses, potentially indicating endometrial or vaginal cancer."
  },
  {
    "element_id": "page_45",
    "page_number": 45,
    "type": "table",
    "raw_text": "Table 2 on Page 45\n\n| Symptom and specific features   | Possible   | Recommendation                      |\n|                                 | cancer     |                                     |\n|:--------------------------------|:-----------|:------------------------------------|\n| Vulval bleeding (unexplained)   | Vulval     | Consider a suspected cancer pathway |\n|                                 |            | referral [1.5.14]                   |\n| Vulval lump or ulceration       | Vulval     | Consider a suspected cancer pathway |\n| (unexplained)                   |            | referral [1.5.14]                   |\n\nTitle: Vulval Symptoms and Cancer Risk | Summary: This table outlines the recommendations for referral based on vulval symptoms that may indicate vulval cancer, specifically unexplained bleeding, lumps or ulcerations.",
    "table_summary": "Title: Vulval Symptoms and Cancer Risk | Summary: This table outlines the recommendations for referral based on vulval symptoms that may indicate vulval cancer, specifically unexplained bleeding, lumps or ulcerations."
  },
  {
    "element_id": "page_45",
    "page_number": 45,
    "type": "table",
    "raw_text": "Table 3 on Page 45\n\n| Symptom and specific   | Possible   | Recommendation                                         |\n| features               | cancer     |                                                        |\n|:-----------------------|:-----------|:-------------------------------------------------------|\n| Anal mass              | Anal       | Consider a suspected cancer pathway referral 1.3.6]    |\n| (unexplained)          |            |                                                        |\n| Axillary lump          | Breast     | Consider a suspected cancer pathway referral [1.4.2]   |\n| (unexplained),         |            |                                                        |\n| 30 and over            |            |                                                        |\n| Breast lump            | Breast     | Refer people using a suspected cancer pathway referral |\n| (unexplained)          |            | [1.4.1]                                                |\n| with or without        |            |                                                        |\n| pain, 30 and over      |            |                                                        |\n\nTitle: Lumps and Masses Referral Guidelines | Summary: This table provides recommendations for suspected cancer pathway referrals based on the presence of unexplained lumps or masses in different areas of the body, specifically the anal area, axilla (for individuals 30 and over), and breast (for individuals 30 and over).",
    "table_summary": "Title: Lumps and Masses Referral Guidelines | Summary: This table provides recommendations for suspected cancer pathway referrals based on the presence of unexplained lumps or masses in different areas of the body, specifically the anal area, axilla (for individuals 30 and over), and breast (for individuals 30 and over)."
  },
  {
    "element_id": "page_46_seq_0",
    "page_number": 46,
    "type": "text",
    "raw_text": "Symptom and specific Possible\nRecommendation\nfeatures cancer\nBreast lump\nConsider non-urgent referral\n(unexplained)\nBreast See also recommendations 1.16.2 and 1.16.3 for\nwith or without\ninformation about seeking specialist advice [1.4.3]\npain, under 30\nConsider an urgent referral (for an appointment within\n2 weeks) for assessment by a dentist [1.8.3]\nLip or oral Consider a suspected cancer pathway referral by the\nOral\ncavitylump dentist in people when assessed by a dentist as having a\nlump on the lip or in the oral cavity consistent with oral\ncancer [1.8.4]\nConsider an urgent, direct access ultrasound scan (to be\ndone within 2 weeks) [1.11.4]\nLump\nSoft Separate recommendations have been made for adults\n(unexplained)\ntissue and for children and young people to reflect that there\nthat is increasing\nsarcoma are different referral pathways. In practice young people\nin size in adults\n(aged 16 to 24) may be referred using either pathway\ndepending on their age and local arrangements\nNeck lump\n\nThis section of the NICE guideline provides specific recommendations for managing patients presenting with lumps, focusing on referral pathways and diagnostic investigations based on the lump's location (breast, oral cavity, soft tissue, neck) and patient age, to facilitate early cancer detection. It aims to guide healthcare professionals in primary care in appropriately triaging patients with lumps to ensure timely specialist assessment when suspicion of cancer is present."
  },
  {
    "element_id": "page_46_seq_0",
    "page_number": 46,
    "type": "text",
    "raw_text": "depending on their age and local arrangements\nNeck lump\n(unexplained), Laryngeal Consider a suspected cancer pathway referral [1.8.1]\n45 and over\nNeck lump\n(persistent and Oral Consider a suspected cancer pathway referral [1.8.2]\nunexplained)\nPenile mass (and\nsexually\ntransmitted\nPenile Consider a suspected cancer pathway referral [1.6.9]\ninfection has\nbeen excluded as\na cause) in men\nThyroid lump\nThyroid Consider a suspected cancer pathway referral [1.8.5]\n(unexplained)\n\nThis section of the document provides guidance on when to consider a suspected cancer pathway referral based on the presence of lumps or masses in specific areas of the body (neck, penis, thyroid), aiding healthcare professionals in identifying potential cancers early. It lists specific symptoms and signs, the possible associated cancer, and the corresponding NICE recommendation regarding referral."
  },
  {
    "element_id": "page_46",
    "page_number": 46,
    "type": "table",
    "raw_text": "Table 1 on Page 46\n\n| Symptom and specific   | Possible   | Recommendation                                             |\n| features               | cancer     |                                                            |\n|:-----------------------|:-----------|:-----------------------------------------------------------|\n| Breast lump            | Breast     | Consider non-urgent referral                               |\n| (unexplained)          |            | See also recommendations 1.16.2 and 1.16.3 for             |\n| with or without        |            | information about seeking specialist advice [1.4.3]        |\n| pain, under 30         |            |                                                            |\n| Lip or oral            | Oral       | Consider an urgent referral (for an appointment within     |\n| cavitylump             |            | 2 weeks) for assessment by a dentist [1.8.3]               |\n|                        |            | Consider a suspected cancer pathway referral by the        |\n|                        |            | dentist in people when assessed by a dentist as having a   |\n|                        |            | lump on the lip or in the oral cavity consistent with oral |\n|                        |            | cancer [1.8.4]                                             |\n| Lump                   | Soft       | Consider an urgent, direct access ultrasound scan (to be   |\n| (unexplained)          | tissue     | done within 2 weeks) [1.11.4]                              |\n| that is increasing     | sarcoma    | Separate recommendations have been made for adults         |\n| in size in adults      |            | and for children and young people to reflect that there    |\n|                        |            | are different referral pathways. In practice young people  |\n|                        |            | (aged 16 to 24) may be referred using either pathway       |\n|                        |            | depending on their age and local arrangements              |\n| Neck lump              | Laryngeal  | Consider a suspected cancer pathway referral [1.8.1]       |\n| (unexplained),         |            |                                                            |\n| 45 and over            |            |                                                            |\n| Neck lump              | Oral       | Consider a suspected cancer pathway referral [1.8.2]       |\n| (persistent and        |            |                                                            |\n| unexplained)           |            |                                                            |\n| Penile mass (and       | Penile     | Consider a suspected cancer pathway referral [1.6.9]       |\n| sexually               |            |                                                            |\n| transmitted            |            |                                                            |\n| infection has          |            |                                                            |\n| been excluded as       |            |                                                            |\n| a cause) in men        |            |                                                            |\n| Thyroid lump           | Thyroid    | Consider a suspected cancer pathway referral [1.8.5]       |\n| (unexplained)          |            |                                                            |\n\nTitle: Lumps and Masses Referral Guidance | Summary: This table provides recommendations for referral based on the location and characteristics of unexplained lumps or masses, indicating the possible cancer type and the appropriate action, such as routine referral, urgent referral, or a suspected cancer pathway referral.",
    "table_summary": "Title: Lumps and Masses Referral Guidance | Summary: This table provides recommendations for referral based on the location and characteristics of unexplained lumps or masses, indicating the possible cancer type and the appropriate action, such as routine referral, urgent referral, or a suspected cancer pathway referral."
  },
  {
    "element_id": "page_47_seq_0",
    "page_number": 47,
    "type": "text",
    "raw_text": "Symptom and specific Possible\nRecommendation\nfeatures cancer\nVaginal mass\n(unexplained and\npalpable) in or at\nVaginal Consider a suspected cancer pathway referral [1.5.15]\nthe entrance to\nthe vagina in\nwomen\nVulval lump\n(unexplained) in Vulval Consider a suspected cancer pathway referral [1.5.14]\nwomen\nSee also the section on abdominal symptoms for abdominal, anal, pelvic and rectal lumps\nor masses.\nLymphadenopathy\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a suspected cancer pathway referral\nWhen considering referral for Hodgkin's\nlymphoma, take into account any associated\nsymptoms, particularly fever, night sweats,\nshortness of breath, pruritus, weight loss or\nalcohol-induced lymph node pain [1.10.8]\nNon-Hodgkin's When considering referral for non-Hodgkin's\nLymphadenopathy\nlymphoma or lymphoma, take into account any associated\n(unexplained) in\nHodgkin's symptoms, particularly fever, night sweats,\nadults\n\nThis chunk, found within the \"Recommendations organised by symptom and findings of primary care investigations\" section, provides specific guidance for healthcare professionals on when to consider a suspected cancer pathway referral based on the presence of vaginal/vulval masses or unexplained lymphadenopathy in adults, emphasizing the importance of associated symptoms. It aims to aid in early cancer detection by outlining scenarios where further investigation is warranted, while also directing readers to other relevant sections for related symptoms."
  },
  {
    "element_id": "page_47_seq_0",
    "page_number": 47,
    "type": "text",
    "raw_text": "(unexplained) in\nHodgkin's symptoms, particularly fever, night sweats,\nadults\nlymphoma shortness of breath, pruritus or weight loss [1.10.6]\nSeparate recommendations have been made for\nadults and for children and young people to reflect\nthat there are different referral pathways. In\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\n\nThis section provides guidance on when to consider a suspected cancer pathway referral for adults presenting with unexplained lymphadenopathy, emphasizing the importance of considering associated symptoms like fever, night sweats, shortness of breath, pruritus, or weight loss, particularly in relation to Hodgkin's lymphoma. It also clarifies that while the guidance is tailored for adults, young people (16-24) may be referred using either the adult or children's pathways based on local practices."
  },
  {
    "element_id": "page_47",
    "page_number": 47,
    "type": "table",
    "raw_text": "Table 1 on Page 47\n\n| Symptom and specific   | Possible   | Recommendation                                        |\n| features               | cancer     |                                                       |\n|:-----------------------|:-----------|:------------------------------------------------------|\n| Vaginal mass           | Vaginal    | Consider a suspected cancer pathway referral [1.5.15] |\n| (unexplained and       |            |                                                       |\n| palpable) in or at     |            |                                                       |\n| the entrance to        |            |                                                       |\n| the vagina in          |            |                                                       |\n| women                  |            |                                                       |\n| Vulval lump            | Vulval     | Consider a suspected cancer pathway referral [1.5.14] |\n| (unexplained) in       |            |                                                       |\n| women                  |            |                                                       |\n\nTitle: Gynaecological Lumps and Masses | Summary: This table provides recommendations for suspected cancer pathway referrals based on the presence of unexplained vaginal or vulval lumps or masses in women.",
    "table_summary": "Title: Gynaecological Lumps and Masses | Summary: This table provides recommendations for suspected cancer pathway referrals based on the presence of unexplained vaginal or vulval lumps or masses in women."
  },
  {
    "element_id": "page_47",
    "page_number": 47,
    "type": "table",
    "raw_text": "Table 2 on Page 47\n\n| Symptom and specific   | Possible cancer   | Recommendation                                        |\n| features               |                   |                                                       |\n|:-----------------------|:------------------|:------------------------------------------------------|\n| Lymphadenopathy        | Non-Hodgkin's     | Consider a suspected cancer pathway referral          |\n| (unexplained) in       | lymphoma or       | When considering referral for Hodgkin's               |\n| adults                 | Hodgkin's         | lymphoma, take into account any associated            |\n|                        | lymphoma          | symptoms, particularly fever, night sweats,           |\n|                        |                   | shortness of breath, pruritus, weight loss or         |\n|                        |                   | alcohol-induced lymph node pain [1.10.8]              |\n|                        |                   | When considering referral for non-Hodgkin's           |\n|                        |                   | lymphoma, take into account any associated            |\n|                        |                   | symptoms, particularly fever, night sweats,           |\n|                        |                   | shortness of breath, pruritus or weight loss [1.10.6] |\n|                        |                   | Separate recommendations have been made for           |\n|                        |                   | adults and for children and young people to reflect   |\n|                        |                   | that there are different referral pathways. In        |\n|                        |                   | practice young people (aged 16 to 24) may be          |\n|                        |                   | referred using either pathway depending on their      |\n|                        |                   | age and local arrangements                            |\n\nTitle: Lymphadenopathy in Adults Table | Summary: This table outlines the NICE recommendations for suspected cancer pathway referrals for adults presenting with unexplained lymphadenopathy, considering both Hodgkin's and Non-Hodgkin's lymphoma. It emphasizes assessing associated symptoms like fever, night sweats, shortness of breath, pruritus, weight loss, and alcohol-induced lymph node pain, and acknowledges the flexibility in referral pathways for young adults.",
    "table_summary": "Title: Lymphadenopathy in Adults Table | Summary: This table outlines the NICE recommendations for suspected cancer pathway referrals for adults presenting with unexplained lymphadenopathy, considering both Hodgkin's and Non-Hodgkin's lymphoma. It emphasizes assessing associated symptoms like fever, night sweats, shortness of breath, pruritus, weight loss, and alcohol-induced lymph node pain, and acknowledges the flexibility in referral pathways for young adults."
  },
  {
    "element_id": "page_48_seq_0",
    "page_number": 48,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nLymphadenopathy\n(supraclavicular or\nConsider an urgent chest X-ray (to be done within\npersistent Lung\n2 weeks) [1.1.3]\ncervical), 40 and\nover\nLymphadenopathy\nConsider a very urgent full blood count (within\n(generalised) in Leukaemia\n48 hours) [1.10.1]\nadults\nOral lesions\nPossible\nSymptom and specific features Recommendation\ncancer\nUlceration in the oral\ncavity (unexplained\nOral Consider a suspected cancer pathway referral [1.8.2]\nand lasting for more\nthan 3 weeks)\nConsider an urgent referral (for an appointment within\n2 weeks) for assessment by a dentist [1.8.3]\nConsider a suspected cancer pathway referral by the\nLip or oral cavity lump Oral\ndentist in people when assessed by a dentist as having\na lump on the lip or in the oral cavity consistent with\noral cancer [1.8.4]\nNeurological symptoms in adults\nNeurological symptoms in adults\nSymptom and specific features Possible cancer Recommendation\nLoss of central Brain or\n\nThis chunk of the NICE guideline provides specific recommendations for investigation and referral based on the symptoms of lymphadenopathy, oral lesions, and neurological symptoms in adults, helping healthcare professionals to identify potential cancers early. It guides clinicians on the appropriate actions, such as urgent blood tests, chest X-rays, or suspected cancer pathway referrals, based on the presenting symptoms."
  },
  {
    "element_id": "page_48_seq_0",
    "page_number": 48,
    "type": "text",
    "raw_text": "Symptom and specific features Possible cancer Recommendation\nLoss of central Brain or\nConsider an urgent, direct access MRI scan of\nneurological function central\nthe brain (or CT scan if MRI is contraindicated;\n(progressive, sub-acute) nervous\nto be done within 2 weeks) [1.9.1]\nin adults system\n\nThis chunk, found within the \"Recommendations organised by symptom and findings of primary care investigations\" section, provides guidance for healthcare professionals on when to consider an urgent MRI (or CT if MRI is not possible) for adults presenting with progressive neurological decline, indicating a possible brain or central nervous system cancer. It emphasizes the importance of timely investigation for these symptoms to facilitate early diagnosis and potential treatment."
  },
  {
    "element_id": "page_48",
    "page_number": 48,
    "type": "table",
    "raw_text": "Table 1 on Page 48\n\n| Symptom and specific   | Possible cancer   | Recommendation                                    |\n| features               |                   |                                                   |\n|:-----------------------|:------------------|:--------------------------------------------------|\n| Lymphadenopathy        | Lung              | Consider an urgent chest X-ray (to be done within |\n| (supraclavicular or    |                   | 2 weeks) [1.1.3]                                  |\n| persistent             |                   |                                                   |\n| cervical), 40 and      |                   |                                                   |\n| over                   |                   |                                                   |\n| Lymphadenopathy        | Leukaemia         | Consider a very urgent full blood count (within   |\n| (generalised) in       |                   | 48 hours) [1.10.1]                                |\n| adults                 |                   |                                                   |\n\nTitle: Lymphadenopathy (Adults): Investigations and Referrals | Summary: This table outlines the recommended investigations and referrals for adults presenting with lymphadenopathy, differentiating between supraclavicular/persistent cervical lymphadenopathy (possible lung cancer) and generalised lymphadenopathy (possible leukaemia). It specifies urgency of the tests.",
    "table_summary": "Title: Lymphadenopathy (Adults): Investigations and Referrals | Summary: This table outlines the recommended investigations and referrals for adults presenting with lymphadenopathy, differentiating between supraclavicular/persistent cervical lymphadenopathy (possible lung cancer) and generalised lymphadenopathy (possible leukaemia). It specifies urgency of the tests."
  },
  {
    "element_id": "page_48",
    "page_number": 48,
    "type": "table",
    "raw_text": "Table 2 on Page 48\n\n| Symptom and specific features   | Possible   | Recommendation                                          |\n|                                 | cancer     |                                                         |\n|:--------------------------------|:-----------|:--------------------------------------------------------|\n| Ulceration in the oral          | Oral       | Consider a suspected cancer pathway referral [1.8.2]    |\n| cavity (unexplained             |            |                                                         |\n| and lasting for more            |            |                                                         |\n| than 3 weeks)                   |            |                                                         |\n| Lip or oral cavity lump         | Oral       | Consider an urgent referral (for an appointment within  |\n|                                 |            | 2 weeks) for assessment by a dentist [1.8.3]            |\n|                                 |            | Consider a suspected cancer pathway referral by the     |\n|                                 |            | dentist in people when assessed by a dentist as having  |\n|                                 |            | a lump on the lip or in the oral cavity consistent with |\n|                                 |            | oral cancer [1.8.4]                                     |\n\nTitle: Oral Lesions and Cancer Referral | Summary: This table details the recommendations for referral based on oral symptoms that may indicate oral cancer. It includes unexplained oral ulceration lasting over 3 weeks and lumps on the lip or in the oral cavity.",
    "table_summary": "Title: Oral Lesions and Cancer Referral | Summary: This table details the recommendations for referral based on oral symptoms that may indicate oral cancer. It includes unexplained oral ulceration lasting over 3 weeks and lumps on the lip or in the oral cavity."
  },
  {
    "element_id": "page_48",
    "page_number": 48,
    "type": "table",
    "raw_text": "Table 3 on Page 48\n\n| Symptom and specific features   | Possible cancer   | Recommendation                                   |\n|:--------------------------------|:------------------|:-------------------------------------------------|\n| Loss of central                 | Brain or          | Consider an urgent, direct access MRI scan of    |\n| neurological function           | central           | the brain (or CT scan if MRI is contraindicated; |\n| (progressive, sub-acute)        | nervous           | to be done within 2 weeks) [1.9.1]               |\n| in adults                       | system            |                                                  |\n\nTitle: Neurological Symptoms in Adults | Summary: This table outlines the recommendation for brain imaging in adults presenting with progressive, sub-acute loss of central neurological function to assess for possible brain or central nervous system cancer.",
    "table_summary": "Title: Neurological Symptoms in Adults | Summary: This table outlines the recommendation for brain imaging in adults presenting with progressive, sub-acute loss of central neurological function to assess for possible brain or central nervous system cancer."
  },
  {
    "element_id": "page_49_seq_0",
    "page_number": 49,
    "type": "text",
    "raw_text": "Pain\nSee also the section on abdominal symptoms for abdominal or pelvic pain.\nPain\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account any\nAlcohol-induced associated symptoms [1.10.8]\nlymph node pain with Separate recommendations have been made for\nHodgkin's\nunexplained adults and for children and young people to\nlymphoma\nlymphadenopathy in reflect that there are different referral pathways.\nadults In practice young people (aged 16 to 24) may be\nreferred using either pathway depending on\ntheir age and local arrangements\nConsider an urgent, direct access CT scan (to\nBack pain with weight\nPancreatic be done within 2 weeks), or an urgent\nloss, 60 and over\nultrasound scan if CT is not available [1.2.5]\nOffer a full blood count and blood tests for:\n• calcium\n• plasma viscosity or erythrocyte\nsedimentation rate\nBack pain\n• paraprotein, using serum protein\n(persistent), 60 and Myeloma\n\nThis section of the NICE guideline provides recommendations for referrals and investigations based on pain as a presenting symptom of suspected cancer. It highlights specific types of pain, such as back pain and alcohol-induced lymph node pain, and links them to potential cancers like pancreatic cancer, myeloma, and Hodgkin's lymphoma, guiding healthcare professionals on appropriate actions based on the specific characteristics of the pain."
  },
  {
    "element_id": "page_49_seq_0",
    "page_number": 49,
    "type": "text",
    "raw_text": "sedimentation rate\nBack pain\n• paraprotein, using serum protein\n(persistent), 60 and Myeloma\nelectrophoresis\nover\n• free light chains contained in serum.\nIf serum free light chain testing is not available,\nuse a Bence–Jones protein urine test. [1.10.4]\nSee the section on primary care investigations\nfor more information on tests for myeloma\n\nThis section of the guideline provides recommendations for assessing myeloma in individuals aged 60 and over experiencing persistent back pain, advising specific blood tests, and an alternative urine test (Bence-Jones protein) if serum free light chain testing isn't available, prompting further investigation outlined in the primary care investigations section. This enables primary care physicians to effectively screen for myeloma based on specific symptoms and lab results."
  },
  {
    "element_id": "page_49",
    "page_number": 49,
    "type": "table",
    "raw_text": "Table 1 on Page 49\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Alcohol-induced        | Hodgkin's         | Consider a suspected cancer pathway referral.       |\n| lymph node pain with   | lymphoma          | When considering referral, take into account any    |\n| unexplained            |                   | associated symptoms [1.10.8]                        |\n| lymphadenopathy in     |                   | Separate recommendations have been made for         |\n| adults                 |                   | adults and for children and young people to         |\n|                        |                   | reflect that there are different referral pathways. |\n|                        |                   | In practice young people (aged 16 to 24) may be     |\n|                        |                   | referred using either pathway depending on          |\n|                        |                   | their age and local arrangements                    |\n| Back pain with weight  | Pancreatic        | Consider an urgent, direct access CT scan (to       |\n| loss, 60 and over      |                   | be done within 2 weeks), or an urgent               |\n|                        |                   | ultrasound scan if CT is not available [1.2.5]      |\n| Back pain              | Myeloma           | Offer a full blood count and blood tests for:       |\n| (persistent), 60 and   |                   | • calcium                                           |\n| over                   |                   | • plasma viscosity or erythrocyte                   |\n|                        |                   | sedimentation rate                                  |\n|                        |                   | • paraprotein, using serum protein                  |\n|                        |                   | electrophoresis                                     |\n|                        |                   | • free light chains contained in serum.             |\n|                        |                   | If serum free light chain testing is not available, |\n|                        |                   | use a Bence–Jones protein urine test. [1.10.4]      |\n|                        |                   | See the section on primary care investigations      |\n|                        |                   | for more information on tests for myeloma           |\n\nTitle: Pain and Cancer Referral Guidance | Summary: This table provides guidance on when to consider a suspected cancer pathway referral or urgent investigation based on the type of pain experienced and other associated symptoms, specifically highlighting Hodgkin's lymphoma, pancreatic cancer, and myeloma.",
    "table_summary": "Title: Pain and Cancer Referral Guidance | Summary: This table provides guidance on when to consider a suspected cancer pathway referral or urgent investigation based on the type of pain experienced and other associated symptoms, specifically highlighting Hodgkin's lymphoma, pancreatic cancer, and myeloma."
  },
  {
    "element_id": "page_50_seq_0",
    "page_number": 50,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nOffer a full blood count and blood tests for:\n• calcium\n• plasma viscosity or erythrocyte\nsedimentation rate\nBone pain\n• paraprotein, using serum protein\n(persistent), 60 and Myeloma\nelectrophoresis\nover\n• free light chains contained in serum.\nIf serum free light chain testing is not available,\nuse a Bence–Jones protein urine test. [1.10.4]\nSee the section on primary care investigations\nfor more information on tests for myeloma\nChest pain\nLung or Offer an urgent chest X-ray (to be done within\n(unexplained), 40 and\nmesothelioma 2 weeks) [1.1.2] [1.1.5]\nover, ever smoked\nChest pain\n(unexplained), 40 and Offer an urgent chest X-ray (to be done within\nMesothelioma\nover, exposed to 2 weeks) [1.1.5]\nasbestos\nChest pain\n(unexplained) with\ncough or fatigue or\nshortness of breath or Lung or Offer an urgent chest X-ray (to be done within\nweight loss or mesothelioma 2 weeks) [1.1.2] [1.1.5]\nappetite loss\n(unexplained), 40 and\nover\n\nThis chunk of the NICE guideline provides specific recommendations for primary care physicians on when to investigate potential cancers based on patient-reported symptoms; it outlines the necessary blood tests for persistent bone pain in older adults to assess for myeloma, and the circumstances requiring urgent chest x-rays to evaluate chest pain for possible lung cancer or mesothelioma. This section helps guide clinicians in determining appropriate actions, like ordering tests or referrals, based on specific symptom presentations."
  },
  {
    "element_id": "page_50",
    "page_number": 50,
    "type": "table",
    "raw_text": "Table 1 on Page 50\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Bone pain              | Myeloma           | Offer a full blood count and blood tests for:       |\n| (persistent), 60 and   |                   | • calcium                                           |\n| over                   |                   | • plasma viscosity or erythrocyte                   |\n|                        |                   | sedimentation rate                                  |\n|                        |                   | • paraprotein, using serum protein                  |\n|                        |                   | electrophoresis                                     |\n|                        |                   | • free light chains contained in serum.             |\n|                        |                   | If serum free light chain testing is not available, |\n|                        |                   | use a Bence–Jones protein urine test. [1.10.4]      |\n|                        |                   | See the section on primary care investigations      |\n|                        |                   | for more information on tests for myeloma           |\n| Chest pain             | Lung or           | Offer an urgent chest X-ray (to be done within      |\n| (unexplained), 40 and  | mesothelioma      | 2 weeks) [1.1.2] [1.1.5]                            |\n| over, ever smoked      |                   |                                                     |\n| Chest pain             | Mesothelioma      | Offer an urgent chest X-ray (to be done within      |\n| (unexplained), 40 and  |                   | 2 weeks) [1.1.5]                                    |\n| over, exposed to       |                   |                                                     |\n| asbestos               |                   |                                                     |\n| Chest pain             | Lung or           | Offer an urgent chest X-ray (to be done within      |\n| (unexplained) with     | mesothelioma      | 2 weeks) [1.1.2] [1.1.5]                            |\n| cough or fatigue or    |                   |                                                     |\n| shortness of breath or |                   |                                                     |\n| weight loss or         |                   |                                                     |\n| appetite loss          |                   |                                                     |\n| (unexplained), 40 and  |                   |                                                     |\n| over                   |                   |                                                     |\n\nTitle: Pain Referral Guidance | Summary: This table outlines recommendations for referral and investigation based on the symptom of pain, specifically bone pain and chest pain, and their potential association with myeloma, lung cancer, or mesothelioma, including specific actions like blood tests and chest X-rays.",
    "table_summary": "Title: Pain Referral Guidance | Summary: This table outlines recommendations for referral and investigation based on the symptom of pain, specifically bone pain and chest pain, and their potential association with myeloma, lung cancer, or mesothelioma, including specific actions like blood tests and chest X-rays."
  },
  {
    "element_id": "page_51_seq_0",
    "page_number": 51,
    "type": "text",
    "raw_text": "Respiratory symptoms\nChest infection\nPossible\nSymptom and specific features Recommendation\ncancer\nChest infection (persistent or Consider an urgent chest X-ray (to be\nLung\nrecurrent), 40 and over done within 2 weeks) [1.1.3]\nChest pain\nSymptom and specific features Possible cancer Recommendation\nOffer an urgent chest\nChest pain (unexplained), 40 and over, ever Lung or\nX-ray (to be done within\nsmoked mesothelioma\n2 weeks) [1.1.2] [1.1.5]\nOffer an urgent chest\nChest pain (unexplained), 40 and over,\nMesothelioma X-ray (to be done within\nexposed to asbestos\n2 weeks) [1.1.5]\nChest pain (unexplained) with cough or Offer an urgent chest\nLung or\nfatigue or shortness of breath or weight loss X-ray (to be done within\nmesothelioma\nor appetite loss (unexplained), 40 and over 2 weeks) [1.1.2] [1.1.5]\nCough\nSymptom and specific features Possible cancer Recommendation\nOffer an urgent chest\nCough (unexplained), 40 and over, ever Lung or\nX-ray (to be done within\nsmoked mesothelioma\n\nThis section of the NICE guideline provides specific recommendations for primary care physicians on when to consider or offer urgent chest X-rays for patients presenting with respiratory symptoms, such as cough, chest pain, or persistent chest infections, particularly in those over 40 or with a history of smoking or asbestos exposure, to aid in the early detection of lung cancer or mesothelioma. It helps guide clinicians in identifying patients who warrant further investigation based on their respiratory symptoms."
  },
  {
    "element_id": "page_51_seq_0",
    "page_number": 51,
    "type": "text",
    "raw_text": "Cough (unexplained), 40 and over, ever Lung or\nX-ray (to be done within\nsmoked mesothelioma\n2 weeks) [1.1.2] [1.1.5]\nOffer an urgent chest\nCough (unexplained), 40 and over, exposed to\nMesothelioma X-ray (to be done within\nasbestos\n2 weeks) [1.1.5]\nCough (unexplained) with fatigue or shortness Offer an urgent chest\nLung or\nof breath or chest pain or weight loss or X-ray (to be done within\nmesothelioma\nappetite loss (unexplained), 40 and over 2 weeks) [1.1.2] [1.1.5]\n\nThis section of the guideline provides specific recommendations for when to offer an urgent chest X-ray to assess for lung cancer or mesothelioma in individuals aged 40 and over presenting with unexplained cough, particularly considering smoking history, asbestos exposure, and related symptoms. Its purpose is to guide healthcare professionals in primary care to identify and promptly investigate potential lung and pleural cancers based on these specific cough-related scenarios."
  },
  {
    "element_id": "page_51",
    "page_number": 51,
    "type": "table",
    "raw_text": "Table 1 on Page 51\n\n| Symptom and specific features   | Possible   | Recommendation                        |\n|                                 | cancer     |                                       |\n|:--------------------------------|:-----------|:--------------------------------------|\n| Chest infection (persistent or  | Lung       | Consider an urgent chest X-ray (to be |\n| recurrent), 40 and over         |            | done within 2 weeks) [1.1.3]          |\n\nTitle: Chest Infection and Lung Cancer | Summary: This table indicates that adults aged 40 and over experiencing persistent or recurrent chest infections should be considered for an urgent chest x-ray to assess for potential lung cancer.",
    "table_summary": "Title: Chest Infection and Lung Cancer | Summary: This table indicates that adults aged 40 and over experiencing persistent or recurrent chest infections should be considered for an urgent chest x-ray to assess for potential lung cancer."
  },
  {
    "element_id": "page_51",
    "page_number": 51,
    "type": "table",
    "raw_text": "Table 2 on Page 51\n\n| Symptom and specific features                 | Possible cancer   | Recommendation           |\n|:----------------------------------------------|:------------------|:-------------------------|\n| Chest pain (unexplained), 40 and over, ever   | Lung or           | Offer an urgent chest    |\n| smoked                                        | mesothelioma      | X-ray (to be done within |\n|                                               |                   | 2 weeks) [1.1.2] [1.1.5] |\n| Chest pain (unexplained), 40 and over,        | Mesothelioma      | Offer an urgent chest    |\n| exposed to asbestos                           |                   | X-ray (to be done within |\n|                                               |                   | 2 weeks) [1.1.5]         |\n| Chest pain (unexplained) with cough or        | Lung or           | Offer an urgent chest    |\n| fatigue or shortness of breath or weight loss | mesothelioma      | X-ray (to be done within |\n| or appetite loss (unexplained), 40 and over   |                   | 2 weeks) [1.1.2] [1.1.5] |\n\nTitle: Chest Pain and Lung/Pleural Cancers | Summary: This table outlines the recommendations for urgent chest X-rays in people aged 40 and over presenting with unexplained chest pain, with consideration for smoking history, asbestos exposure, and other associated symptoms, to assess for lung cancer or mesothelioma.",
    "table_summary": "Title: Chest Pain and Lung/Pleural Cancers | Summary: This table outlines the recommendations for urgent chest X-rays in people aged 40 and over presenting with unexplained chest pain, with consideration for smoking history, asbestos exposure, and other associated symptoms, to assess for lung cancer or mesothelioma."
  },
  {
    "element_id": "page_51",
    "page_number": 51,
    "type": "table",
    "raw_text": "Table 3 on Page 51\n\n| Symptom and specific features                 | Possible cancer   | Recommendation           |\n|:----------------------------------------------|:------------------|:-------------------------|\n| Cough (unexplained), 40 and over, ever        | Lung or           | Offer an urgent chest    |\n| smoked                                        | mesothelioma      | X-ray (to be done within |\n|                                               |                   | 2 weeks) [1.1.2] [1.1.5] |\n| Cough (unexplained), 40 and over, exposed to  | Mesothelioma      | Offer an urgent chest    |\n| asbestos                                      |                   | X-ray (to be done within |\n|                                               |                   | 2 weeks) [1.1.5]         |\n| Cough (unexplained) with fatigue or shortness | Lung or           | Offer an urgent chest    |\n| of breath or chest pain or weight loss or     | mesothelioma      | X-ray (to be done within |\n| appetite loss (unexplained), 40 and over      |                   | 2 weeks) [1.1.2] [1.1.5] |\n\nTitle: Cough and Potential Lung or Mesothelioma | Summary: This table outlines the recommendations for chest X-rays based on cough symptoms, age, smoking history, and asbestos exposure, to assess for potential lung cancer or mesothelioma.",
    "table_summary": "Title: Cough and Potential Lung or Mesothelioma | Summary: This table outlines the recommendations for chest X-rays based on cough symptoms, age, smoking history, and asbestos exposure, to assess for potential lung cancer or mesothelioma."
  },
  {
    "element_id": "page_52_seq_0",
    "page_number": 52,
    "type": "text",
    "raw_text": "Hoarseness\nPossible\nSymptom and specific features Recommendation\ncancer\nHoarseness (persistent and Consider a suspected cancer\nLaryngeal\nunexplained), 45 and over pathway referral [1.8.1]\nRespiratory examination findings\nSymptom and signs Possible cancer Recommendation\nChest signsconsistent with Consider an urgent chest X-ray (to be\nLung\nlung cancer, 40 and over done within 2 weeks) [1.1.3]\nChest signs compatible with Consider an urgent chest X-ray (to be\nMesothelioma\npleural disease, 40 and over done within 2 weeks) [1.1.6]\nLung or Consider an urgent chest X-ray (to be\nFinger clubbing, 40 and over\nmesothelioma done within 2 weeks) [1.1.3] [1.1.6]\nShortness of breath\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nShortness of breath\n(unexplained), Lung or Offer an urgent chest X-ray (to be done within\n40 and over, ever mesothelioma 2 weeks) [1.1.2] [1.1.5]\nsmoked\nShortness of breath\n(unexplained),\nOffer an urgent chest X-ray (to be done within\n\nThis chunk of the NICE guideline provides recommendations for referral and investigation of suspected cancers based on specific respiratory symptoms and examination findings, primarily focusing on lung, laryngeal cancers, and mesothelioma. It guides healthcare professionals in primary care to identify patients who require further evaluation based on symptoms like hoarseness, chest signs, finger clubbing, and shortness of breath, including offering urgent chest x-rays in certain cases."
  },
  {
    "element_id": "page_52_seq_0",
    "page_number": 52,
    "type": "text",
    "raw_text": "smoked\nShortness of breath\n(unexplained),\nOffer an urgent chest X-ray (to be done within\n40 and over, and Mesothelioma\n2 weeks) [1.1.5]\nexposed to\nasbestos\nShortness of breath\nwith cough or\nfatigue or chest\nLung or Offer an urgent chest X-ray (to be done within\npain or weight loss\nmesothelioma 2 weeks) [1.1.2] [1.1.5]\nor appetite loss\n(unexplained),\n40 and over\n\nThis section of the guideline provides specific recommendations for when to offer an urgent chest X-ray for lung cancer or mesothelioma, based on symptoms and risk factors like smoking or asbestos exposure in people aged 40 and over, helping healthcare professionals to identify potential cancers early. It also addresses the overlap in symptoms between the two conditions and suggests urgent action if symptoms such as unexplained shortness of breath are present."
  },
  {
    "element_id": "page_52",
    "page_number": 52,
    "type": "table",
    "raw_text": "Table 1 on Page 52\n\n| Symptom and specific features   | Possible   | Recommendation              |\n|                                 | cancer     |                             |\n|:--------------------------------|:-----------|:----------------------------|\n| Hoarseness (persistent and      | Laryngeal  | Consider a suspected cancer |\n| unexplained), 45 and over       |            | pathway referral [1.8.1]    |\n\nTitle: Hoarseness and Laryngeal Cancer Referral | Summary: This table provides guidance on when to consider a suspected cancer pathway referral for laryngeal cancer based on the symptom of persistent and unexplained hoarseness in individuals aged 45 and over.",
    "table_summary": "Title: Hoarseness and Laryngeal Cancer Referral | Summary: This table provides guidance on when to consider a suspected cancer pathway referral for laryngeal cancer based on the symptom of persistent and unexplained hoarseness in individuals aged 45 and over."
  },
  {
    "element_id": "page_52",
    "page_number": 52,
    "type": "table",
    "raw_text": "Table 2 on Page 52\n\n| Symptom and signs            | Possible cancer   | Recommendation                        |\n|:-----------------------------|:------------------|:--------------------------------------|\n| Chest signsconsistent with   | Lung              | Consider an urgent chest X-ray (to be |\n| lung cancer, 40 and over     |                   | done within 2 weeks) [1.1.3]          |\n| Chest signs compatible with  | Mesothelioma      | Consider an urgent chest X-ray (to be |\n| pleural disease, 40 and over |                   | done within 2 weeks) [1.1.6]          |\n| Finger clubbing, 40 and over | Lung or           | Consider an urgent chest X-ray (to be |\n|                              | mesothelioma      | done within 2 weeks) [1.1.3] [1.1.6]  |\n\nTitle: Respiratory Examination Findings | Summary: This table provides recommendations for urgent chest X-rays based on chest signs or finger clubbing in people aged 40 and over, to assess for potential lung cancer or mesothelioma.",
    "table_summary": "Title: Respiratory Examination Findings | Summary: This table provides recommendations for urgent chest X-rays based on chest signs or finger clubbing in people aged 40 and over, to assess for potential lung cancer or mesothelioma."
  },
  {
    "element_id": "page_52",
    "page_number": 52,
    "type": "table",
    "raw_text": "Table 3 on Page 52\n\n| Symptom and specific   | Possible cancer   | Recommendation                                 |\n| features               |                   |                                                |\n|:-----------------------|:------------------|:-----------------------------------------------|\n| Shortness of breath    | Lung or           | Offer an urgent chest X-ray (to be done within |\n| (unexplained),         | mesothelioma      | 2 weeks) [1.1.2] [1.1.5]                       |\n| 40 and over, ever      |                   |                                                |\n| smoked                 |                   |                                                |\n| Shortness of breath    | Mesothelioma      | Offer an urgent chest X-ray (to be done within |\n| (unexplained),         |                   | 2 weeks) [1.1.5]                               |\n| 40 and over, and       |                   |                                                |\n| exposed to             |                   |                                                |\n| asbestos               |                   |                                                |\n| Shortness of breath    | Lung or           | Offer an urgent chest X-ray (to be done within |\n| with cough or          | mesothelioma      | 2 weeks) [1.1.2] [1.1.5]                       |\n| fatigue or chest       |                   |                                                |\n| pain or weight loss    |                   |                                                |\n| or appetite loss       |                   |                                                |\n| (unexplained),         |                   |                                                |\n| 40 and over            |                   |                                                |\n\nTitle: Shortness of Breath | Summary: This table outlines recommendations for urgent chest X-rays in individuals aged 40 and over experiencing unexplained shortness of breath, particularly those with a history of smoking or asbestos exposure, to assess for potential lung cancer or mesothelioma.",
    "table_summary": "Title: Shortness of Breath | Summary: This table outlines recommendations for urgent chest X-rays in individuals aged 40 and over experiencing unexplained shortness of breath, particularly those with a history of smoking or asbestos exposure, to assess for potential lung cancer or mesothelioma."
  },
  {
    "element_id": "page_53_seq_0",
    "page_number": 53,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account any\nassociated symptoms [1.10.6]\nShortness of breath Non-Hodgkin's\nSeparate recommendations have been made for\nwith unexplained lymphoma or\nadults and for children and young people to\nlymphadenopathy in Hodgkin's\nreflect that there are different referral pathways.\nadults lymphoma\nIn practice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account any\nassociated symptoms [1.10.6]\nShortness of breath\nSeparate recommendations have been made for\nwith unexplained Non-Hodgkin's\nadults and for children and young people to\nsplenomegaly in lymphoma\nreflect that there are different referral pathways.\nadults\nIn practice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\n\nThis chunk of the NICE guideline provides recommendations for suspected cancer pathway referrals for adults presenting with shortness of breath and either unexplained lymphadenopathy or splenomegaly, symptoms that may indicate Non-Hodgkin's or Hodgkin's lymphoma. It emphasizes considering associated symptoms when making the referral decision, and acknowledges that young people may be referred using either adult or child pathways depending on local arrangements."
  },
  {
    "element_id": "page_53_seq_0",
    "page_number": 53,
    "type": "text",
    "raw_text": "In practice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nSkeletal symptoms\nBack pain\nSymptom and specific Possible\nRecommendation\nfeatures cancer\nBack pain with Consider an urgent, direct access CT scan (to be done\nweight loss, Pancreatic within 2 weeks), or an urgent ultrasound scan if CT is not\n60 and over available [1.2.5]\n\nThis chunk provides guidance on when to consider imaging for back pain with weight loss as a potential symptom of pancreatic cancer and highlights that young people may be referred using either adult or children's pathways, depending on local protocols. The information is important for healthcare professionals in primary care to appropriately assess and refer patients with suspected cancer."
  },
  {
    "element_id": "page_53",
    "page_number": 53,
    "type": "table",
    "raw_text": "Table 1 on Page 53\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Shortness of breath    | Non-Hodgkin's     | Consider a suspected cancer pathway referral.       |\n| with unexplained       | lymphoma or       | When considering referral, take into account any    |\n| lymphadenopathy in     | Hodgkin's         | associated symptoms [1.10.6]                        |\n| adults                 | lymphoma          | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to         |\n|                        |                   | reflect that there are different referral pathways. |\n|                        |                   | In practice young people (aged 16 to 24) may be     |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Shortness of breath    | Non-Hodgkin's     | Consider a suspected cancer pathway referral.       |\n| with unexplained       | lymphoma          | When considering referral, take into account any    |\n| splenomegaly in        |                   | associated symptoms [1.10.6]                        |\n| adults                 |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to         |\n|                        |                   | reflect that there are different referral pathways. |\n|                        |                   | In practice young people (aged 16 to 24) may be     |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Shortness of Breath and Lymphoma in Adults | Summary: This table outlines the recommendations for suspected cancer pathway referrals for adults presenting with shortness of breath and unexplained lymphadenopathy or splenomegaly, indicating possible Non-Hodgkin's or Hodgkin's lymphoma. It emphasizes considering associated symptoms and notes different referral pathways for young people.",
    "table_summary": "Title: Shortness of Breath and Lymphoma in Adults | Summary: This table outlines the recommendations for suspected cancer pathway referrals for adults presenting with shortness of breath and unexplained lymphadenopathy or splenomegaly, indicating possible Non-Hodgkin's or Hodgkin's lymphoma. It emphasizes considering associated symptoms and notes different referral pathways for young people."
  },
  {
    "element_id": "page_53",
    "page_number": 53,
    "type": "table",
    "raw_text": "Table 2 on Page 53\n\n| Symptom and specific   | Possible   | Recommendation                                             |\n| features               | cancer     |                                                            |\n|:-----------------------|:-----------|:-----------------------------------------------------------|\n| Back pain with         | Pancreatic | Consider an urgent, direct access CT scan (to be done      |\n| weight loss,           |            | within 2 weeks), or an urgent ultrasound scan if CT is not |\n| 60 and over            |            | available [1.2.5]                                          |\n\nTitle: Back Pain and Pancreatic Cancer | Summary: This table outlines the recommendation for investigating pancreatic cancer in individuals aged 60 and over presenting with back pain and weight loss, advising an urgent CT or ultrasound scan.",
    "table_summary": "Title: Back Pain and Pancreatic Cancer | Summary: This table outlines the recommendation for investigating pancreatic cancer in individuals aged 60 and over presenting with back pain and weight loss, advising an urgent CT or ultrasound scan."
  },
  {
    "element_id": "page_54_seq_0",
    "page_number": 54,
    "type": "text",
    "raw_text": "Symptom and specific Possible\nRecommendation\nfeatures cancer\nOffer a full blood count and blood tests for:\n• calcium\n• plasma viscosity or erythrocyte sedimentation rate\nBack pain\n• paraprotein, using serum protein electrophoresis\n(persistent), Myeloma\n60 and over • free light chains contained in serum.\nIf serum free light chain testing is not available, use a\nBence–Jones protein urine test. [1.10.4]\nSee the section on primary care investigations for more\ninformation on tests for myeloma\nBone pain\nSymptom and specific Possible\nRecommendation\nfeatures cancer\nOffer a full blood count and blood tests for:\n• calcium\n• plasma viscosity or erythrocyte sedimentation rate\nBone pain\n• paraprotein, using serum protein electrophoresis\n(persistent), 60 and Myeloma\nover • free light chains contained in serum.\nIf serum free light chain testing is not available, use a\nBence–Jones protein urine test. [1.10.4]\nSee the section on primary care investigations for\nmore information on tests for myeloma\n\nThis section of the NICE guideline provides recommendations for primary care physicians on how to assess patients aged 60 and over presenting with persistent back pain or bone pain, specifically outlining the necessary blood tests to assess for possible myeloma and directing readers to further information on those tests. It aims to guide GPs in the diagnostic process for myeloma, ensuring appropriate investigations are carried out to facilitate timely referrals and diagnosis."
  },
  {
    "element_id": "page_54",
    "page_number": 54,
    "type": "table",
    "raw_text": "Table 1 on Page 54\n\n| Symptom and specific   | Possible   | Recommendation                                            |\n| features               | cancer     |                                                           |\n|:-----------------------|:-----------|:----------------------------------------------------------|\n| Back pain              | Myeloma    | Offer a full blood count and blood tests for:             |\n| (persistent),          |            | • calcium                                                 |\n| 60 and over            |            | • plasma viscosity or erythrocyte sedimentation rate      |\n|                        |            | • paraprotein, using serum protein electrophoresis        |\n|                        |            | • free light chains contained in serum.                   |\n|                        |            | If serum free light chain testing is not available, use a |\n|                        |            | Bence–Jones protein urine test. [1.10.4]                  |\n|                        |            | See the section on primary care investigations for more   |\n|                        |            | information on tests for myeloma                          |\n\nTitle: Back Pain and Myeloma | Summary: This table details the recommended blood tests for assessing myeloma in individuals aged 60 and over experiencing persistent back pain. It also directs the user to further information about myeloma tests.",
    "table_summary": "Title: Back Pain and Myeloma | Summary: This table details the recommended blood tests for assessing myeloma in individuals aged 60 and over experiencing persistent back pain. It also directs the user to further information about myeloma tests."
  },
  {
    "element_id": "page_54",
    "page_number": 54,
    "type": "table",
    "raw_text": "Table 2 on Page 54\n\n| Symptom and specific   | Possible   | Recommendation                                            |\n| features               | cancer     |                                                           |\n|:-----------------------|:-----------|:----------------------------------------------------------|\n| Bone pain              | Myeloma    | Offer a full blood count and blood tests for:             |\n| (persistent), 60 and   |            | • calcium                                                 |\n| over                   |            | • plasma viscosity or erythrocyte sedimentation rate      |\n|                        |            | • paraprotein, using serum protein electrophoresis        |\n|                        |            | • free light chains contained in serum.                   |\n|                        |            | If serum free light chain testing is not available, use a |\n|                        |            | Bence–Jones protein urine test. [1.10.4]                  |\n|                        |            | See the section on primary care investigations for        |\n|                        |            | more information on tests for myeloma                     |\n\nTitle: Bone Pain and Myeloma Testing in Adults | Summary: This table outlines the recommended blood tests for assessing myeloma in adults aged 60 and over presenting with persistent bone pain.",
    "table_summary": "Title: Bone Pain and Myeloma Testing in Adults | Summary: This table outlines the recommended blood tests for assessing myeloma in adults aged 60 and over presenting with persistent bone pain."
  },
  {
    "element_id": "page_55_seq_0",
    "page_number": 55,
    "type": "text",
    "raw_text": "Fracture\nSymptom and specific Possible\nRecommendation\nfeatures cancer\nOffer a full blood count and blood tests for:\n• calcium\n• plasma viscosity or erythrocyte sedimentation rate\nFracture\n• paraprotein, using serum protein electrophoresis\n(unexplained), Myeloma\n60 and over • free light chains contained in serum.\nIf serum free light chain testing is not available, use a\nBence–Jones protein urine test. [1.10.4]\nSee the section on primary care investigations for\nmore information on tests for myeloma\nSkin or surface symptoms\nSee also the section on lumps or masses for oral lesions.\nSkin or surface symptoms\nSymptoms and signs Possible cancer Recommendation\nAnal ulceration Consider a suspected cancer pathway\nAnal\n(unexplained) referral [1.3.6]\nBruising (unexplained) in Consider a very urgent full blood count\nLeukaemia\nadults (within 48 hours) [1.10.1]\nNipple changes of\nconcern (in one nipple\nRefer people using a suspected cancer\nonly) including discharge Breast\npathway referral [1.4.1]\n\nThis chunk of the NICE guideline provides recommendations for primary care physicians on how to assess and refer patients with suspected cancer based on specific symptoms and signs, focusing on unexplained fractures in older adults and various skin or surface symptoms in adults. It guides clinicians in determining appropriate actions, such as blood tests for myeloma in cases of unexplained fractures and considering cancer pathway referrals for anal ulceration, unexplained bruising, or concerning nipple changes."
  },
  {
    "element_id": "page_55_seq_0",
    "page_number": 55,
    "type": "text",
    "raw_text": "Refer people using a suspected cancer\nonly) including discharge Breast\npathway referral [1.4.1]\nand retraction, 50 and\nover\n\nThis chunk, found in the breast cancer section of the NICE guideline, advises healthcare professionals to refer patients aged 50 and over for suspected breast cancer via an expedited pathway if they experience nipple discharge or retraction in only one nipple. This recommendation aims to facilitate earlier diagnosis and treatment for a specific, concerning presentation of potential breast cancer."
  },
  {
    "element_id": "page_55",
    "page_number": 55,
    "type": "table",
    "raw_text": "Table 1 on Page 55\n\n| Symptom and specific   | Possible   | Recommendation                                            |\n| features               | cancer     |                                                           |\n|:-----------------------|:-----------|:----------------------------------------------------------|\n| Fracture               | Myeloma    | Offer a full blood count and blood tests for:             |\n| (unexplained),         |            | • calcium                                                 |\n| 60 and over            |            | • plasma viscosity or erythrocyte sedimentation rate      |\n|                        |            | • paraprotein, using serum protein electrophoresis        |\n|                        |            | • free light chains contained in serum.                   |\n|                        |            | If serum free light chain testing is not available, use a |\n|                        |            | Bence–Jones protein urine test. [1.10.4]                  |\n|                        |            | See the section on primary care investigations for        |\n|                        |            | more information on tests for myeloma                     |\n\nTitle: Unexplained Fractures in Adults Aged 60 and Over | Summary: This table outlines the recommended blood tests and urine test (if necessary) for assessing myeloma in adults aged 60 and over presenting with an unexplained fracture. It also references where to find more information on the tests.",
    "table_summary": "Title: Unexplained Fractures in Adults Aged 60 and Over | Summary: This table outlines the recommended blood tests and urine test (if necessary) for assessing myeloma in adults aged 60 and over presenting with an unexplained fracture. It also references where to find more information on the tests."
  },
  {
    "element_id": "page_55",
    "page_number": 55,
    "type": "table",
    "raw_text": "Table 2 on Page 55\n\n| Symptoms and signs        | Possible cancer   | Recommendation                          |\n|:--------------------------|:------------------|:----------------------------------------|\n| Anal ulceration           | Anal              | Consider a suspected cancer pathway     |\n| (unexplained)             |                   | referral [1.3.6]                        |\n| Bruising (unexplained) in | Leukaemia         | Consider a very urgent full blood count |\n| adults                    |                   | (within 48 hours) [1.10.1]              |\n| Nipple changes of         | Breast            | Refer people using a suspected cancer   |\n| concern (in one nipple    |                   | pathway referral [1.4.1]                |\n| only) including discharge |                   |                                         |\n| and retraction, 50 and    |                   |                                         |\n| over                      |                   |                                         |\n\nTitle: Skin or Surface Symptoms Table | Summary: This table lists various skin or surface symptoms, the possible cancer they might indicate, and the recommended action, such as referral or blood tests.",
    "table_summary": "Title: Skin or Surface Symptoms Table | Summary: This table lists various skin or surface symptoms, the possible cancer they might indicate, and the recommended action, such as referral or blood tests."
  },
  {
    "element_id": "page_56_seq_0",
    "page_number": 56,
    "type": "text",
    "raw_text": "Symptoms and signs Possible cancer Recommendation\nConsider urgent referral (for an\nappointment within 2 weeks) for\nassessment by a dentist [1.8.3]\nOral cavity red or red and\nConsider a suspected cancer pathway\nwhite patchconsistent\nOral referral by the dentist for people when\nwith erythroplakia or\nassessed by a dentist as having a red or\nerythroleukoplakia\nred and white patch in the oral cavity\nconsistent with erythroplakia or\nerythroleukoplakia [1.8.4]\nConsider a very urgent full blood count\nPallor Leukaemia\n(within 48 hours) [1.10.1]\nPenile lesion (ulcerated\nand sexually transmitted\ninfection has been\nexcluded, or persistent Consider a suspected cancer pathway\nPenile\nafter treatment for a referral [1.6.9]\nsexually transmitted\ninfection has been\ncompleted) in men\nPenile mass (and sexually\ntransmitted infection has Consider a suspected cancer pathway\nPenile\nbeen excluded as a cause) referral [1.6.9]\nin men\nPenile symptomsaffecting\n\nThis chunk, found within the \"Recommendations organised by symptom and findings of primary care investigations\" section, provides guidance on specific skin or surface symptoms that may indicate cancer, and details the recommended actions (referrals or blood tests) based on those symptoms. It helps healthcare professionals quickly identify potential cancers based on easily observable signs and determine the appropriate next steps."
  },
  {
    "element_id": "page_56_seq_0",
    "page_number": 56,
    "type": "text",
    "raw_text": "Penile\nbeen excluded as a cause) referral [1.6.9]\nin men\nPenile symptomsaffecting\nthe foreskin or glans Consider a suspected cancer pathway\nPenile\n(unexplained or persistent) referral [1.6.10]\nin men\nPetechiae (unexplained) in Consider a very urgent full blood count\nLeukaemia\nadults (within 48 hours) [1.10.1]\n\nThis section of the NICE guideline provides recommendations for healthcare professionals on when to suspect penile cancer and leukemia based on specific symptoms observed in patients. It advises on appropriate referral pathways (suspected cancer pathway referral or a very urgent full blood count) to ensure timely diagnosis and management of these conditions."
  },
  {
    "element_id": "page_56",
    "page_number": 56,
    "type": "table",
    "raw_text": "Table 1 on Page 56\n\n| Symptoms and signs          | Possible cancer   | Recommendation                           |\n|:----------------------------|:------------------|:-----------------------------------------|\n| Oral cavity red or red and  | Oral              | Consider urgent referral (for an         |\n| white patchconsistent       |                   | appointment within 2 weeks) for          |\n| with erythroplakia or       |                   | assessment by a dentist [1.8.3]          |\n| erythroleukoplakia          |                   | Consider a suspected cancer pathway      |\n|                             |                   | referral by the dentist for people when  |\n|                             |                   | assessed by a dentist as having a red or |\n|                             |                   | red and white patch in the oral cavity   |\n|                             |                   | consistent with erythroplakia or         |\n|                             |                   | erythroleukoplakia [1.8.4]               |\n| Pallor                      | Leukaemia         | Consider a very urgent full blood count  |\n|                             |                   | (within 48 hours) [1.10.1]               |\n| Penile lesion (ulcerated    | Penile            | Consider a suspected cancer pathway      |\n| and sexually transmitted    |                   | referral [1.6.9]                         |\n| infection has been          |                   |                                          |\n| excluded, or persistent     |                   |                                          |\n| after treatment for a       |                   |                                          |\n| sexually transmitted        |                   |                                          |\n| infection has been          |                   |                                          |\n| completed) in men           |                   |                                          |\n| Penile mass (and sexually   | Penile            | Consider a suspected cancer pathway      |\n| transmitted infection has   |                   | referral [1.6.9]                         |\n| been excluded as a cause)   |                   |                                          |\n| in men                      |                   |                                          |\n| Penile symptomsaffecting    | Penile            | Consider a suspected cancer pathway      |\n| the foreskin or glans       |                   | referral [1.6.10]                        |\n| (unexplained or persistent) |                   |                                          |\n| in men                      |                   |                                          |\n| Petechiae (unexplained) in  | Leukaemia         | Consider a very urgent full blood count  |\n| adults                      |                   | (within 48 hours) [1.10.1]               |\n\nTitle: Skin or Surface Symptoms and Possible Cancer Referrals | Summary: This table details various skin or surface symptoms that may indicate cancer in adults and specifies the recommended actions, such as urgent blood tests or suspected cancer pathway referrals, based on the symptom and potential cancer type.",
    "table_summary": "Title: Skin or Surface Symptoms and Possible Cancer Referrals | Summary: This table details various skin or surface symptoms that may indicate cancer in adults and specifies the recommended actions, such as urgent blood tests or suspected cancer pathway referrals, based on the symptom and potential cancer type."
  },
  {
    "element_id": "page_57_seq_0",
    "page_number": 57,
    "type": "text",
    "raw_text": "Symptoms and signs Possible cancer Recommendation\nConsider a suspected cancer pathway\nreferral. When considering referral, take\ninto account any associated symptoms\n[1.10.6]\nSeparate recommendations have been\nPruritus with unexplained Non-Hodgkin's\nmade for adults and for children and young\nsplenomegaly in adults lymphoma\npeople to reflect that there are different\nreferral pathways. In practice young\npeople (aged 16 to 24) may be referred\nusing either pathway depending on their\nage and local arrangements\nConsider a suspected cancer pathway\nreferral. When considering referral, take\ninto account any associated symptoms\n[1.10.8]\nHodgkin's\nSeparate recommendations have been\nPruritus with unexplained lymphoma or\nmade for adults and for children and young\nlymphadenopathy in adults non-Hodgkin's\npeople to reflect that there are different\nlymphoma\nreferral pathways. In practice young\npeople (aged 16 to 24) may be referred\nusing either pathway depending on their\nage and local arrangements\n\nThis section of the NICE guideline provides recommendations for when to suspect and refer adults for Non-Hodgkin's or Hodgkin's lymphoma based on the presence of pruritus (itching) along with unexplained splenomegaly (enlarged spleen) or lymphadenopathy (swollen lymph nodes), emphasizing the importance of considering associated symptoms and tailoring referral pathways based on age. It helps healthcare professionals identify potential cases of lymphoma in adults, highlighting key symptoms that warrant further investigation and referral to specialist services."
  },
  {
    "element_id": "page_57_seq_0",
    "page_number": 57,
    "type": "text",
    "raw_text": "using either pathway depending on their\nage and local arrangements\nSkin changes that Consider a suspected cancer pathway\nBreast\nsuggest breast cancer referral [1.4.2]\nSkin lesion (pigmented\nand suspicious) with a Refer people using a suspected cancer\nMelanoma\nweighted 7-point checklist pathway referral [1.7.1]\nscore of 3 or more\nSkin lesion (pigmented or\nnon-pigmented) that Consider a suspected cancer pathway\nMelanoma\nsuggests nodular referral [1.7.3]\nmelanoma\n\nThis excerpt provides specific recommendations for suspected breast and skin cancers, detailing when to consider or make a suspected cancer pathway referral based on observed skin changes or lesion characteristics. It is part of a larger section organizing recommendations by symptom to guide healthcare professionals in appropriately referring patients for further investigation of potential cancer."
  },
  {
    "element_id": "page_57",
    "page_number": 57,
    "type": "table",
    "raw_text": "Table 1 on Page 57\n\n| Symptoms and signs         | Possible cancer   | Recommendation                             |\n|:---------------------------|:------------------|:-------------------------------------------|\n| Pruritus with unexplained  | Non-Hodgkin's     | Consider a suspected cancer pathway        |\n| splenomegaly in adults     | lymphoma          | referral. When considering referral, take  |\n|                            |                   | into account any associated symptoms       |\n|                            |                   | [1.10.6]                                   |\n|                            |                   | Separate recommendations have been         |\n|                            |                   | made for adults and for children and young |\n|                            |                   | people to reflect that there are different |\n|                            |                   | referral pathways. In practice young       |\n|                            |                   | people (aged 16 to 24) may be referred     |\n|                            |                   | using either pathway depending on their    |\n|                            |                   | age and local arrangements                 |\n| Pruritus with unexplained  | Hodgkin's         | Consider a suspected cancer pathway        |\n| lymphadenopathy in adults  | lymphoma or       | referral. When considering referral, take  |\n|                            | non-Hodgkin's     | into account any associated symptoms       |\n|                            | lymphoma          | [1.10.8]                                   |\n|                            |                   | Separate recommendations have been         |\n|                            |                   | made for adults and for children and young |\n|                            |                   | people to reflect that there are different |\n|                            |                   | referral pathways. In practice young       |\n|                            |                   | people (aged 16 to 24) may be referred     |\n|                            |                   | using either pathway depending on their    |\n|                            |                   | age and local arrangements                 |\n| Skin changes that          | Breast            | Consider a suspected cancer pathway        |\n| suggest breast cancer      |                   | referral [1.4.2]                           |\n| Skin lesion (pigmented     | Melanoma          | Refer people using a suspected cancer      |\n| and suspicious) with a     |                   | pathway referral [1.7.1]                   |\n| weighted 7-point checklist |                   |                                            |\n| score of 3 or more         |                   |                                            |\n| Skin lesion (pigmented or  | Melanoma          | Consider a suspected cancer pathway        |\n| non-pigmented) that        |                   | referral [1.7.3]                           |\n| suggests nodular           |                   |                                            |\n| melanoma                   |                   |                                            |\n\nTitle: Skin or Surface Symptoms Table | Summary: This table outlines the recommended actions (referral types) based on skin or surface symptoms that could indicate specific cancers, differentiating between Hodgkin's and Non-Hodgkin's lymphoma and including important details about referral pathways and age considerations.",
    "table_summary": "Title: Skin or Surface Symptoms Table | Summary: This table outlines the recommended actions (referral types) based on skin or surface symptoms that could indicate specific cancers, differentiating between Hodgkin's and Non-Hodgkin's lymphoma and including important details about referral pathways and age considerations."
  },
  {
    "element_id": "page_58_seq_0",
    "page_number": 58,
    "type": "text",
    "raw_text": "Symptoms and signs Possible cancer Recommendation\nSkin lesion that raises the\nSquamous cell Consider a suspected cancer pathway\nsuspicion of a squamous\ncarcinoma referral [1.7.4]\ncell carcinoma\nConsider routine referral [1.7.5]\nOnly consider a suspected cancer\npathway referral if there is particular\nconcern that a delay may have a\nSkin lesion that raises the significant impact, because of factors such\nBasal cell\nsuspicion of a basal cell as lesion site or size [1.7.6]\ncarcinoma\ncarcinoma\nTypical features of basal cell carcinoma\ninclude: an ulcer with a raised rolled edge;\nprominent fine blood vessels around a\nlesion; or a nodule on the skin (particularly\npearly or waxy nodules)\nVulval lump or ulceration Consider a suspected cancer pathway\nVulval\n(unexplained) in women referral [1.5.14]\nUrological symptoms\nDysuria\nPossible\nSymptom and specific features Recommendation\ncancer\nDysuria with unexplained non-visible Refer people using a suspected\nBladder\n\nThis chunk provides guidance on recognizing and referring suspected skin cancers (squamous cell carcinoma and basal cell carcinoma) and vulval cancer based on observed symptoms and signs, contributing to the guideline's overall aim of early cancer detection and appropriate referral pathways. It also begins the transition to a new section on urological symptoms."
  },
  {
    "element_id": "page_58_seq_0",
    "page_number": 58,
    "type": "text",
    "raw_text": "cancer\nDysuria with unexplained non-visible Refer people using a suspected\nBladder\nhaematuria, 60 and over cancer pathway referral [1.6.4]\nErectile dysfunction\nSymptom and Possible\nRecommendation\nspecific features cancer\nConsider a prostate-specific antigen (PSA) test and digital\nErectile\nrectal examination [1.6.2]\ndysfunction in Prostate\nSee the section on primary care investigations for more\nmen\ninformation on PSA tests and digital rectal examination\n\nThis excerpt from the NICE guideline provides specific recommendations for urological symptoms, outlining when a suspected cancer pathway referral is necessary (dysuria with non-visible haematuria for bladder cancer) and when further investigation with PSA testing and digital rectal exam is warranted (erectile dysfunction for prostate cancer). It serves as a quick reference for healthcare professionals to determine the appropriate course of action for patients presenting with these symptoms, aiding in the early detection and management of potential urological cancers."
  },
  {
    "element_id": "page_58",
    "page_number": 58,
    "type": "table",
    "raw_text": "Table 1 on Page 58\n\n| Symptoms and signs          | Possible cancer   | Recommendation                                |\n|:----------------------------|:------------------|:----------------------------------------------|\n| Skin lesion that raises the | Squamous cell     | Consider a suspected cancer pathway           |\n| suspicion of a squamous     | carcinoma         | referral [1.7.4]                              |\n| cell carcinoma              |                   |                                               |\n| Skin lesion that raises the | Basal cell        | Consider routine referral [1.7.5]             |\n| suspicion of a basal cell   | carcinoma         | Only consider a suspected cancer              |\n| carcinoma                   |                   | pathway referral if there is particular       |\n|                             |                   | concern that a delay may have a               |\n|                             |                   | significant impact, because of factors such   |\n|                             |                   | as lesion site or size [1.7.6]                |\n|                             |                   | Typical features of basal cell carcinoma      |\n|                             |                   | include: an ulcer with a raised rolled edge;  |\n|                             |                   | prominent fine blood vessels around a         |\n|                             |                   | lesion; or a nodule on the skin (particularly |\n|                             |                   | pearly or waxy nodules)                       |\n| Vulval lump or ulceration   | Vulval            | Consider a suspected cancer pathway           |\n| (unexplained) in women      |                   | referral [1.5.14]                             |\n\nTitle: Skin or Surface Symptoms Table | Summary: This table provides recommendations for referral based on skin or surface symptoms that may indicate skin cancer or vulval cancer in women. It details specific features of skin lesions and suggests appropriate referral pathways, including routine referral for suspected basal cell carcinoma and suspected cancer pathway referrals for squamous cell carcinoma and vulval cancer.",
    "table_summary": "Title: Skin or Surface Symptoms Table | Summary: This table provides recommendations for referral based on skin or surface symptoms that may indicate skin cancer or vulval cancer in women. It details specific features of skin lesions and suggests appropriate referral pathways, including routine referral for suspected basal cell carcinoma and suspected cancer pathway referrals for squamous cell carcinoma and vulval cancer."
  },
  {
    "element_id": "page_58",
    "page_number": 58,
    "type": "table",
    "raw_text": "Table 2 on Page 58\n\n| Symptom and specific features        | Possible   | Recommendation                  |\n|                                      | cancer     |                                 |\n|:-------------------------------------|:-----------|:--------------------------------|\n| Dysuria with unexplained non-visible | Bladder    | Refer people using a suspected  |\n| haematuria, 60 and over              |            | cancer pathway referral [1.6.4] |\n\nTitle: Urological Symptoms Table | Summary: This table lists urological symptoms and specific features, the possible cancer they may indicate, and the corresponding recommendation for referral or action.",
    "table_summary": "Title: Urological Symptoms Table | Summary: This table lists urological symptoms and specific features, the possible cancer they may indicate, and the corresponding recommendation for referral or action."
  },
  {
    "element_id": "page_58",
    "page_number": 58,
    "type": "table",
    "raw_text": "Table 3 on Page 58\n\n| Symptom and         | Possible   | Recommendation                                              |\n| specific features   | cancer     |                                                             |\n|:--------------------|:-----------|:------------------------------------------------------------|\n| Erectile            | Prostate   | Consider a prostate-specific antigen (PSA) test and digital |\n| dysfunction in      |            | rectal examination [1.6.2]                                  |\n| men                 |            | See the section on primary care investigations for more     |\n|                     |            | information on PSA tests and digital rectal examination     |\n\nTitle: Erectile Dysfunction Urological Symptoms | Summary: This table outlines the recommendation for assessing prostate cancer in men presenting with erectile dysfunction, advising a PSA test and digital rectal examination. It refers to the primary care investigations section for more details on these tests.",
    "table_summary": "Title: Erectile Dysfunction Urological Symptoms | Summary: This table outlines the recommendation for assessing prostate cancer in men presenting with erectile dysfunction, advising a PSA test and digital rectal examination. It refers to the primary care investigations section for more details on these tests."
  },
  {
    "element_id": "page_59_seq_0",
    "page_number": 59,
    "type": "text",
    "raw_text": "Haematuria\nSymptom and specific features Possible cancer Recommendation\nHaematuria (visible and unexplained) either\nwithout urinary tract infection or that Refer people using a\nBladder or\npersists or recurs after successful suspected cancer pathway\nrenal\ntreatment of urinary tract infection, 45 and referral [1.6.4] [1.6.6]\nover\nHaematuria (non-visible and unexplained) Refer people using a\nwith dysuria or raised white cell count on a Bladder suspected cancer pathway\nblood test, 60 and over referral [1.6.4]\nHaematuria (visible) with low haemoglobin\nlevels or thrombocytosis or high blood Consider a direct access\nEndometrial\nglucose levels or unexplained vaginal ultrasound scan [1.5.12]\ndischarge in women 55 and over\nConsider a prostate-specific\nantigen (PSA) test and digital\nrectal examination [1.6.2]\nHaematuria (visible) in men Prostate See the section on primary\ncare investigations for more\ninformation on PSA tests and\ndigital rectal examination\nTesticular symptoms\nPossible\n\nThis chunk, found within the \"Recommendations organised by symptom and findings of primary care investigations\" section, provides specific guidance to healthcare professionals on the appropriate actions to take when a patient presents with haematuria (blood in the urine), including suspected cancer pathway referrals and further investigations based on age, other symptoms, and test results. It's purpose is to help clinicians determine the likelihood of urological or other cancers based on the specific presentation of haematuria."
  },
  {
    "element_id": "page_59_seq_0",
    "page_number": 59,
    "type": "text",
    "raw_text": "information on PSA tests and\ndigital rectal examination\nTesticular symptoms\nPossible\nSymptom and specific features Recommendation\ncancer\nTestis enlargement or change in shape or Consider a suspected cancer\nTesticular\ntexture (non-painful) in men pathway referral [1.6.7]\nTesticular symptoms (unexplained or Consider a direct access\nTesticular\npersistent) in men ultrasound scan [1.6.8]\n\nThis chunk provides specific guidance on when to suspect testicular cancer and what actions to take, either a suspected cancer pathway referral or a direct access ultrasound scan, based on particular symptoms. It is part of a larger section that helps healthcare professionals quickly identify potential cancers based on specific symptoms, enabling timely referrals and investigations."
  },
  {
    "element_id": "page_59",
    "page_number": 59,
    "type": "table",
    "raw_text": "Table 1 on Page 59\n\n| Symptom and specific features                | Possible cancer   | Recommendation                 |\n|:---------------------------------------------|:------------------|:-------------------------------|\n| Haematuria (visible and unexplained) either  | Bladder or        | Refer people using a           |\n| without urinary tract infection or that      | renal             | suspected cancer pathway       |\n| persists or recurs after successful          |                   | referral [1.6.4] [1.6.6]       |\n| treatment of urinary tract infection, 45 and |                   |                                |\n| over                                         |                   |                                |\n| Haematuria (non-visible and unexplained)     | Bladder           | Refer people using a           |\n| with dysuria or raised white cell count on a |                   | suspected cancer pathway       |\n| blood test, 60 and over                      |                   | referral [1.6.4]               |\n| Haematuria (visible) with low haemoglobin    | Endometrial       | Consider a direct access       |\n| levels or thrombocytosis or high blood       |                   | ultrasound scan [1.5.12]       |\n| glucose levels or unexplained vaginal        |                   |                                |\n| discharge in women 55 and over               |                   |                                |\n| Haematuria (visible) in men                  | Prostate          | Consider a prostate-specific   |\n|                                              |                   | antigen (PSA) test and digital |\n|                                              |                   | rectal examination [1.6.2]     |\n|                                              |                   | See the section on primary     |\n|                                              |                   | care investigations for more   |\n|                                              |                   | information on PSA tests and   |\n|                                              |                   | digital rectal examination     |\n\nTitle: Haematuria Recommendations | Summary: This table details recommendations for referral and testing based on haematuria symptoms, differentiating by age, presence of other symptoms, and sex, and linking these symptoms to potential bladder, renal, endometrial, or prostate cancer.",
    "table_summary": "Title: Haematuria Recommendations | Summary: This table details recommendations for referral and testing based on haematuria symptoms, differentiating by age, presence of other symptoms, and sex, and linking these symptoms to potential bladder, renal, endometrial, or prostate cancer."
  },
  {
    "element_id": "page_59",
    "page_number": 59,
    "type": "table",
    "raw_text": "Table 2 on Page 59\n\n| Symptom and specific features            | Possible   | Recommendation              |\n|                                          | cancer     |                             |\n|:-----------------------------------------|:-----------|:----------------------------|\n| Testis enlargement or change in shape or | Testicular | Consider a suspected cancer |\n| texture (non-painful) in men             |            | pathway referral [1.6.7]    |\n| Testicular symptoms (unexplained or      | Testicular | Consider a direct access    |\n| persistent) in men                       |            | ultrasound scan [1.6.8]     |\n\nTitle: Testicular Symptoms Table | Summary: This table provides recommendations for referral and investigation of suspected testicular cancer based on specific symptoms and findings during examination.",
    "table_summary": "Title: Testicular Symptoms Table | Summary: This table provides recommendations for referral and investigation of suspected testicular cancer based on specific symptoms and findings during examination."
  },
  {
    "element_id": "page_60_seq_0",
    "page_number": 60,
    "type": "text",
    "raw_text": "Other urinary tract symptoms\nPossible\nSymptom and specific features Recommendation\ncancer\nConsider non-urgent referral for\nUrinary tract infection (unexplained bladder cancer in people aged\nand recurrent or persistent), 60 and Bladder 60 and over with recurrent or\nover persistent unexplained urinary tract\ninfection [1.6.5]\nConsider a prostate-specific antigen\n(PSA) test and digital rectal\nLower urinary tract symptoms, such examination [1.6.2]\nas nocturia, urinary frequency, Prostate See the section on primary care\nhesitancy, urgency or retention in men investigations for more information\non PSA tests and digital rectal\nexamination\nCarry out tests in primary care [1.5.2]\nMeasure serum CA125 in primary\nUrinary urgency or frequency\ncare [1.5.6]\n(increased and persistent or frequent\nSee the section on primary care\n– particularly more than 12 times per Ovarian\ninvestigations for information on tests\nmonth) in women, especially if 50 and\nfor ovarian cancer\nover\nThese recommendations apply to\n\nThis chunk of the NICE guideline provides recommendations for healthcare professionals on how to assess and manage patients presenting with various urinary tract symptoms, specifically focusing on the potential for underlying bladder, prostate, or ovarian cancer depending on the symptom profile and patient demographics. It guides clinicians on when to consider further investigations, such as PSA testing or CA125, or when to make a non-urgent referral for suspected cancer."
  },
  {
    "element_id": "page_60_seq_0",
    "page_number": 60,
    "type": "text",
    "raw_text": "month) in women, especially if 50 and\nfor ovarian cancer\nover\nThese recommendations apply to\nwomen aged 18 and over\n\nThis chunk, found within the Gynaecological cancers section, specifies that if women (especially those aged 50 and over) persistently experience abdominal distension, feeling full, pelvic or abdominal pain, or increased urinary urgency/frequency (more than 12 times a month), primary care tests for ovarian cancer are recommended. It emphasizes that these recommendations are applicable to all women aged 18 and over."
  },
  {
    "element_id": "page_60",
    "page_number": 60,
    "type": "table",
    "raw_text": "Table 1 on Page 60\n\n| Symptom and specific features          | Possible   | Recommendation                          |\n|                                        | cancer     |                                         |\n|:---------------------------------------|:-----------|:----------------------------------------|\n| Urinary tract infection (unexplained   | Bladder    | Consider non-urgent referral for        |\n| and recurrent or persistent), 60 and   |            | bladder cancer in people aged           |\n| over                                   |            | 60 and over with recurrent or           |\n|                                        |            | persistent unexplained urinary tract    |\n|                                        |            | infection [1.6.5]                       |\n| Lower urinary tract symptoms, such     | Prostate   | Consider a prostate-specific antigen    |\n| as nocturia, urinary frequency,        |            | (PSA) test and digital rectal           |\n| hesitancy, urgency or retention in men |            | examination [1.6.2]                     |\n|                                        |            | See the section on primary care         |\n|                                        |            | investigations for more information     |\n|                                        |            | on PSA tests and digital rectal         |\n|                                        |            | examination                             |\n| Urinary urgency or frequency           | Ovarian    | Carry out tests in primary care [1.5.2] |\n| (increased and persistent or frequent  |            | Measure serum CA125 in primary          |\n| – particularly more than 12 times per  |            | care [1.5.6]                            |\n| month) in women, especially if 50 and  |            | See the section on primary care         |\n| over                                   |            | investigations for information on tests |\n|                                        |            | for ovarian cancer                      |\n|                                        |            | These recommendations apply to          |\n|                                        |            | women aged 18 and over                  |\n\nTitle: Urological Symptoms Table | Summary: This table outlines recommendations for assessment and referral based on urological symptoms, differentiating between bladder, prostate, and ovarian cancer, and specifying necessary actions like PSA tests, digital rectal exams, CA125 measurements, and referrals based on age and symptom presentation.",
    "table_summary": "Title: Urological Symptoms Table | Summary: This table outlines recommendations for assessment and referral based on urological symptoms, differentiating between bladder, prostate, and ovarian cancer, and specifying necessary actions like PSA tests, digital rectal exams, CA125 measurements, and referrals based on age and symptom presentation."
  },
  {
    "element_id": "page_61_seq_0",
    "page_number": 61,
    "type": "text",
    "raw_text": "Non-specific features of cancer\nAppetite loss or early satiety\nSymptom and specific features Possible cancer Recommendation\nCarry out an assessment for\nadditional symptoms, signs or\nSeveral, including\nfindings that may help to\nlung, oesophageal,\nclarify which cancer is most\nAppetite loss (unexplained) stomach, colorectal,\nlikely\npancreatic, bladder\nOffer urgent investigation or\nor renal\na suspected cancer pathway\nreferral [1.13.3]\nOffer an urgent chest X-ray\nAppetite loss (unexplained), Lung or\n(to be done within 2 weeks)\n40 and over, ever smoked mesothelioma\n[1.1.2] [1.1.5]\nAppetite loss (unexplained), Offer an urgent chest X-ray\n40 and over, exposed to Mesothelioma (to be done within 2 weeks)\nasbestos [1.1.5]\nAppetite loss (unexplained) with\nOffer an urgent chest X-ray\ncough or fatigue or shortness of Lung or\n(to be done within 2 weeks)\nbreath or chest pain or weight mesothelioma\n[1.1.2] [1.1.5]\nloss (unexplained), 40 and over\nCarry out tests in primary\ncare [1.5.2]\n\nThis section addresses non-specific symptoms like appetite loss, which can be indicative of several cancers, and provides guidance for healthcare professionals on how to proceed with assessment, investigation, and referral based on specific factors like age, smoking history, and asbestos exposure. It emphasizes a tiered approach starting with a broad assessment and potentially leading to urgent investigations to identify the most likely cancer."
  },
  {
    "element_id": "page_61_seq_0",
    "page_number": 61,
    "type": "text",
    "raw_text": "[1.1.2] [1.1.5]\nloss (unexplained), 40 and over\nCarry out tests in primary\ncare [1.5.2]\nMeasure serum CA125 in\nAppetite loss or early satiety primary care [1.5.6]\n(persistent or frequent – See the section on primary\nparticularly more than 12 times Ovarian care investigations for\nper month) in women, especially information on tests for\nif 50 and over ovarian cancer\nThese recommendations\napply to women aged 18 and\nover\n\nThis section provides guidance on when to consider testing for ovarian cancer in women presenting with appetite loss or early satiety, particularly if these symptoms are persistent or frequent. It emphasizes the importance of considering ovarian cancer in women over 50, as well as directing the reader to the appropriate primary care investigations."
  },
  {
    "element_id": "page_61",
    "page_number": 61,
    "type": "table",
    "raw_text": "Table 1 on Page 61\n\n| Symptom and specific features    | Possible cancer      | Recommendation                |\n|:---------------------------------|:---------------------|:------------------------------|\n| Appetite loss (unexplained)      | Several, including   | Carry out an assessment for   |\n|                                  | lung, oesophageal,   | additional symptoms, signs or |\n|                                  | stomach, colorectal, | findings that may help to     |\n|                                  | pancreatic, bladder  | clarify which cancer is most  |\n|                                  | or renal             | likely                        |\n|                                  |                      | Offer urgent investigation or |\n|                                  |                      | a suspected cancer pathway    |\n|                                  |                      | referral [1.13.3]             |\n| Appetite loss (unexplained),     | Lung or              | Offer an urgent chest X-ray   |\n| 40 and over, ever smoked         | mesothelioma         | (to be done within 2 weeks)   |\n|                                  |                      | [1.1.2] [1.1.5]               |\n| Appetite loss (unexplained),     | Mesothelioma         | Offer an urgent chest X-ray   |\n| 40 and over, exposed to          |                      | (to be done within 2 weeks)   |\n| asbestos                         |                      | [1.1.5]                       |\n| Appetite loss (unexplained) with | Lung or              | Offer an urgent chest X-ray   |\n| cough or fatigue or shortness of | mesothelioma         | (to be done within 2 weeks)   |\n| breath or chest pain or weight   |                      | [1.1.2] [1.1.5]               |\n| loss (unexplained), 40 and over  |                      |                               |\n| Appetite loss or early satiety   | Ovarian              | Carry out tests in primary    |\n| (persistent or frequent –        |                      | care [1.5.2]                  |\n| particularly more than 12 times  |                      | Measure serum CA125 in        |\n| per month) in women, especially  |                      | primary care [1.5.6]          |\n| if 50 and over                   |                      | See the section on primary    |\n|                                  |                      | care investigations for       |\n|                                  |                      | information on tests for      |\n|                                  |                      | ovarian cancer                |\n|                                  |                      | These recommendations         |\n|                                  |                      | apply to women aged 18 and    |\n|                                  |                      | over                          |\n\nTitle: Appetite Loss Cancer Referral Guidelines | Summary: This table outlines recommendations for investigating and referring patients with unexplained appetite loss, considering potential cancers and specific factors like age, smoking history, asbestos exposure, and other symptoms. It also provides guidance on primary care tests for women with persistent appetite loss or early satiety, especially those over 50, to assess for ovarian cancer.",
    "table_summary": "Title: Appetite Loss Cancer Referral Guidelines | Summary: This table outlines recommendations for investigating and referring patients with unexplained appetite loss, considering potential cancers and specific factors like age, smoking history, asbestos exposure, and other symptoms. It also provides guidance on primary care tests for women with persistent appetite loss or early satiety, especially those over 50, to assess for ovarian cancer."
  },
  {
    "element_id": "page_62_seq_0",
    "page_number": 62,
    "type": "text",
    "raw_text": "Deep vein thrombosis\nSymptom and\nPossible cancer Recommendation\nspecific features\nCarry out an assessment for additional\nSeveral, including symptoms, signs or findings that may help to\nDeep vein\nurogenital, breast, clarify which cancer is most likely\nthrombosis\ncolorectal and lung Consider urgent investigation or a suspected\ncancer pathway referral [1.13.4]\nDiabetes\nSymptom and specific Possible\nRecommendation\nfeatures cancer\nDiabetes (new Consider an urgent, direct access CT scan (to be\nonset) with weight Pancreatic done within 2 weeks), or urgent ultrasound scan if\nloss, 60 and over CT is not available [1.2.5]\nFatigue\nSymptom and specific features Possible cancer Recommendation\nOffer an urgent chest X-ray (to\nFatigue (unexplained), 40 and over, Lung or\nbe done within 2 weeks) [1.1.2]\never smoked mesothelioma\n[1.1.5]\nFatigue (unexplained), 40 and over, Offer an urgent chest X-ray (to\nMesothelioma\nexposed to asbestos be done within 2 weeks) [1.1.5]\nFatigue with cough or shortness of\n\nThis chunk of the NICE guideline provides recommendations for investigating potential cancers based on non-specific symptoms like deep vein thrombosis, new-onset diabetes with weight loss, and unexplained fatigue. Its purpose is to guide healthcare professionals in primary care to assess and refer patients with these symptoms for further investigation, considering the possibility of underlying cancers."
  },
  {
    "element_id": "page_62_seq_0",
    "page_number": 62,
    "type": "text",
    "raw_text": "Mesothelioma\nexposed to asbestos be done within 2 weeks) [1.1.5]\nFatigue with cough or shortness of\nOffer an urgent chest X-ray (to\nbreath or chest pain or weight loss or Lung or\nbe done within 2 weeks) [1.1.2]\nappetite loss (unexplained), 40 and mesothelioma\n[1.1.5]\nover\nConsider a very urgent full\nFatigue (persistent) in adults Leukaemia blood count (within 48 hours)\n[1.10.1]\n\nThis section provides guidance on when to suspect mesothelioma and leukemia based on specific symptoms, particularly fatigue. It highlights the need for urgent chest X-rays for those with asbestos exposure or certain symptom combinations related to mesothelioma and a very urgent full blood count for persistent fatigue to rule out leukemia."
  },
  {
    "element_id": "page_62",
    "page_number": 62,
    "type": "table",
    "raw_text": "Table 1 on Page 62\n\n| Symptom and         | Possible cancer     | Recommendation                               |\n| specific features   |                     |                                              |\n|:--------------------|:--------------------|:---------------------------------------------|\n| Deep vein           | Several, including  | Carry out an assessment for additional       |\n| thrombosis          | urogenital, breast, | symptoms, signs or findings that may help to |\n|                     | colorectal and lung | clarify which cancer is most likely          |\n|                     |                     | Consider urgent investigation or a suspected |\n|                     |                     | cancer pathway referral [1.13.4]             |\n\nTitle: Deep Vein Thrombosis and Cancer Risk | Summary: This table outlines the recommendation for patients presenting with deep vein thrombosis to be assessed for other signs/symptoms of cancers including urogenital, breast, colorectal and lung cancer and to consider urgent investigation or suspected cancer pathway referral",
    "table_summary": "Title: Deep Vein Thrombosis and Cancer Risk | Summary: This table outlines the recommendation for patients presenting with deep vein thrombosis to be assessed for other signs/symptoms of cancers including urogenital, breast, colorectal and lung cancer and to consider urgent investigation or suspected cancer pathway referral"
  },
  {
    "element_id": "page_62",
    "page_number": 62,
    "type": "table",
    "raw_text": "Table 2 on Page 62\n\n| Symptom and specific   | Possible   | Recommendation                                     |\n| features               | cancer     |                                                    |\n|:-----------------------|:-----------|:---------------------------------------------------|\n| Diabetes (new          | Pancreatic | Consider an urgent, direct access CT scan (to be   |\n| onset) with weight     |            | done within 2 weeks), or urgent ultrasound scan if |\n| loss, 60 and over      |            | CT is not available [1.2.5]                        |\n\nTitle: Diabetes and Pancreatic Cancer Referral | Summary: This table outlines the recommendation for people aged 60 and over with new-onset diabetes and weight loss to be considered for an urgent CT scan or ultrasound to assess for pancreatic cancer.",
    "table_summary": "Title: Diabetes and Pancreatic Cancer Referral | Summary: This table outlines the recommendation for people aged 60 and over with new-onset diabetes and weight loss to be considered for an urgent CT scan or ultrasound to assess for pancreatic cancer."
  },
  {
    "element_id": "page_62",
    "page_number": 62,
    "type": "table",
    "raw_text": "Table 3 on Page 62\n\n| Symptom and specific features          | Possible cancer   | Recommendation                  |\n|:---------------------------------------|:------------------|:--------------------------------|\n| Fatigue (unexplained), 40 and over,    | Lung or           | Offer an urgent chest X-ray (to |\n| ever smoked                            | mesothelioma      | be done within 2 weeks) [1.1.2] |\n|                                        |                   | [1.1.5]                         |\n| Fatigue (unexplained), 40 and over,    | Mesothelioma      | Offer an urgent chest X-ray (to |\n| exposed to asbestos                    |                   | be done within 2 weeks) [1.1.5] |\n| Fatigue with cough or shortness of     | Lung or           | Offer an urgent chest X-ray (to |\n| breath or chest pain or weight loss or | mesothelioma      | be done within 2 weeks) [1.1.2] |\n| appetite loss (unexplained), 40 and    |                   | [1.1.5]                         |\n| over                                   |                   |                                 |\n| Fatigue (persistent) in adults         | Leukaemia         | Consider a very urgent full     |\n|                                        |                   | blood count (within 48 hours)   |\n|                                        |                   | [1.10.1]                        |\n\nTitle: Table 3: Fatigue as a Possible Cancer Symptom | Summary: This table outlines the recommended actions based on fatigue symptoms, differentiating between unexplained fatigue in specific demographics (age, smoking history, asbestos exposure) and persistent fatigue, and associating them with possible cancers like lung cancer, mesothelioma, and leukemia.",
    "table_summary": "Title: Table 3: Fatigue as a Possible Cancer Symptom | Summary: This table outlines the recommended actions based on fatigue symptoms, differentiating between unexplained fatigue in specific demographics (age, smoking history, asbestos exposure) and persistent fatigue, and associating them with possible cancers like lung cancer, mesothelioma, and leukemia."
  },
  {
    "element_id": "page_63_seq_0",
    "page_number": 63,
    "type": "text",
    "raw_text": "Symptom and specific features Possible cancer Recommendation\nCarry out tests in primary care\n[1.5.2]\nMeasure serum CA125 in\nprimary care [1.5.6]\nSee the section on primary\nFatigue (unexplained) in women Ovarian\ncare investigations for\ninformation on tests for\novarian cancer\nThese recommendations apply\nto women aged 18 and over\nFever\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nFever Consider a very urgent full blood count (within\nLeukaemia\n(unexplained) 48 hours) [1.10.1]\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account any\nassociated symptoms [1.10.6]\nFever with\nSeparate recommendations have been made for\nunexplained Non-Hodgkin's\nadults and for children and young people to reflect\nsplenomegaly in lymphoma\nthat there are different referral pathways. In\nadults\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nConsider a suspected cancer pathway referral.\n\nThis chunk provides guidance on managing patients presenting with unexplained fatigue (specifically in women regarding ovarian cancer) and unexplained fever (in adults, regarding leukaemia and non-Hodgkin's lymphoma). It outlines specific tests and referral considerations to aid healthcare professionals in appropriately assessing and managing these patients, differentiating between urgent actions (like a full blood count for suspected leukaemia) and further investigation for other potential cancers."
  },
  {
    "element_id": "page_63_seq_0",
    "page_number": 63,
    "type": "text",
    "raw_text": "age and local arrangements\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account any\nassociated symptoms [1.10.8]\nFever with Hodgkin's\nSeparate recommendations have been made for\nunexplained lymphoma or\nadults and for children and young people to reflect\nlymphadenopathy non-Hodgkin's\nthat there are different referral pathways. In\nin adults lymphoma\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\n\nThis chunk explains that while separate referral pathways exist for adults and children/young people regarding Hodgkin's and Non-Hodgkin's lymphoma, young people aged 16-24 may be referred through either pathway based on local practices; it also reiterates the importance of considering associated symptoms when deciding on a referral. The inclusion of associated symptoms is crucial for accurately assessing the need for referral."
  },
  {
    "element_id": "page_63",
    "page_number": 63,
    "type": "table",
    "raw_text": "Table 1 on Page 63\n\n| Symptom and specific features   | Possible cancer   | Recommendation                  |\n|:--------------------------------|:------------------|:--------------------------------|\n| Fatigue (unexplained) in women  | Ovarian           | Carry out tests in primary care |\n|                                 |                   | [1.5.2]                         |\n|                                 |                   | Measure serum CA125 in          |\n|                                 |                   | primary care [1.5.6]            |\n|                                 |                   | See the section on primary      |\n|                                 |                   | care investigations for         |\n|                                 |                   | information on tests for        |\n|                                 |                   | ovarian cancer                  |\n|                                 |                   | These recommendations apply     |\n|                                 |                   | to women aged 18 and over       |\n\nTitle: Fatigue in Women Table | Summary: This table details the recommendations for investigating unexplained fatigue in women for potential ovarian cancer, including carrying out tests in primary care and measuring serum CA125 levels. It also refers to the primary care investigations section for more details on ovarian cancer tests and clarifies that the recommendations apply to women aged 18 and over.",
    "table_summary": "Title: Fatigue in Women Table | Summary: This table details the recommendations for investigating unexplained fatigue in women for potential ovarian cancer, including carrying out tests in primary care and measuring serum CA125 levels. It also refers to the primary care investigations section for more details on ovarian cancer tests and clarifies that the recommendations apply to women aged 18 and over."
  },
  {
    "element_id": "page_63",
    "page_number": 63,
    "type": "table",
    "raw_text": "Table 2 on Page 63\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Fever                  | Leukaemia         | Consider a very urgent full blood count (within     |\n| (unexplained)          |                   | 48 hours) [1.10.1]                                  |\n| Fever with             | Non-Hodgkin's     | Consider a suspected cancer pathway referral.       |\n| unexplained            | lymphoma          | When considering referral, take into account any    |\n| splenomegaly in        |                   | associated symptoms [1.10.6]                        |\n| adults                 |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Fever with             | Hodgkin's         | Consider a suspected cancer pathway referral.       |\n| unexplained            | lymphoma or       | When considering referral, take into account any    |\n| lymphadenopathy        | non-Hodgkin's     | associated symptoms [1.10.8]                        |\n| in adults              | lymphoma          | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Fever in Adults and Potential Cancer Associations | Summary: This table outlines recommendations for adults presenting with unexplained fever, either alone or accompanied by splenomegaly or lymphadenopathy, focusing on the potential association with leukemia, Hodgkin's lymphoma, or Non-Hodgkin's lymphoma, and the appropriate referral pathways.",
    "table_summary": "Title: Fever in Adults and Potential Cancer Associations | Summary: This table outlines recommendations for adults presenting with unexplained fever, either alone or accompanied by splenomegaly or lymphadenopathy, focusing on the potential association with leukemia, Hodgkin's lymphoma, or Non-Hodgkin's lymphoma, and the appropriate referral pathways."
  },
  {
    "element_id": "page_64_seq_0",
    "page_number": 64,
    "type": "text",
    "raw_text": "See also the section on respiratory symptoms for chest infection.\nInfection\nPossible\nSymptom and specific features Recommendation\ncancer\nInfection (unexplained and Consider a very urgent full blood\nLeukaemia\npersistent or recurrent) in adults count (within 48 hours) [1.10.1]\nNight sweats\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account any\nassociated symptoms [1.10.6]\nNight sweats\nSeparate recommendations have been made for\nwith unexplained Non-Hodgkin's\nadults and for children and young people to reflect\nsplenomegaly in lymphoma\nthat there are different referral pathways. In\nadults\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account any\nassociated symptoms [1.10.8]\nNight sweats Hodgkin's\n\nThis section of the NICE guideline provides recommendations for primary care physicians on when to suspect cancer based on the symptoms of infection and night sweats in adults, advising urgent blood tests for potential leukemia and suspected cancer pathway referrals for potential lymphomas, considering associated symptoms and age-specific referral pathways. It is part of a broader document aiming to improve early cancer detection and referral accuracy."
  },
  {
    "element_id": "page_64_seq_0",
    "page_number": 64,
    "type": "text",
    "raw_text": "When considering referral, take into account any\nassociated symptoms [1.10.8]\nNight sweats Hodgkin's\nSeparate recommendations have been made for\nwith unexplained lymphoma or\nadults and for children and young people to reflect\nlymphadenopathy non-Hodgkin's\nthat there are different referral pathways. In\nin adults lymphoma\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nPallor\nSymptom and specific Possible\nRecommendation\nfeatures cancer\nConsider a very urgent full blood count (within\nPallor Leukaemia\n48 hours) [1.10.1]\n\nThis excerpt details referral guidelines for adults presenting with night sweats and unexplained lymphadenopathy, symptoms potentially indicative of Hodgkin's or Non-Hodgkin's lymphoma, emphasizing the need to consider associated symptoms when making referral decisions and highlighting different referral pathways for adults versus children/young people. Additionally, it provides guidance on the assessment of pallor, a symptom that could indicate leukemia, with a recommendation for a very urgent full blood count."
  },
  {
    "element_id": "page_64",
    "page_number": 64,
    "type": "table",
    "raw_text": "Table 1 on Page 64\n\n| Symptom and specific features      | Possible   | Recommendation                    |\n|                                    | cancer     |                                   |\n|:-----------------------------------|:-----------|:----------------------------------|\n| Infection (unexplained and         | Leukaemia  | Consider a very urgent full blood |\n| persistent or recurrent) in adults |            | count (within 48 hours) [1.10.1]  |\n\nTitle: Infection and Leukaemia in Adults | Summary: This table provides guidance on when to consider a very urgent full blood count in adults with unexplained and persistent or recurrent infections, as it could be a sign of leukaemia.",
    "table_summary": "Title: Infection and Leukaemia in Adults | Summary: This table provides guidance on when to consider a very urgent full blood count in adults with unexplained and persistent or recurrent infections, as it could be a sign of leukaemia."
  },
  {
    "element_id": "page_64",
    "page_number": 64,
    "type": "table",
    "raw_text": "Table 2 on Page 64\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Night sweats           | Non-Hodgkin's     | Consider a suspected cancer pathway referral.       |\n| with unexplained       | lymphoma          | When considering referral, take into account any    |\n| splenomegaly in        |                   | associated symptoms [1.10.6]                        |\n| adults                 |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Night sweats           | Hodgkin's         | Consider a suspected cancer pathway referral.       |\n| with unexplained       | lymphoma or       | When considering referral, take into account any    |\n| lymphadenopathy        | non-Hodgkin's     | associated symptoms [1.10.8]                        |\n| in adults              | lymphoma          | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Night Sweats - Adult Referral Guidance | Summary: This table provides recommendations for suspected cancer pathway referrals for adults presenting with night sweats and either unexplained splenomegaly (Non-Hodgkin's lymphoma) or unexplained lymphadenopathy (Hodgkin's lymphoma or Non-Hodgkin's lymphoma), noting considerations and referral pathway variations for young adults.",
    "table_summary": "Title: Night Sweats - Adult Referral Guidance | Summary: This table provides recommendations for suspected cancer pathway referrals for adults presenting with night sweats and either unexplained splenomegaly (Non-Hodgkin's lymphoma) or unexplained lymphadenopathy (Hodgkin's lymphoma or Non-Hodgkin's lymphoma), noting considerations and referral pathway variations for young adults."
  },
  {
    "element_id": "page_64",
    "page_number": 64,
    "type": "table",
    "raw_text": "Table 3 on Page 64\n\n| Symptom and specific   | Possible   | Recommendation                                  |\n| features               | cancer     |                                                 |\n|:-----------------------|:-----------|:------------------------------------------------|\n| Pallor                 | Leukaemia  | Consider a very urgent full blood count (within |\n|                        |            | 48 hours) [1.10.1]                              |\n\nTitle: Pallor Symptom Table | Summary: This table describes when to suspect leukaemia based on pallor as a symptom in adults, and recommends a very urgent full blood count within 48 hours.",
    "table_summary": "Title: Pallor Symptom Table | Summary: This table describes when to suspect leukaemia based on pallor as a symptom in adults, and recommends a very urgent full blood count within 48 hours."
  },
  {
    "element_id": "page_65_seq_0",
    "page_number": 65,
    "type": "text",
    "raw_text": "Pruritus\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account any\nassociated symptoms [1.10.6]\nPruritus with\nSeparate recommendations have been made for\nunexplained Non-Hodgkin's\nadults and for children and young people to reflect\nsplenomegaly in lymphoma\nthat there are different referral pathways. In\nadults\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nConsider a suspected cancer pathway referral.\nWhen considering referral, take into account any\nassociated symptoms [1.10.8]\nPruritus with Hodgkin's\nSeparate recommendations have been made for\nunexplained lymphoma or\nadults and for children and young people to reflect\nlymphadenopathy non-Hodgkin's\nthat there are different referral pathways. In\nin adults lymphoma\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\n\nThis section of the NICE guideline focuses on pruritus (itching) as a symptom that could indicate Non-Hodgkin's or Hodgkin's lymphoma in adults, especially when accompanied by unexplained splenomegaly or lymphadenopathy, and advises considering a suspected cancer pathway referral while accounting for other associated symptoms. It highlights that referral pathways differ for adults and children/young people, acknowledging that young people may be referred using either pathway depending on age and local arrangements."
  },
  {
    "element_id": "page_65_seq_0",
    "page_number": 65,
    "type": "text",
    "raw_text": "practice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nWeight loss\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nSeveral, including\nCarry out an assessment for additional\ncolorectal,\nsymptoms, signs or findings that may help\nWeight loss gastro-oesophageal,\nto clarify which cancer is most likely\n(unexplained) lung, prostate,\nOffer urgent investigation or a suspected\npancreatic or\ncancer pathway referral [1.13.2]\nurological cancer\nWeight loss\n(unexplained) with Offer quantitative faecal immunochemical\nColorectal\nabdominal pain, testing [1.3.1]\n40 and over\n\nThis chunk clarifies that for patients aged 16-24, local protocols dictate whether adult or pediatric referral pathways are used for suspected lymphomas or sarcomas. Additionally, this snippet specifies guidance for unexplained weight loss and when to consider further investigation for various cancers including colorectal, gastro-oesophageal, lung, prostate, pancreatic or urological cancer."
  },
  {
    "element_id": "page_65",
    "page_number": 65,
    "type": "table",
    "raw_text": "Table 1 on Page 65\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Pruritus with          | Non-Hodgkin's     | Consider a suspected cancer pathway referral.       |\n| unexplained            | lymphoma          | When considering referral, take into account any    |\n| splenomegaly in        |                   | associated symptoms [1.10.6]                        |\n| adults                 |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Pruritus with          | Hodgkin's         | Consider a suspected cancer pathway referral.       |\n| unexplained            | lymphoma or       | When considering referral, take into account any    |\n| lymphadenopathy        | non-Hodgkin's     | associated symptoms [1.10.8]                        |\n| in adults              | lymphoma          | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Pruritus with Splenomegaly or Lymphadenopathy in Adults | Summary: This table provides recommendations for adults experiencing pruritus (itching) along with either unexplained splenomegaly (enlarged spleen) or unexplained lymphadenopathy (enlarged lymph nodes), outlining the possible cancers (Non-Hodgkin's lymphoma or Hodgkin's lymphoma/Non-Hodgkin's lymphoma) and the appropriate action (consider a suspected cancer pathway referral, taking associated symptoms into account). It also notes that referral pathways may differ for young people (16-24).",
    "table_summary": "Title: Pruritus with Splenomegaly or Lymphadenopathy in Adults | Summary: This table provides recommendations for adults experiencing pruritus (itching) along with either unexplained splenomegaly (enlarged spleen) or unexplained lymphadenopathy (enlarged lymph nodes), outlining the possible cancers (Non-Hodgkin's lymphoma or Hodgkin's lymphoma/Non-Hodgkin's lymphoma) and the appropriate action (consider a suspected cancer pathway referral, taking associated symptoms into account). It also notes that referral pathways may differ for young people (16-24)."
  },
  {
    "element_id": "page_65",
    "page_number": 65,
    "type": "table",
    "raw_text": "Table 2 on Page 65\n\n| Symptom and specific   | Possible cancer     | Recommendation                            |\n| features               |                     |                                           |\n|:-----------------------|:--------------------|:------------------------------------------|\n| Weight loss            | Several, including  | Carry out an assessment for additional    |\n| (unexplained)          | colorectal,         | symptoms, signs or findings that may help |\n|                        | gastro-oesophageal, | to clarify which cancer is most likely    |\n|                        | lung, prostate,     | Offer urgent investigation or a suspected |\n|                        | pancreatic or       | cancer pathway referral [1.13.2]          |\n|                        | urological cancer   |                                           |\n| Weight loss            | Colorectal          | Offer quantitative faecal immunochemical  |\n| (unexplained) with     |                     | testing [1.3.1]                           |\n| abdominal pain,        |                     |                                           |\n| 40 and over            |                     |                                           |\n\nTitle: Weight Loss - Cancer Risk and Action | Summary: This table outlines recommendations for action based on weight loss, including further assessment and potential referral for suspected cancer, with specific focus on colorectal cancer in individuals 40 and over with abdominal pain, which warrants quantitative faecal immunochemical testing.",
    "table_summary": "Title: Weight Loss - Cancer Risk and Action | Summary: This table outlines recommendations for action based on weight loss, including further assessment and potential referral for suspected cancer, with specific focus on colorectal cancer in individuals 40 and over with abdominal pain, which warrants quantitative faecal immunochemical testing."
  },
  {
    "element_id": "page_66_seq_0",
    "page_number": 66,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nWeight loss\n(unexplained) with Offer quantitative faecal immunochemical\nColorectal\nrectal bleeding in testing [1.3.1]\nadults under 50\nWeight loss\nOffer quantitative faecal immunochemical\n(unexplained), Colorectal\ntesting [1.3.1]\n50 and over\nWeight loss\n(unexplained), Lung or Offer an urgent chest X-ray (to be done\n40 and over, ever mesothelioma within 2 weeks) [1.1.2] [1.1.5]\nsmoked\nWeight loss\n(unexplained),\nOffer an urgent chest X-ray (to be done\n40 and over, Mesothelioma\nwithin 2 weeks) [1.1.5]\nexposed to\nasbestos\nWeight loss with\ncough or fatigue or\nshortness of breath\nor chest pain or Lung or Offer an urgent chest X-ray (to be done\nappetite loss mesothelioma within 2 weeks) [1.1.2] [1.1.5]\n(unexplained),\n40 and over, never\nsmoked\n\nThis section of the NICE guideline provides recommendations for when to investigate or refer patients presenting with unexplained weight loss, a symptom common to several cancers. It specifies actions based on the presence of other symptoms and risk factors, such as age, smoking history, and asbestos exposure, to help healthcare professionals determine the appropriate urgency and type of investigation, including faecal immunochemical testing and chest X-rays."
  },
  {
    "element_id": "page_66",
    "page_number": 66,
    "type": "table",
    "raw_text": "Table 1 on Page 66\n\n| Symptom and specific   | Possible cancer   | Recommendation                           |\n| features               |                   |                                          |\n|:-----------------------|:------------------|:-----------------------------------------|\n| Weight loss            | Colorectal        | Offer quantitative faecal immunochemical |\n| (unexplained) with     |                   | testing [1.3.1]                          |\n| rectal bleeding in     |                   |                                          |\n| adults under 50        |                   |                                          |\n| Weight loss            | Colorectal        | Offer quantitative faecal immunochemical |\n| (unexplained),         |                   | testing [1.3.1]                          |\n| 50 and over            |                   |                                          |\n| Weight loss            | Lung or           | Offer an urgent chest X-ray (to be done  |\n| (unexplained),         | mesothelioma      | within 2 weeks) [1.1.2] [1.1.5]          |\n| 40 and over, ever      |                   |                                          |\n| smoked                 |                   |                                          |\n| Weight loss            | Mesothelioma      | Offer an urgent chest X-ray (to be done  |\n| (unexplained),         |                   | within 2 weeks) [1.1.5]                  |\n| 40 and over,           |                   |                                          |\n| exposed to             |                   |                                          |\n| asbestos               |                   |                                          |\n| Weight loss with       | Lung or           | Offer an urgent chest X-ray (to be done  |\n| cough or fatigue or    | mesothelioma      | within 2 weeks) [1.1.2] [1.1.5]          |\n| shortness of breath    |                   |                                          |\n| or chest pain or       |                   |                                          |\n| appetite loss          |                   |                                          |\n| (unexplained),         |                   |                                          |\n| 40 and over, never     |                   |                                          |\n| smoked                 |                   |                                          |\n\nTitle: Weight Loss and Cancer Risk | Summary: This table lists the recommendations for investigating weight loss, considering factors like rectal bleeding, age, smoking history, and asbestos exposure to assess the risk of colorectal cancer, lung cancer, and mesothelioma.",
    "table_summary": "Title: Weight Loss and Cancer Risk | Summary: This table lists the recommendations for investigating weight loss, considering factors like rectal bleeding, age, smoking history, and asbestos exposure to assess the risk of colorectal cancer, lung cancer, and mesothelioma."
  },
  {
    "element_id": "page_67_seq_0",
    "page_number": 67,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a suspected cancer pathway\nreferral. When considering referral, take\ninto account any associated symptoms\n[1.10.6]\nWeight loss with\nSeparate recommendations have been\nunexplained Non-Hodgkin's\nmade for adults and for children and young\nsplenomegaly in lymphoma\npeople to reflect that there are different\nadults\nreferral pathways. In practice young people\n(aged 16 to 24) may be referred using\neither pathway depending on their age and\nlocal arrangements\nConsider a suspected cancer pathway\nreferral. When considering referral, take\ninto account any associated symptoms\n[1.10.6] [1.10.8]\nWeight loss with Hodgkin's\nSeparate recommendations have been\nunexplained lymphoma or\nmade for adults and for children and young\nlymphadenopathy in non-Hodgkin's\npeople to reflect that there are different\nadults lymphoma\nreferral pathways. In practice young people\n(aged 16 to 24) may be referred using\n\nThis section of the NICE guideline focuses on referral recommendations for adults presenting with unexplained weight loss and either splenomegaly or lymphadenopathy, symptoms that may indicate Non-Hodgkin's or Hodgkin's lymphoma, emphasizing the need to consider associated symptoms and acknowledging separate referral pathways for adults versus children/young people. It highlights that the decision to refer for suspected lymphoma should involve careful consideration of the patient's overall clinical picture and local referral protocols, especially for young adults (16-24) who may fall under either adult or pediatric pathways."
  },
  {
    "element_id": "page_67_seq_0",
    "page_number": 67,
    "type": "text",
    "raw_text": "adults lymphoma\nreferral pathways. In practice young people\n(aged 16 to 24) may be referred using\neither pathway depending on their age and\nlocal arrangements\nWeight loss with\nupper abdominal\nOesophageal or Refer using a suspected cancer pathway\npain or reflux or\nstomach referral [1.2.1] [1.2.7]\ndyspepsia, 55 and\nover\n\nThis excerpt provides guidance on when to refer adults with suspected lymphoma (Hodgkin's or Non-Hodgkin's) for specialist assessment, noting that the decision to refer young people aged 16-24 might vary based on local protocols; additionally, it specifies referral criteria (weight loss with upper abdominal pain, reflux, or dyspepsia) for individuals 55 and older who may have oesophageal or stomach cancer."
  },
  {
    "element_id": "page_67",
    "page_number": 67,
    "type": "table",
    "raw_text": "Table 1 on Page 67\n\n| Symptom and specific   | Possible cancer   | Recommendation                              |\n| features               |                   |                                             |\n|:-----------------------|:------------------|:--------------------------------------------|\n| Weight loss with       | Non-Hodgkin's     | Consider a suspected cancer pathway         |\n| unexplained            | lymphoma          | referral. When considering referral, take   |\n| splenomegaly in        |                   | into account any associated symptoms        |\n| adults                 |                   | [1.10.6]                                    |\n|                        |                   | Separate recommendations have been          |\n|                        |                   | made for adults and for children and young  |\n|                        |                   | people to reflect that there are different  |\n|                        |                   | referral pathways. In practice young people |\n|                        |                   | (aged 16 to 24) may be referred using       |\n|                        |                   | either pathway depending on their age and   |\n|                        |                   | local arrangements                          |\n| Weight loss with       | Hodgkin's         | Consider a suspected cancer pathway         |\n| unexplained            | lymphoma or       | referral. When considering referral, take   |\n| lymphadenopathy in     | non-Hodgkin's     | into account any associated symptoms        |\n| adults                 | lymphoma          | [1.10.6] [1.10.8]                           |\n|                        |                   | Separate recommendations have been          |\n|                        |                   | made for adults and for children and young  |\n|                        |                   | people to reflect that there are different  |\n|                        |                   | referral pathways. In practice young people |\n|                        |                   | (aged 16 to 24) may be referred using       |\n|                        |                   | either pathway depending on their age and   |\n|                        |                   | local arrangements                          |\n| Weight loss with       | Oesophageal or    | Refer using a suspected cancer pathway      |\n| upper abdominal        | stomach           | referral [1.2.1] [1.2.7]                    |\n| pain or reflux or      |                   |                                             |\n| dyspepsia, 55 and      |                   |                                             |\n| over                   |                   |                                             |\n\nTitle: Weight Loss and Cancer in Adults | Summary: This table outlines recommendations for suspected cancer pathway referrals based on weight loss in adults, considering associated symptoms like splenomegaly, lymphadenopathy, upper abdominal pain, reflux, or dyspepsia. It differentiates between Hodgkin's and Non-Hodgkin's lymphoma and esophageal or stomach cancers, noting age-specific considerations and referral pathway differences.",
    "table_summary": "Title: Weight Loss and Cancer in Adults | Summary: This table outlines recommendations for suspected cancer pathway referrals based on weight loss in adults, considering associated symptoms like splenomegaly, lymphadenopathy, upper abdominal pain, reflux, or dyspepsia. It differentiates between Hodgkin's and Non-Hodgkin's lymphoma and esophageal or stomach cancers, noting age-specific considerations and referral pathway differences."
  },
  {
    "element_id": "page_68_seq_0",
    "page_number": 68,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nConsider carrying out tests in primary care\n[1.5.3]\nMeasure serum CA125 in primary care\nWeight loss [1.5.6]\n(unexplained) in Ovarian See the section on primary care\nwomen investigations for information on tests for\novarian cancer\nThese recommendations apply to women\naged 18 and over\nWeight loss with\ndiarrhoea or back\npain or abdominal\nConsider an urgent, direct access CT scan\npain or nausea or\nPancreatic (to be done within 2 weeks), or an urgent\nvomiting or\nultrasound scan if CT is not available [1.2.5]\nconstipation or\nnew-onset diabetes,\n60 and over\nWeight loss with\nraised platelet count\nOesophageal or Consider non-urgent, direct access upper\nor nausea or\nstomach gastrointestinal endoscopy [1.2.3] [1.2.9]\nvomiting, 55 and\nover\nPrimary care investigations\nBlood test findings\nInvestigation findings and specific features Possible cancer Recommendation\nOffer quantitative faecal\n\nThis chunk of the NICE guideline provides specific recommendations for primary care physicians on how to proceed when patients present with weight loss, particularly in relation to possible ovarian or pancreatic cancer, guiding investigation and referral decisions based on accompanying symptoms and age. It also lists the recommendation for primary care investigations, where blood test will be taken based on patients' symptoms."
  },
  {
    "element_id": "page_68_seq_0",
    "page_number": 68,
    "type": "text",
    "raw_text": "Offer quantitative faecal\nAnaemia (iron-deficiency) Colorectal immunochemical testing\n[1.3.1]\nOffer quantitative faecal\nAnaemia (non-iron-deficiency), 60 and over Colorectal immunochemical testing\n[1.3.1]\n\nThis chunk, found within the \"Primary care investigations\" section, specifies that adults presenting with either iron-deficiency or non-iron-deficiency anemia (if 60 and over) should be offered quantitative faecal immunochemical testing (FIT) to assess their risk of colorectal cancer. This recommendation aims to identify potential colorectal cancer cases early by using a non-invasive test in individuals with anemia, a symptom that can be associated with the disease."
  },
  {
    "element_id": "page_68",
    "page_number": 68,
    "type": "table",
    "raw_text": "Table 1 on Page 68\n\n| Symptom and specific   | Possible cancer   | Recommendation                                 |\n| features               |                   |                                                |\n|:-----------------------|:------------------|:-----------------------------------------------|\n| Weight loss            | Ovarian           | Consider carrying out tests in primary care    |\n| (unexplained) in       |                   | [1.5.3]                                        |\n| women                  |                   | Measure serum CA125 in primary care            |\n|                        |                   | [1.5.6]                                        |\n|                        |                   | See the section on primary care                |\n|                        |                   | investigations for information on tests for    |\n|                        |                   | ovarian cancer                                 |\n|                        |                   | These recommendations apply to women           |\n|                        |                   | aged 18 and over                               |\n| Weight loss with       | Pancreatic        | Consider an urgent, direct access CT scan      |\n| diarrhoea or back      |                   | (to be done within 2 weeks), or an urgent      |\n| pain or abdominal      |                   | ultrasound scan if CT is not available [1.2.5] |\n| pain or nausea or      |                   |                                                |\n| vomiting or            |                   |                                                |\n| constipation or        |                   |                                                |\n| new-onset diabetes,    |                   |                                                |\n| 60 and over            |                   |                                                |\n| Weight loss with       | Oesophageal or    | Consider non-urgent, direct access upper       |\n| raised platelet count  | stomach           | gastrointestinal endoscopy [1.2.3] [1.2.9]     |\n| or nausea or           |                   |                                                |\n| vomiting, 55 and       |                   |                                                |\n| over                   |                   |                                                |\n\nTitle: Weight Loss & Cancer: Investigations and Referrals | Summary: This table provides guidance on appropriate investigations and referral pathways based on weight loss, considering factors like accompanying symptoms, age, and gender. It distinguishes between ovarian, pancreatic, esophageal, and stomach cancers, recommending specific tests like CA125 measurement, CT scans, ultrasound scans, and upper gastrointestinal endoscopy.",
    "table_summary": "Title: Weight Loss & Cancer: Investigations and Referrals | Summary: This table provides guidance on appropriate investigations and referral pathways based on weight loss, considering factors like accompanying symptoms, age, and gender. It distinguishes between ovarian, pancreatic, esophageal, and stomach cancers, recommending specific tests like CA125 measurement, CT scans, ultrasound scans, and upper gastrointestinal endoscopy."
  },
  {
    "element_id": "page_68",
    "page_number": 68,
    "type": "table",
    "raw_text": "Table 2 on Page 68\n\n| Investigation findings and specific features   | Possible cancer   | Recommendation            |\n|:-----------------------------------------------|:------------------|:--------------------------|\n| Anaemia (iron-deficiency)                      | Colorectal        | Offer quantitative faecal |\n|                                                |                   | immunochemical testing    |\n|                                                |                   | [1.3.1]                   |\n| Anaemia (non-iron-deficiency), 60 and over     | Colorectal        | Offer quantitative faecal |\n|                                                |                   | immunochemical testing    |\n|                                                |                   | [1.3.1]                   |\n\nTitle: Primary Care Blood Test Findings and Cancer Risk | Summary: This table outlines how certain blood test results (anaemia) can raise suspicion of colorectal cancer and the recommended next step of offering quantitative faecal immunochemical testing (FIT).",
    "table_summary": "Title: Primary Care Blood Test Findings and Cancer Risk | Summary: This table outlines how certain blood test results (anaemia) can raise suspicion of colorectal cancer and the recommended next step of offering quantitative faecal immunochemical testing (FIT)."
  },
  {
    "element_id": "page_69_seq_0",
    "page_number": 69,
    "type": "text",
    "raw_text": "Investigation findings and specific features Possible cancer Recommendation\nBlood glucose levels high with visible Consider a direct access\nEndometrial\nhaematuria in women 55 and over ultrasound scan [1.5.12]\nConsider an urgent, direct\naccess CT scan (to be\nDiabetes (new-onset) with weight loss, done within 2 weeks), or\nPancreatic\n60 and over an urgent ultrasound scan\nif CT is not available\n[1.2.5]\nHaemoglobin levels low with visible Consider a direct access\nEndometrial\nhaematuria in women 55 and over ultrasound scan [1.5.12]\nConsider non-urgent,\nHaemoglobin levels low with upper Oesophageal direct access upper\nabdominal pain, 55 and over or stomach gastrointestinal\nendoscopy [1.2.3] [1.2.9]\nHypercalcaemia or leukopenia with Refer using a suspected\npersistent bone pain, particularly back pain, Myeloma cancer pathway referral\nor unexplained fracture, 60 and over [1.10.5]\nPlasma viscosity or erythrocyte\nRefer using a suspected\nsedimentation rate suggests myeloma, plus\n\nThis chunk, taken from the \"Recommendations organised by symptom and findings of primary care investigations\" section, provides guidance to healthcare professionals on appropriate actions, specifically referrals or further investigations, based on specific blood test results and corresponding symptoms in patients suspected of having cancer. It is significant because it translates lab findings into actionable steps for cancer diagnosis, ensuring timely intervention based on objective measures."
  },
  {
    "element_id": "page_69_seq_0",
    "page_number": 69,
    "type": "text",
    "raw_text": "Plasma viscosity or erythrocyte\nRefer using a suspected\nsedimentation rate suggests myeloma, plus\nMyeloma cancer pathway referral\npersistent bone pain, particularly back pain,\n[1.10.5]\nor unexplained fracture\nPlatelet count raised with nausea or Consider non-urgent,\nvomiting or weight loss or reflux or Oesophageal direct access upper\ndyspepsia or upper abdominal pain, 55 and or stomach gastrointestinal\nover endoscopy [1.2.3] [1.2.9]\nProstate-specific antigenlevels above the\nage-specific threshold in table 1 plus lower\nConsider a suspected\nurinary tract symptoms such as nocturia,\nProstate cancer pathway referral\nurinary frequency, hesitancy, urgency or\n[1.6.3]\nretention or erectile dysfunction or visible\nhaematuria\n\nThis section of the NICE guideline provides specific recommendations for primary care physicians on when to refer patients for suspected cancer based on blood test results. It outlines scenarios where elevated plasma viscosity or erythrocyte sedimentation rate, raised platelet count, or elevated prostate-specific antigen levels, in conjunction with certain symptoms, should prompt consideration of a suspected cancer pathway referral or further investigation."
  },
  {
    "element_id": "page_69",
    "page_number": 69,
    "type": "table",
    "raw_text": "Table 1 on Page 69\n\n| Investigation findings and specific features   | Possible cancer   | Recommendation             |\n|:-----------------------------------------------|:------------------|:---------------------------|\n| Blood glucose levels high with visible         | Endometrial       | Consider a direct access   |\n| haematuria in women 55 and over                |                   | ultrasound scan [1.5.12]   |\n| Diabetes (new-onset) with weight loss,         | Pancreatic        | Consider an urgent, direct |\n| 60 and over                                    |                   | access CT scan (to be      |\n|                                                |                   | done within 2 weeks), or   |\n|                                                |                   | an urgent ultrasound scan  |\n|                                                |                   | if CT is not available     |\n|                                                |                   | [1.2.5]                    |\n| Haemoglobin levels low with visible            | Endometrial       | Consider a direct access   |\n| haematuria in women 55 and over                |                   | ultrasound scan [1.5.12]   |\n| Haemoglobin levels low with upper              | Oesophageal       | Consider non-urgent,       |\n| abdominal pain, 55 and over                    | or stomach        | direct access upper        |\n|                                                |                   | gastrointestinal           |\n|                                                |                   | endoscopy [1.2.3] [1.2.9]  |\n| Hypercalcaemia or leukopenia with              | Myeloma           | Refer using a suspected    |\n| persistent bone pain, particularly back pain,  |                   | cancer pathway referral    |\n| or unexplained fracture, 60 and over           |                   | [1.10.5]                   |\n| Plasma viscosity or erythrocyte                | Myeloma           | Refer using a suspected    |\n| sedimentation rate suggests myeloma, plus      |                   | cancer pathway referral    |\n| persistent bone pain, particularly back pain,  |                   | [1.10.5]                   |\n| or unexplained fracture                        |                   |                            |\n| Platelet count raised with nausea or           | Oesophageal       | Consider non-urgent,       |\n| vomiting or weight loss or reflux or           | or stomach        | direct access upper        |\n| dyspepsia or upper abdominal pain, 55 and      |                   | gastrointestinal           |\n| over                                           |                   | endoscopy [1.2.3] [1.2.9]  |\n| Prostate-specific antigenlevels above the      | Prostate          | Consider a suspected       |\n| age-specific threshold in table 1 plus lower   |                   | cancer pathway referral    |\n| urinary tract symptoms such as nocturia,       |                   | [1.6.3]                    |\n| urinary frequency, hesitancy, urgency or       |                   |                            |\n| retention or erectile dysfunction or visible   |                   |                            |\n| haematuria                                     |                   |                            |\n\nTitle: Abnormal Blood Test Findings and Cancer Referral Guidance | Summary: This table provides guidance on cancer referrals based on abnormal blood test results in specific patient populations. It outlines the relevant cancer types to consider and the recommended actions, such as direct access investigations or suspected cancer pathway referrals.",
    "table_summary": "Title: Abnormal Blood Test Findings and Cancer Referral Guidance | Summary: This table provides guidance on cancer referrals based on abnormal blood test results in specific patient populations. It outlines the relevant cancer types to consider and the recommended actions, such as direct access investigations or suspected cancer pathway referrals."
  },
  {
    "element_id": "page_70_seq_0",
    "page_number": 70,
    "type": "text",
    "raw_text": "Investigation findings and specific features Possible cancer Recommendation\nSerum protein electrophoresis result\nRefer people using a\nsuggests myeloma, plus persistent bone\nMyeloma suspected cancer\npain, particularly back pain, or unexplained\npathway referral [1.10.5]\nfracture\nIf serum CA125 is 35 IU/ml\nor greater, arrange an\nultrasound scan of the\nabdomen and pelvis\n[1.5.7]\nNormal serum CA125 (less\nthan 35 IU/ml), or CA125\nof 35 IU/ml or greater but\na normal ultrasound:\nassess her carefully for\nother clinical causes of\nSerum CA125 results Ovarian\nher symptoms and\ninvestigate if appropriate\nif no other clinical cause is\napparent, advise her to\nreturn to her GP if her\nsymptoms become more\nfrequent and/or\npersistent. [1.5.9]\nThese recommendations\napply to women aged\n18 and over\nSerum free light chain testing suggests\nRefer people using a\nmyeloma, plus persistent bone pain,\nMyeloma suspected cancer\nparticularly back pain, or unexplained\npathway referral [1.10.5]\nfracture\n\nThis chunk, found within the \"Primary care investigations\" section, provides guidance on interpreting specific blood test results (serum protein electrophoresis, serum CA125, and serum free light chain) to determine appropriate actions, particularly referrals, for suspected myeloma and ovarian cancer. It emphasizes that these recommendations are specific to women aged 18 and over for ovarian cancer."
  },
  {
    "element_id": "page_70_seq_0",
    "page_number": 70,
    "type": "text",
    "raw_text": "Myeloma suspected cancer\nparticularly back pain, or unexplained\npathway referral [1.10.5]\nfracture\nConsider an urgent chest\nThrombocytosis, 40 and over Lung X-ray (to be done within\n2 weeks) [1.1.3]\n\nThis section of the guideline provides specific recommendations for primary care physicians on when to suspect myeloma or lung cancer based on certain symptoms and lab results and when to refer patients for further evaluation. Specifically, it advises referral for suspected myeloma in patients with persistent back pain or unexplained fractures and thrombocytosis in patients over 40, and that chest X-rays should be performed to determine the next course of action."
  },
  {
    "element_id": "page_70",
    "page_number": 70,
    "type": "table",
    "raw_text": "Table 1 on Page 70\n\n| Investigation findings and specific features   | Possible cancer   | Recommendation                |\n|:-----------------------------------------------|:------------------|:------------------------------|\n| Serum protein electrophoresis result           | Myeloma           | Refer people using a          |\n| suggests myeloma, plus persistent bone         |                   | suspected cancer              |\n| pain, particularly back pain, or unexplained   |                   | pathway referral [1.10.5]     |\n| fracture                                       |                   |                               |\n| Serum CA125 results                            | Ovarian           | If serum CA125 is 35 IU/ml    |\n|                                                |                   | or greater, arrange an        |\n|                                                |                   | ultrasound scan of the        |\n|                                                |                   | abdomen and pelvis            |\n|                                                |                   | [1.5.7]                       |\n|                                                |                   | Normal serum CA125 (less      |\n|                                                |                   | than 35 IU/ml), or CA125      |\n|                                                |                   | of 35 IU/ml or greater but    |\n|                                                |                   | a normal ultrasound:          |\n|                                                |                   | assess her carefully for      |\n|                                                |                   | other clinical causes of      |\n|                                                |                   | her symptoms and              |\n|                                                |                   | investigate if appropriate    |\n|                                                |                   | if no other clinical cause is |\n|                                                |                   | apparent, advise her to       |\n|                                                |                   | return to her GP if her       |\n|                                                |                   | symptoms become more          |\n|                                                |                   | frequent and/or               |\n|                                                |                   | persistent. [1.5.9]           |\n|                                                |                   | These recommendations         |\n|                                                |                   | apply to women aged           |\n|                                                |                   | 18 and over                   |\n| Serum free light chain testing suggests        | Myeloma           | Refer people using a          |\n| myeloma, plus persistent bone pain,            |                   | suspected cancer              |\n| particularly back pain, or unexplained         |                   | pathway referral [1.10.5]     |\n| fracture                                       |                   |                               |\n| Thrombocytosis, 40 and over                    | Lung              | Consider an urgent chest      |\n|                                                |                   | X-ray (to be done within      |\n|                                                |                   | 2 weeks) [1.1.3]              |\n\nTitle: Primary Care Blood Test Findings and Cancer Recommendations | Summary: This table outlines the recommended actions based on specific blood test results found during primary care investigations, indicating potential cancers such as myeloma, ovarian cancer, and lung cancer. It specifies whether a referral to a specialist is necessary or if further investigation is needed within primary care.",
    "table_summary": "Title: Primary Care Blood Test Findings and Cancer Recommendations | Summary: This table outlines the recommended actions based on specific blood test results found during primary care investigations, indicating potential cancers such as myeloma, ovarian cancer, and lung cancer. It specifies whether a referral to a specialist is necessary or if further investigation is needed within primary care."
  },
  {
    "element_id": "page_71_seq_0",
    "page_number": 71,
    "type": "text",
    "raw_text": "Investigation findings and specific features Possible cancer Recommendation\nThrombocytosis with visible haematuria or\nConsider a direct access\nvaginal discharge (unexplained) in women Endometrial\nultrasound scan [1.5.12]\n55 and over\nWhite cell count raised on a blood test with Refer people using a\nunexplained non-visible haematuria, 60 and Bladder suspected cancer\nover pathway referral [1.6.4]\nDermoscopy findings\nInvestigation findings and specific Possible\nRecommendation\nfeatures cancer\nDermoscopy suggests Refer people using a suspected cancer\nMelanoma\nmelanoma of the skin pathway referral [1.7.2]\nDigital rectal examination findings\nPossible\nExamination findings and specific features Recommendation\ncancer\nProstate feels malignant on digital Refer men using a suspected cancer\nProstate\nrectal examination pathway referral [1.6.1]\nFaecal tests\nInvestigation findings and specific Possible\nRecommendation\nfeatures cancer\nRefer adults using a suspected cancer pathway\n\nThis excerpt from the NICE guideline provides specific recommendations for healthcare professionals on when to refer patients for suspected cancer based on the findings of primary care investigations. It outlines the appropriate actions, such as direct access scans or suspected cancer pathway referrals, based on specific blood test results, dermoscopy findings, digital rectal exams, and faecal tests, helping to guide timely and appropriate management of potential cancer cases."
  },
  {
    "element_id": "page_71_seq_0",
    "page_number": 71,
    "type": "text",
    "raw_text": "Recommendation\nfeatures cancer\nRefer adults using a suspected cancer pathway\nOccult blood in faeces Colorectal\nreferral [1.3.2]\nImaging tests\nInvestigation findings and\nPossible cancer Recommendation\nspecific features\nChest X-ray\nRefer people using a suspected cancer pathway\nsuggests lung Lung\nreferral [1.1.1]\ncancer\nChest X-ray\nRefer people using a suspected cancer pathway\nsuggests Mesothelioma\nreferral [1.1.4]\nmesothelioma\n\nThis excerpt, found in the \"Recommendations organised by symptom and findings of primary care investigations\" section, provides guidance to healthcare professionals on when to make a suspected cancer pathway referral based on specific investigation results. It highlights that occult blood in faeces should prompt a referral for suspected colorectal cancer and abnormal chest X-rays warrant referrals for suspected lung cancer or mesothelioma."
  },
  {
    "element_id": "page_71",
    "page_number": 71,
    "type": "table",
    "raw_text": "Table 1 on Page 71\n\n| Investigation findings and specific features   | Possible cancer   | Recommendation           |\n|:-----------------------------------------------|:------------------|:-------------------------|\n| Thrombocytosis with visible haematuria or      | Endometrial       | Consider a direct access |\n| vaginal discharge (unexplained) in women       |                   | ultrasound scan [1.5.12] |\n| 55 and over                                    |                   |                          |\n| White cell count raised on a blood test with   | Bladder           | Refer people using a     |\n| unexplained non-visible haematuria, 60 and     |                   | suspected cancer         |\n| over                                           |                   | pathway referral [1.6.4] |\n\nTitle: Blood Test Findings and Cancer Recommendations | Summary: This table outlines specific blood test results (thrombocytosis with haematuria/vaginal discharge, raised white cell count with haematuria) and provides recommendations for further action, specifically relating to the potential for endometrial or bladder cancer.",
    "table_summary": "Title: Blood Test Findings and Cancer Recommendations | Summary: This table outlines specific blood test results (thrombocytosis with haematuria/vaginal discharge, raised white cell count with haematuria) and provides recommendations for further action, specifically relating to the potential for endometrial or bladder cancer."
  },
  {
    "element_id": "page_71",
    "page_number": 71,
    "type": "table",
    "raw_text": "Table 2 on Page 71\n\n| Investigation findings and specific   | Possible   | Recommendation                        |\n| features                              | cancer     |                                       |\n|:--------------------------------------|:-----------|:--------------------------------------|\n| Dermoscopy suggests                   | Melanoma   | Refer people using a suspected cancer |\n| melanoma of the skin                  |            | pathway referral [1.7.2]              |\n\nTitle: Dermoscopy Findings and Melanoma Referral | Summary: This table outlines the recommendation for referral when dermoscopy suggests melanoma of the skin, advising referral using a suspected cancer pathway.",
    "table_summary": "Title: Dermoscopy Findings and Melanoma Referral | Summary: This table outlines the recommendation for referral when dermoscopy suggests melanoma of the skin, advising referral using a suspected cancer pathway."
  },
  {
    "element_id": "page_71",
    "page_number": 71,
    "type": "table",
    "raw_text": "Table 3 on Page 71\n\n| Examination findings and specific features   | Possible   | Recommendation                     |\n|                                              | cancer     |                                    |\n|:---------------------------------------------|:-----------|:-----------------------------------|\n| Prostate feels malignant on digital          | Prostate   | Refer men using a suspected cancer |\n| rectal examination                           |            | pathway referral [1.6.1]           |\n\nTitle: Prostate Examination Findings | Summary: This table outlines the recommendation for suspected prostate cancer referral based on findings from a digital rectal examination.",
    "table_summary": "Title: Prostate Examination Findings | Summary: This table outlines the recommendation for suspected prostate cancer referral based on findings from a digital rectal examination."
  },
  {
    "element_id": "page_71",
    "page_number": 71,
    "type": "table",
    "raw_text": "Table 4 on Page 71\n\n| Investigation findings and specific   | Possible   | Recommendation                                |\n| features                              | cancer     |                                               |\n|:--------------------------------------|:-----------|:----------------------------------------------|\n| Occult blood in faeces                | Colorectal | Refer adults using a suspected cancer pathway |\n|                                       |            | referral [1.3.2]                              |\n\nTitle: Faecal Occult Blood Test Results and Colorectal Cancer Referral | Summary: This table outlines the recommendation for referral based on the finding of occult blood in faeces, which warrants referral of adults using a suspected cancer pathway referral for colorectal cancer.",
    "table_summary": "Title: Faecal Occult Blood Test Results and Colorectal Cancer Referral | Summary: This table outlines the recommendation for referral based on the finding of occult blood in faeces, which warrants referral of adults using a suspected cancer pathway referral for colorectal cancer."
  },
  {
    "element_id": "page_71",
    "page_number": 71,
    "type": "table",
    "raw_text": "Table 5 on Page 71\n\n| Investigation findings and   | Possible cancer   | Recommendation                                |\n| specific features            |                   |                                               |\n|:-----------------------------|:------------------|:----------------------------------------------|\n| Chest X-ray                  | Lung              | Refer people using a suspected cancer pathway |\n| suggests lung                |                   | referral [1.1.1]                              |\n| cancer                       |                   |                                               |\n| Chest X-ray                  | Mesothelioma      | Refer people using a suspected cancer pathway |\n| suggests                     |                   | referral [1.1.4]                              |\n| mesothelioma                 |                   |                                               |\n\nTitle: Chest X-ray Findings and Cancer Referral | Summary: This table outlines the NICE guideline recommendations for suspected cancer pathway referrals based on chest X-ray findings suggestive of lung cancer or mesothelioma.",
    "table_summary": "Title: Chest X-ray Findings and Cancer Referral | Summary: This table outlines the NICE guideline recommendations for suspected cancer pathway referrals based on chest X-ray findings suggestive of lung cancer or mesothelioma."
  },
  {
    "element_id": "page_72_seq_0",
    "page_number": 72,
    "type": "text",
    "raw_text": "Investigation findings and\nPossible cancer Recommendation\nspecific features\nRefer women using a suspected cancer pathway\nUltrasound\nreferral [1.5.8]\nsuggests ovarian Ovarian\nThese recommendations apply to women aged\ncancer\n18 and over\nAssess carefully for other clinical causes of her\nsymptoms and investigate if appropriate\nUltrasound normal If no other clinical cause is apparent, advise her to\nwith CA125 of Ovarian return to her GP if her symptoms become more\n35 IU/ml or greater frequent and/or persistent [1.5.9]\nThese recommendations apply to women aged\n18 and over\nConsider a suspected cancer pathway referral\n[1.11.5]\nUltrasoundsuggests\nSeparate recommendations have been made for\nsoft tissue sarcoma\nSoft tissue adults and for children and young people to\nor is uncertain and\nsarcoma reflect that there are different referral pathways.\nclinical concern\nIn practice young people (aged 16 to 24) may be\npersists in adults\nreferred using either pathway depending on their\n\nThis chunk provides guidance on how to act based on ultrasound findings, specifically in relation to suspected ovarian and soft tissue sarcomas, emphasizing referral pathways and further investigation when ultrasound results are inconclusive, within the context of NICE guidelines for suspected cancer recognition and referral. It informs healthcare professionals on the appropriate next steps following an ultrasound, ensuring timely management of potential cancers while considering differential diagnoses and patient monitoring."
  },
  {
    "element_id": "page_72_seq_0",
    "page_number": 72,
    "type": "text",
    "raw_text": "persists in adults\nreferred using either pathway depending on their\nage and local arrangements\nConsider a suspected cancer pathway referral\n[1.11.1]\nSeparate recommendations have been made for\nX-ray suggests the\nBone adults and for children and young people to\npossibility of bone\nsarcoma reflect that there are different referral pathways.\nsarcoma in adults\nIn practice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nJaundice\nInvestigation findings and Possible\nRecommendation\nspecific features cancer\nRefer people using a suspected cancer pathway\nJaundice, 40 and over Pancreatic\nreferral [1.2.4]\n\nThis excerpt provides guidance on when to suspect specific cancers (bone sarcoma and pancreatic cancer) based on X-ray findings and jaundice, respectively, and details the appropriate referral pathways (suspected cancer pathway). It highlights that referral pathways may differ for adults versus children/young people with bone sarcoma, while emphasizing a suspected cancer pathway referral for individuals 40 and over presenting with jaundice, indicating possible pancreatic cancer."
  },
  {
    "element_id": "page_72",
    "page_number": 72,
    "type": "table",
    "raw_text": "Table 1 on Page 72\n\n| Investigation findings and   | Possible cancer   | Recommendation                                        |\n| specific features            |                   |                                                       |\n|:-----------------------------|:------------------|:------------------------------------------------------|\n| Ultrasound                   | Ovarian           | Refer women using a suspected cancer pathway          |\n| suggests ovarian             |                   | referral [1.5.8]                                      |\n| cancer                       |                   | These recommendations apply to women aged             |\n|                              |                   | 18 and over                                           |\n| Ultrasound normal            | Ovarian           | Assess carefully for other clinical causes of her     |\n| with CA125 of                |                   | symptoms and investigate if appropriate               |\n| 35 IU/ml or greater          |                   | If no other clinical cause is apparent, advise her to |\n|                              |                   | return to her GP if her symptoms become more          |\n|                              |                   | frequent and/or persistent [1.5.9]                    |\n|                              |                   | These recommendations apply to women aged             |\n|                              |                   | 18 and over                                           |\n| Ultrasoundsuggests           | Soft tissue       | Consider a suspected cancer pathway referral          |\n| soft tissue sarcoma          | sarcoma           | [1.11.5]                                              |\n| or is uncertain and          |                   | Separate recommendations have been made for           |\n| clinical concern             |                   | adults and for children and young people to           |\n| persists in adults           |                   | reflect that there are different referral pathways.   |\n|                              |                   | In practice young people (aged 16 to 24) may be       |\n|                              |                   | referred using either pathway depending on their      |\n|                              |                   | age and local arrangements                            |\n| X-ray suggests the           | Bone              | Consider a suspected cancer pathway referral          |\n| possibility of bone          | sarcoma           | [1.11.1]                                              |\n| sarcoma in adults            |                   | Separate recommendations have been made for           |\n|                              |                   | adults and for children and young people to           |\n|                              |                   | reflect that there are different referral pathways.   |\n|                              |                   | In practice young people (aged 16 to 24) may be       |\n|                              |                   | referred using either pathway depending on their      |\n|                              |                   | age and local arrangements                            |\n\nTitle: Imaging Test Findings and Cancer Recommendations | Summary: This table outlines recommendations for suspected cancer pathway referrals or further assessment based on ultrasound and X-ray imaging results, specifically for ovarian cancer, soft tissue sarcoma, and bone sarcoma in adults. It also specifies considerations for people of different age groups, especially children and young adults (aged 16-24).",
    "table_summary": "Title: Imaging Test Findings and Cancer Recommendations | Summary: This table outlines recommendations for suspected cancer pathway referrals or further assessment based on ultrasound and X-ray imaging results, specifically for ovarian cancer, soft tissue sarcoma, and bone sarcoma in adults. It also specifies considerations for people of different age groups, especially children and young adults (aged 16-24)."
  },
  {
    "element_id": "page_72",
    "page_number": 72,
    "type": "table",
    "raw_text": "Table 2 on Page 72\n\n| Investigation findings and   | Possible   | Recommendation                                |\n| specific features            | cancer     |                                               |\n|:-----------------------------|:-----------|:----------------------------------------------|\n| Jaundice, 40 and over        | Pancreatic | Refer people using a suspected cancer pathway |\n|                              |            | referral [1.2.4]                              |\n\nTitle: Jaundice and Pancreatic Cancer Referral | Summary: This table specifies that individuals aged 40 and over presenting with jaundice should be referred using a suspected cancer pathway due to the possibility of pancreatic cancer.",
    "table_summary": "Title: Jaundice and Pancreatic Cancer Referral | Summary: This table specifies that individuals aged 40 and over presenting with jaundice should be referred using a suspected cancer pathway due to the possibility of pancreatic cancer."
  },
  {
    "element_id": "page_73_seq_0",
    "page_number": 73,
    "type": "text",
    "raw_text": "Urine test findings\nPossible\nInvestigation findings and specific features Recommendation\ncancer\nBence–Jones protein urine results (used if serum free Refer people using\nlight chain testing is not available)suggest myeloma, a suspected\nMyeloma\nplus persistent bone pain, particularly back pain, or cancer pathway\nunexplained fracture referral [1.10.5]\nSymptoms in children and young people\nAbdominal symptoms\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nHepatosplenomegaly\n(unexplained) in Refer for immediate specialist assessment\nLeukaemia\nchildren and young [1.10.2]\npeople\nAbdominal mass\n(palpable) or Neuroblastoma Consider very urgent referral (for an\nenlarged abdominal or Wilms' appointment within 48 hours) for specialist\norgan (unexplained) tumour assessment [1.12.1] [1.12.3]\nin children\nConsider a very urgent referral (for an\nappointment within 48 hours) for specialist\nassessment. When considering referral, take\ninto account any associated symptoms,\n\nThis excerpt from the NICE guideline provides specific guidance for healthcare professionals on when to suspect cancer based on urine test findings (specifically Bence-Jones protein) and abdominal symptoms in children and young people, and the appropriate referral actions to take. It aims to aid in the early recognition and timely referral of potential cancer cases in these specific contexts."
  },
  {
    "element_id": "page_73_seq_0",
    "page_number": 73,
    "type": "text",
    "raw_text": "assessment. When considering referral, take\ninto account any associated symptoms,\nSplenomegaly particularly fever, night sweats, shortness of\n(unexplained) in Non-Hodgkin's breath, pruritus or weight loss [1.10.7]\nchildren and young lymphoma Separate recommendations have been made\npeople for adults and for children and young people to\nreflect that there are different referral\npathways. In practice young people (aged 16 to\n24) may be referred using either pathway\ndepending on their age and local arrangements\n\nThis section of the NICE guideline provides guidance for healthcare professionals on when to consider a very urgent referral for children and young people presenting with unexplained splenomegaly, a potential sign of Non-Hodgkin's lymphoma, emphasizing the importance of considering associated symptoms like fever, night sweats, shortness of breath, pruritus, or weight loss to inform the referral decision. It also acknowledges the possibility of using adult or child/young person pathways depending on local arrangements for young people aged 16-24."
  },
  {
    "element_id": "page_73",
    "page_number": 73,
    "type": "table",
    "raw_text": "Table 1 on Page 73\n\n| Investigation findings and specific features          | Possible   | Recommendation     |\n|                                                       | cancer     |                    |\n|:------------------------------------------------------|:-----------|:-------------------|\n| Bence–Jones protein urine results (used if serum free | Myeloma    | Refer people using |\n| light chain testing is not available)suggest myeloma, |            | a suspected        |\n| plus persistent bone pain, particularly back pain, or |            | cancer pathway     |\n| unexplained fracture                                  |            | referral [1.10.5]  |\n\nTitle: Urine Test Findings for Myeloma | Summary: This table outlines the recommendation to refer patients for suspected myeloma via a cancer pathway referral if Bence-Jones protein is detected in their urine, alongside persistent bone pain (particularly back pain) or unexplained fractures. Bence-Jones protein urine test is only to be used if serum free light chain testing is unavailable.",
    "table_summary": "Title: Urine Test Findings for Myeloma | Summary: This table outlines the recommendation to refer patients for suspected myeloma via a cancer pathway referral if Bence-Jones protein is detected in their urine, alongside persistent bone pain (particularly back pain) or unexplained fractures. Bence-Jones protein urine test is only to be used if serum free light chain testing is unavailable."
  },
  {
    "element_id": "page_73",
    "page_number": 73,
    "type": "table",
    "raw_text": "Table 2 on Page 73\n\n| Symptom and specific   | Possible cancer   | Recommendation                                  |\n| features               |                   |                                                 |\n|:-----------------------|:------------------|:------------------------------------------------|\n| Hepatosplenomegaly     | Leukaemia         | Refer for immediate specialist assessment       |\n| (unexplained) in       |                   | [1.10.2]                                        |\n| children and young     |                   |                                                 |\n| people                 |                   |                                                 |\n| Abdominal mass         | Neuroblastoma     | Consider very urgent referral (for an           |\n| (palpable) or          | or Wilms'         | appointment within 48 hours) for specialist     |\n| enlarged abdominal     | tumour            | assessment [1.12.1] [1.12.3]                    |\n| organ (unexplained)    |                   |                                                 |\n| in children            |                   |                                                 |\n| Splenomegaly           | Non-Hodgkin's     | Consider a very urgent referral (for an         |\n| (unexplained) in       | lymphoma          | appointment within 48 hours) for specialist     |\n| children and young     |                   | assessment. When considering referral, take     |\n| people                 |                   | into account any associated symptoms,           |\n|                        |                   | particularly fever, night sweats, shortness of  |\n|                        |                   | breath, pruritus or weight loss [1.10.7]        |\n|                        |                   | Separate recommendations have been made         |\n|                        |                   | for adults and for children and young people to |\n|                        |                   | reflect that there are different referral       |\n|                        |                   | pathways. In practice young people (aged 16 to  |\n|                        |                   | 24) may be referred using either pathway        |\n|                        |                   | depending on their age and local arrangements   |\n\nTitle: Abdominal Symptoms in Children and Young People | Summary: This table outlines specific abdominal symptoms or examination findings in children and young people, the possible associated cancers (Leukaemia, Neuroblastoma, Wilms' tumour, and Non-Hodgkin's lymphoma), and the recommended actions, including referrals and specialist assessments.",
    "table_summary": "Title: Abdominal Symptoms in Children and Young People | Summary: This table outlines specific abdominal symptoms or examination findings in children and young people, the possible associated cancers (Leukaemia, Neuroblastoma, Wilms' tumour, and Non-Hodgkin's lymphoma), and the recommended actions, including referrals and specialist assessments."
  },
  {
    "element_id": "page_74_seq_0",
    "page_number": 74,
    "type": "text",
    "raw_text": "Bleeding, bruising or rashes\nPossible\nSymptom and specific features Recommendation\ncancer\nPetechiae (unexplained) in children Refer for immediate specialist\nLeukaemia\nand young people assessment [1.10.2]\nBleeding or bruising (unexplained) in Offer a very urgent full blood count\nLeukaemia\nchildren and young people (within 48 hours) [1.10.3]\nLumps or masses\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nassociated symptoms, particularly fever, night\nLymphadenopathy Non-Hodgkin's sweats, shortness of breath, pruritus or weight\n(unexplained) in lymphoma or loss [1.10.7] [1.10.9]\nchildren and Hodgkin's Separate recommendations have been made for\nyoung people lymphoma adults and for children and young people to reflect\nthat there are different referral pathways. In\npractice young people (aged 16 to 24) may be\n\nThis chunk of the NICE guideline provides specific recommendations for referral and investigation of suspected cancer in children and young people presenting with bleeding/bruising/rashes, or unexplained lumps/masses, emphasizing the urgency of assessment for potential hematological malignancies like leukemia and lymphoma. It guides healthcare professionals in primary care to promptly identify and refer children and young people who exhibit these symptoms, ensuring timely access to specialist care."
  },
  {
    "element_id": "page_74_seq_0",
    "page_number": 74,
    "type": "text",
    "raw_text": "that there are different referral pathways. In\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nLymphadenopathy\n(generalised) in Offer a very urgent full blood count (within\nLeukaemia\nchildren and 48 hours) [1.10.3]\nyoung people\n\nThis section addresses referral pathways for young people (16-24) with suspected Non-Hodgkin's or Hodgkin's lymphoma, noting that they may be referred through either adult or children/young people pathways based on age and local protocols; specifically, generalized lymphadenopathy in children and young people should prompt a very urgent full blood count to assess for leukemia."
  },
  {
    "element_id": "page_74",
    "page_number": 74,
    "type": "table",
    "raw_text": "Table 1 on Page 74\n\n| Symptom and specific features         | Possible   | Recommendation                       |\n|                                       | cancer     |                                      |\n|:--------------------------------------|:-----------|:-------------------------------------|\n| Petechiae (unexplained) in children   | Leukaemia  | Refer for immediate specialist       |\n| and young people                      |            | assessment [1.10.2]                  |\n| Bleeding or bruising (unexplained) in | Leukaemia  | Offer a very urgent full blood count |\n| children and young people             |            | (within 48 hours) [1.10.3]           |\n\nTitle: Petechiae, Bleeding and Bruising in Children and Young People Table | Summary: This table outlines the recommended actions for children and young people presenting with unexplained petechiae, bleeding, or bruising, with a focus on immediate specialist assessment or urgent full blood counts for possible leukaemia.",
    "table_summary": "Title: Petechiae, Bleeding and Bruising in Children and Young People Table | Summary: This table outlines the recommended actions for children and young people presenting with unexplained petechiae, bleeding, or bruising, with a focus on immediate specialist assessment or urgent full blood counts for possible leukaemia."
  },
  {
    "element_id": "page_74",
    "page_number": 74,
    "type": "table",
    "raw_text": "Table 2 on Page 74\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Lymphadenopathy        | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| (unexplained) in       | lymphoma or       | within 48 hours) for specialist assessment. When    |\n| children and           | Hodgkin's         | considering referral, take into account any         |\n| young people           | lymphoma          | associated symptoms, particularly fever, night      |\n|                        |                   | sweats, shortness of breath, pruritus or weight     |\n|                        |                   | loss [1.10.7] [1.10.9]                              |\n|                        |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Lymphadenopathy        | Leukaemia         | Offer a very urgent full blood count (within        |\n| (generalised) in       |                   | 48 hours) [1.10.3]                                  |\n| children and           |                   |                                                     |\n| young people           |                   |                                                     |\n\nTitle: Lymphadenopathy in Children and Young People | Summary: This table outlines the recommendations for referral and blood tests for children and young people presenting with lymphadenopathy, depending on whether the lymphadenopathy is unexplained, generalised or associated with other symptoms. It includes considerations for Non-Hodgkin's lymphoma, Hodgkin's lymphoma and Leukaemia.",
    "table_summary": "Title: Lymphadenopathy in Children and Young People | Summary: This table outlines the recommendations for referral and blood tests for children and young people presenting with lymphadenopathy, depending on whether the lymphadenopathy is unexplained, generalised or associated with other symptoms. It includes considerations for Non-Hodgkin's lymphoma, Hodgkin's lymphoma and Leukaemia."
  },
  {
    "element_id": "page_75_seq_0",
    "page_number": 75,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a very urgent, direct access ultrasound\nscan (to be done within 48 hours) [1.11.6]\nSee the section on primary care investigations for\nLump\nmore information on ultrasound scans\n(unexplained) that\nSoft tissue\nSeparate recommendations have been made for\nis increasing in\nsarcoma\nadults and for children and young people to reflect\nsize in children\nthat there are different referral pathways. In\nand young people\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nSee also the section on abdominal symptoms for abdominal mass or unexplained enlarged\nabdominal organ, splenomegaly and hepatosplenomegaly.\nNeurological symptoms\nSymptom and specific features Possible cancer Recommendation\nNewly abnormal cerebellar or other Brain or central Consider a very urgent\ncentral neurological function in nervous referral (for an appointment\n\nThis section of the NICE guideline provides recommendations for healthcare professionals on recognizing and referring suspected cancers, specifically focusing on soft tissue sarcomas in children and young people presenting with an unexplained and growing lump, and neurological symptoms. It advises a very urgent ultrasound scan for the lump and a very urgent referral for neurological issues, emphasizing the need for prompt action in these age groups."
  },
  {
    "element_id": "page_75_seq_0",
    "page_number": 75,
    "type": "text",
    "raw_text": "central neurological function in nervous referral (for an appointment\nchildren and young people system cancer within 48 hours) [1.9.2]\nRespiratory symptoms\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nShortness of\nNon-Hodgkin's associated symptoms [1.10.7] [1.10.9]\nbreath with\nlymphoma or Separate recommendations have been made for\nlymphadenopathy\nHodgkin's adults and for children and young people to reflect\nin children and\nlymphoma that there are different referral pathways. In\nyoung people\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\n\nThis section of the NICE guideline provides recommendations for referral of children and young people with suspected brain/central nervous system cancers, specifically neurological symptoms and respiratory symptoms such as shortness of breath with lymphadenopathy, in the context of suspected Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma. It outlines the urgency of referral (within 48 hours) and emphasizes considering associated symptoms when making referral decisions, highlighting the distinct referral pathways for adults versus children/young people."
  },
  {
    "element_id": "page_75",
    "page_number": 75,
    "type": "table",
    "raw_text": "Table 1 on Page 75\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Lump                   | Soft tissue       | Consider a very urgent, direct access ultrasound    |\n| (unexplained) that     | sarcoma           | scan (to be done within 48 hours) [1.11.6]          |\n| is increasing in       |                   | See the section on primary care investigations for  |\n| size in children       |                   | more information on ultrasound scans                |\n| and young people       |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Soft Tissue Sarcoma Lump Ultrasound Recommendation | Summary: This table outlines the recommendation for children and young people presenting with an unexplained lump that is increasing in size and suspected of being a soft tissue sarcoma. It recommends a very urgent, direct access ultrasound scan within 48 hours and refers to the primary care investigations section for more information.",
    "table_summary": "Title: Soft Tissue Sarcoma Lump Ultrasound Recommendation | Summary: This table outlines the recommendation for children and young people presenting with an unexplained lump that is increasing in size and suspected of being a soft tissue sarcoma. It recommends a very urgent, direct access ultrasound scan within 48 hours and refers to the primary care investigations section for more information."
  },
  {
    "element_id": "page_75",
    "page_number": 75,
    "type": "table",
    "raw_text": "Table 2 on Page 75\n\n| Symptom and specific features      | Possible cancer   | Recommendation               |\n|:-----------------------------------|:------------------|:-----------------------------|\n| Newly abnormal cerebellar or other | Brain or central  | Consider a very urgent       |\n| central neurological function in   | nervous           | referral (for an appointment |\n| children and young people          | system cancer     | within 48 hours) [1.9.2]     |\n\nTitle: Neurological Symptoms in Children and Young People | Summary: This table details the recommendation for referral of children and young people presenting with newly abnormal cerebellar or other central neurological function, indicating possible brain or central nervous system cancer. The recommendation is a very urgent referral (appointment within 48 hours).",
    "table_summary": "Title: Neurological Symptoms in Children and Young People | Summary: This table details the recommendation for referral of children and young people presenting with newly abnormal cerebellar or other central neurological function, indicating possible brain or central nervous system cancer. The recommendation is a very urgent referral (appointment within 48 hours)."
  },
  {
    "element_id": "page_75",
    "page_number": 75,
    "type": "table",
    "raw_text": "Table 3 on Page 75\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Shortness of           | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| breath with            | lymphoma or       | within 48 hours) for specialist assessment. When    |\n| lymphadenopathy        | Hodgkin's         | considering referral, take into account any         |\n| in children and        | lymphoma          | associated symptoms [1.10.7] [1.10.9]               |\n| young people           |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Shortness of Breath and Lymphadenopathy in Children and Young People | Summary: This table outlines the recommendations for referral in children and young people presenting with shortness of breath and lymphadenopathy, indicating a possible Non-Hodgkin's or Hodgkin's lymphoma. It specifies the need for a very urgent referral for specialist assessment, considering associated symptoms, and notes the varying referral pathways based on age.",
    "table_summary": "Title: Shortness of Breath and Lymphadenopathy in Children and Young People | Summary: This table outlines the recommendations for referral in children and young people presenting with shortness of breath and lymphadenopathy, indicating a possible Non-Hodgkin's or Hodgkin's lymphoma. It specifies the need for a very urgent referral for specialist assessment, considering associated symptoms, and notes the varying referral pathways based on age."
  },
  {
    "element_id": "page_76_seq_0",
    "page_number": 76,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nShortness of considering referral, take into account any\nbreath with associated symptoms [1.10.7]\nsplenomegaly Non-Hodgkin's Separate recommendations have been made for\n(unexplained) in lymphoma adults and for children and young people to reflect\nchildren and that there are different referral pathways. In\nyoung people practice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nSkeletal symptoms\nPossible\nSymptom and specific features Recommendation\ncancer\nBone pain (persistent or\nOffer a very urgent full blood count\nunexplained) in children and Leukaemia\n(within 48 hours) [1.10.3]\nyoung people\nConsider a very urgent, direct access\nX-ray (to be done within 48 hours)\nBone pain (unexplained) in Bone [1.11.3]\n\nThis excerpt from the NICE guideline outlines specific recommendations for children and young people presenting with shortness of breath and splenomegaly (enlarged spleen), suggesting a possible Non-Hodgkin's lymphoma, or bone pain, indicating potential Leukaemia or Bone sarcoma, emphasizing the need for prompt specialist assessment and investigations to rule out cancer. It helps healthcare professionals quickly identify high-risk symptoms in young patients and initiate appropriate urgent referrals or tests."
  },
  {
    "element_id": "page_76_seq_0",
    "page_number": 76,
    "type": "text",
    "raw_text": "X-ray (to be done within 48 hours)\nBone pain (unexplained) in Bone [1.11.3]\nchildren and young people sarcoma See the section on primary care\ninvestigations for more information on\nX-rays\nConsider a very urgent, direct access\nX-ray (to be done within 48 hours)\nBone swelling (unexplained) in Bone [1.11.3]\nchildren and young people sarcoma See the section on primary care\ninvestigations for more information on\nX-rays\nSkin or surface symptoms\nPossible\nSymptom and specific features Recommendation\ncancer\nPetechiae (unexplained) in Refer for immediate specialist\nLeukaemia\nchildren and young people assessment [1.10.2]\n\nThis chunk provides guidance on when to urgently investigate potential bone sarcomas in children and young people using X-rays, and highlights the need for immediate specialist assessment for unexplained petechiae which may indicate leukemia. The X-ray recommendations aim to expedite diagnosis and referral for suspected bone cancers, while the petechiae recommendation emphasizes prompt action for a potentially serious blood disorder."
  },
  {
    "element_id": "page_76",
    "page_number": 76,
    "type": "table",
    "raw_text": "Table 1 on Page 76\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Shortness of           | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| breath with            | lymphoma          | within 48 hours) for specialist assessment. When    |\n| splenomegaly           |                   | considering referral, take into account any         |\n| (unexplained) in       |                   | associated symptoms [1.10.7]                        |\n| children and           |                   | Separate recommendations have been made for         |\n| young people           |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\n**Title:** Shortness of Breath and Splenomegaly in Children and Young People | **Summary:** This table outlines the recommended action (consider a very urgent referral) for children and young people presenting with unexplained shortness of breath and splenomegaly, linking it to the possible cancer of Non-Hodgkin's lymphoma. It also references the relevant NICE recommendation (1.10.7) and notes differing referral pathways for adults versus children/young people.",
    "table_summary": "**Title:** Shortness of Breath and Splenomegaly in Children and Young People | **Summary:** This table outlines the recommended action (consider a very urgent referral) for children and young people presenting with unexplained shortness of breath and splenomegaly, linking it to the possible cancer of Non-Hodgkin's lymphoma. It also references the relevant NICE recommendation (1.10.7) and notes differing referral pathways for adults versus children/young people."
  },
  {
    "element_id": "page_76",
    "page_number": 76,
    "type": "table",
    "raw_text": "Table 2 on Page 76\n\n| Symptom and specific features   | Possible   | Recommendation                         |\n|                                 | cancer     |                                        |\n|:--------------------------------|:-----------|:---------------------------------------|\n| Bone pain (persistent or        | Leukaemia  | Offer a very urgent full blood count   |\n| unexplained) in children and    |            | (within 48 hours) [1.10.3]             |\n| young people                    |            |                                        |\n| Bone pain (unexplained) in      | Bone       | Consider a very urgent, direct access  |\n| children and young people       | sarcoma    | X-ray (to be done within 48 hours)     |\n|                                 |            | [1.11.3]                               |\n|                                 |            | See the section on primary care        |\n|                                 |            | investigations for more information on |\n|                                 |            | X-rays                                 |\n| Bone swelling (unexplained) in  | Bone       | Consider a very urgent, direct access  |\n| children and young people       | sarcoma    | X-ray (to be done within 48 hours)     |\n|                                 |            | [1.11.3]                               |\n|                                 |            | See the section on primary care        |\n|                                 |            | investigations for more information on |\n|                                 |            | X-rays                                 |\n\nTitle: Skeletal Symptoms in Children and Young People | Summary: This table outlines the recommended actions, including blood tests and X-rays, for children and young people presenting with unexplained bone pain or swelling, and indicates the potential cancer diagnoses (Leukaemia, Bone sarcoma) these symptoms may suggest.",
    "table_summary": "Title: Skeletal Symptoms in Children and Young People | Summary: This table outlines the recommended actions, including blood tests and X-rays, for children and young people presenting with unexplained bone pain or swelling, and indicates the potential cancer diagnoses (Leukaemia, Bone sarcoma) these symptoms may suggest."
  },
  {
    "element_id": "page_76",
    "page_number": 76,
    "type": "table",
    "raw_text": "Table 3 on Page 76\n\n| Symptom and specific features   | Possible   | Recommendation                 |\n|                                 | cancer     |                                |\n|:--------------------------------|:-----------|:-------------------------------|\n| Petechiae (unexplained) in      | Leukaemia  | Refer for immediate specialist |\n| children and young people       |            | assessment [1.10.2]            |\n\nTitle: Petechiae Recommendation for Children and Young People | Summary: This table specifies that children and young people with unexplained petechiae should be referred for immediate specialist assessment for possible leukemia.",
    "table_summary": "Title: Petechiae Recommendation for Children and Young People | Summary: This table specifies that children and young people with unexplained petechiae should be referred for immediate specialist assessment for possible leukemia."
  },
  {
    "element_id": "page_77_seq_0",
    "page_number": 77,
    "type": "text",
    "raw_text": "Possible\nSymptom and specific features Recommendation\ncancer\nBruising (unexplained) in children Offer a very urgent full blood count\nLeukaemia\nand young people (within 48 hours) [1.10.3]\nPallor in children and young Offer a very urgent full blood count\nLeukaemia\npeople (within 48 hours) [1.10.3]\nUrological symptoms\nPossible\nSymptom and specific features Recommendation\ncancer\nHaematuria (visible and Wilms' Consider very urgent referral (for an appointment\nunexplained) in children tumour within 48 hours) for specialist assessment [1.12.3]\nNon-specific features of cancer\nSymptom and specific\nPossible cancer Recommendation\nfeatures\nFatigue\n(persistent) in Offer a very urgent full blood count (within\nLeukaemia\nchildren and 48 hours) [1.10.3]\nyoung people\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nFever with\nNon-Hodgkin's associated symptoms [1.10.7] [1.10.9]\nlymphadenopathy\n\nThis section of the NICE guideline provides specific recommendations for investigating potential cancers in children and young people based on certain symptoms. It advises healthcare professionals on the appropriate and urgent actions to take, like ordering a full blood count or making a specialist referral, when children and young people present with symptoms such as unexplained bruising, pallor, visible haematuria, persistent fatigue, or fever with lymphadenopathy."
  },
  {
    "element_id": "page_77_seq_0",
    "page_number": 77,
    "type": "text",
    "raw_text": "Fever with\nNon-Hodgkin's associated symptoms [1.10.7] [1.10.9]\nlymphadenopathy\nlymphoma or Separate recommendations have been made for\n(unexplained) in\nHodgkin's adults and for children and young people to reflect\nchildren and\nlymphoma that there are different referral pathways. In\nyoung people\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\n\nThis section of the NICE guideline provides guidance on when to consider very urgent referral for specialist assessment of Non-Hodgkin's lymphoma or Hodgkin's lymphoma in children and young people presenting with unexplained fever and lymphadenopathy, emphasizing the importance of considering associated symptoms and acknowledging differing referral pathways based on age and local arrangements. This helps healthcare professionals promptly identify and manage potential haematological cancers in this vulnerable population."
  },
  {
    "element_id": "page_77",
    "page_number": 77,
    "type": "table",
    "raw_text": "Table 1 on Page 77\n\n| Symptom and specific features      | Possible   | Recommendation                       |\n|                                    | cancer     |                                      |\n|:-----------------------------------|:-----------|:-------------------------------------|\n| Bruising (unexplained) in children | Leukaemia  | Offer a very urgent full blood count |\n| and young people                   |            | (within 48 hours) [1.10.3]           |\n| Pallor in children and young       | Leukaemia  | Offer a very urgent full blood count |\n| people                             |            | (within 48 hours) [1.10.3]           |\n\nTitle: Leukaemia Symptoms in Children and Young People | Summary: The table outlines the recommendations for investigating potential leukaemia in children and young people presenting with unexplained bruising or pallor, advising a very urgent full blood count (within 48 hours).",
    "table_summary": "Title: Leukaemia Symptoms in Children and Young People | Summary: The table outlines the recommendations for investigating potential leukaemia in children and young people presenting with unexplained bruising or pallor, advising a very urgent full blood count (within 48 hours)."
  },
  {
    "element_id": "page_77",
    "page_number": 77,
    "type": "table",
    "raw_text": "Table 2 on Page 77\n\n| Symptom and specific features   | Possible   | Recommendation                                      |\n|                                 | cancer     |                                                     |\n|:--------------------------------|:-----------|:----------------------------------------------------|\n| Haematuria (visible and         | Wilms'     | Consider very urgent referral (for an appointment   |\n| unexplained) in children        | tumour     | within 48 hours) for specialist assessment [1.12.3] |\n\n**Title:** Visible Haematuria in Children | **Summary:** The table provides guidance on when to consider a very urgent referral for specialist assessment of Wilms' tumour in children presenting with unexplained visible haematuria.",
    "table_summary": "**Title:** Visible Haematuria in Children | **Summary:** The table provides guidance on when to consider a very urgent referral for specialist assessment of Wilms' tumour in children presenting with unexplained visible haematuria."
  },
  {
    "element_id": "page_77",
    "page_number": 77,
    "type": "table",
    "raw_text": "Table 3 on Page 77\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Fatigue                | Leukaemia         | Offer a very urgent full blood count (within        |\n| (persistent) in        |                   | 48 hours) [1.10.3]                                  |\n| children and           |                   |                                                     |\n| young people           |                   |                                                     |\n| Fever with             | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| lymphadenopathy        | lymphoma or       | within 48 hours) for specialist assessment. When    |\n| (unexplained) in       | Hodgkin's         | considering referral, take into account any         |\n| children and           | lymphoma          | associated symptoms [1.10.7] [1.10.9]               |\n| young people           |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Symptoms in children and young people | Summary: This table provides recommendations for referral and testing of children and young people based on symptoms that could indicate cancer, including fatigue and fever with lymphadenopathy. It specifies the type of cancer that may be suspected based on the symptom and the recommended action, such as a blood test or urgent referral to a specialist.",
    "table_summary": "Title: Symptoms in children and young people | Summary: This table provides recommendations for referral and testing of children and young people based on symptoms that could indicate cancer, including fatigue and fever with lymphadenopathy. It specifies the type of cancer that may be suspected based on the symptom and the recommended action, such as a blood test or urgent referral to a specialist."
  },
  {
    "element_id": "page_78_seq_0",
    "page_number": 78,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nFever with\nassociated symptoms [1.10.7]\nsplenomegaly\nNon-Hodgkin's Separate recommendations have been made for\n(unexplained) in\nlymphoma adults and for children and young people to reflect\nchildren and\nthat there are different referral pathways. In\nyoung people\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nFever\n(unexplained) in Offer a very urgent full blood count (within\nLeukaemia\nchildren and 48 hours) [1.10.3]\nyoung people\nInfection\n(unexplained and\nOffer a very urgent full blood count (within\npersistent) in Leukaemia\n48 hours) [1.10.3]\nchildren and\nyoung people\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\n\nThis section of the NICE guideline focuses on symptoms in children and young people, specifically fever, splenomegaly and infection, and provides recommendations for assessment and referral based on the likelihood of underlying cancers like Non-Hodgkin's lymphoma and Leukemia. It emphasizes the urgency of investigation with very urgent referrals and full blood counts, acknowledging different referral pathways for young people versus adults."
  },
  {
    "element_id": "page_78_seq_0",
    "page_number": 78,
    "type": "text",
    "raw_text": "within 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nassociated symptoms, particularly fever, night\nLymphadenopathy Non-Hodgkin's sweats, shortness of breath, pruritus or weight\n(unexplained) in lymphoma or loss [1.10.7] [1.10.9]\nchildren and Hodgkin's Separate recommendations have been made for\nyoung people lymphoma adults and for children and young people to reflect\nthat there are different referral pathways. In\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\n\nThis section of the NICE guideline provides recommendations for when to refer children and young people with unexplained lymphadenopathy for specialist assessment, specifically when Non-Hodgkin's or Hodgkin's lymphoma is suspected, emphasizing a very urgent (within 48 hours) referral should be considered, especially if other concerning symptoms are present. It highlights the need for age-appropriate referral pathways, given the differences in how cancer is managed in adults versus children."
  },
  {
    "element_id": "page_78",
    "page_number": 78,
    "type": "table",
    "raw_text": "Table 1 on Page 78\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Fever with             | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| splenomegaly           | lymphoma          | within 48 hours) for specialist assessment. When    |\n| (unexplained) in       |                   | considering referral, take into account any         |\n| children and           |                   | associated symptoms [1.10.7]                        |\n| young people           |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Fever                  | Leukaemia         | Offer a very urgent full blood count (within        |\n| (unexplained) in       |                   | 48 hours) [1.10.3]                                  |\n| children and           |                   |                                                     |\n| young people           |                   |                                                     |\n| Infection              | Leukaemia         | Offer a very urgent full blood count (within        |\n| (unexplained and       |                   | 48 hours) [1.10.3]                                  |\n| persistent) in         |                   |                                                     |\n| children and           |                   |                                                     |\n| young people           |                   |                                                     |\n| Lymphadenopathy        | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| (unexplained) in       | lymphoma or       | within 48 hours) for specialist assessment. When    |\n| children and           | Hodgkin's         | considering referral, take into account any         |\n| young people           | lymphoma          | associated symptoms, particularly fever, night      |\n|                        |                   | sweats, shortness of breath, pruritus or weight     |\n|                        |                   | loss [1.10.7] [1.10.9]                              |\n|                        |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Symptoms in Children and Young People Associated with Fever, Infection, or Lymphadenopathy | Summary: This table outlines the specific symptoms of fever, infection, and lymphadenopathy in children and young people that may indicate leukemia or non-Hodgkin's/Hodgkin's lymphoma, and the recommended actions, including blood tests and specialist referrals, based on the specific symptom and potential cancer.",
    "table_summary": "Title: Symptoms in Children and Young People Associated with Fever, Infection, or Lymphadenopathy | Summary: This table outlines the specific symptoms of fever, infection, and lymphadenopathy in children and young people that may indicate leukemia or non-Hodgkin's/Hodgkin's lymphoma, and the recommended actions, including blood tests and specialist referrals, based on the specific symptom and potential cancer."
  },
  {
    "element_id": "page_79_seq_0",
    "page_number": 79,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nLymphadenopathy\n(generalised) in Offer a very urgent full blood count (within\nLeukaemia\nchildren and 48 hours) [1.10.3]\nyoung people\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nNight sweats with\nNon-Hodgkin's associated symptoms [1.10.7] [1.10.9]\nlymphadenopathy\nlymphoma or Separate recommendations have been made for\n(unexplained) in\nHodgkin's adults and for children and young people to reflect\nchildren and\nlymphoma that there are different referral pathways. In\nyoung people\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nNight sweats with\nassociated symptoms [1.10.7]\nsplenomegaly\n\nThis chunk of the NICE guideline provides recommendations for when to suspect cancer in children and young people presenting with lymphadenopathy (swollen lymph nodes) and night sweats, specifically pointing towards leukemia, Non-Hodgkin's lymphoma, or Hodgkin's lymphoma, and outlines the appropriate next steps, including blood tests and urgent referrals. It aims to guide healthcare professionals in promptly identifying potential cases of cancer in this age group, emphasizing the need for specialist assessment and considering associated symptoms."
  },
  {
    "element_id": "page_79_seq_0",
    "page_number": 79,
    "type": "text",
    "raw_text": "Night sweats with\nassociated symptoms [1.10.7]\nsplenomegaly\nNon-Hodgkin's Separate recommendations have been made for\n(unexplained) in\nlymphoma adults and for children and young people to reflect\nchildren and\nthat there are different referral pathways. In\nyoung people\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nPruritus with\nNon-Hodgkin's associated symptoms [1.10.7] [1.10.9]\nlymphadenopathy\nlymphoma or Separate recommendations have been made for\n(unexplained) in\nHodgkin's adults and for children and young people to reflect\nchildren and\nlymphoma that there are different referral pathways. In\nyoung people\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\n\nThis section of the guideline addresses symptoms in children and young people that may indicate Non-Hodgkin's or Hodgkin's lymphoma and provides guidance on referral urgency, emphasizing that in children and young people with unexplained night sweats and splenomegaly or pruritus and lymphadenopathy, a very urgent referral (within 48 hours) for specialist assessment should be considered, taking associated symptoms into account. It acknowledges differing referral pathways for adults vs. children/young people."
  },
  {
    "element_id": "page_79",
    "page_number": 79,
    "type": "table",
    "raw_text": "Table 1 on Page 79\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Lymphadenopathy        | Leukaemia         | Offer a very urgent full blood count (within        |\n| (generalised) in       |                   | 48 hours) [1.10.3]                                  |\n| children and           |                   |                                                     |\n| young people           |                   |                                                     |\n| Night sweats with      | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| lymphadenopathy        | lymphoma or       | within 48 hours) for specialist assessment. When    |\n| (unexplained) in       | Hodgkin's         | considering referral, take into account any         |\n| children and           | lymphoma          | associated symptoms [1.10.7] [1.10.9]               |\n| young people           |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Night sweats with      | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| splenomegaly           | lymphoma          | within 48 hours) for specialist assessment. When    |\n| (unexplained) in       |                   | considering referral, take into account any         |\n| children and           |                   | associated symptoms [1.10.7]                        |\n| young people           |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Pruritus with          | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| lymphadenopathy        | lymphoma or       | within 48 hours) for specialist assessment. When    |\n| (unexplained) in       | Hodgkin's         | considering referral, take into account any         |\n| children and           | lymphoma          | associated symptoms [1.10.7] [1.10.9]               |\n| young people           |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Symptoms in Children and Young People: Lymphadenopathy, Night Sweats, and Pruritus | Summary: This table provides recommendations for children and young people presenting with lymphadenopathy, night sweats, or pruritus, outlining the possible cancers associated with these symptoms (Leukaemia, Non-Hodgkin's lymphoma, Hodgkin's lymphoma) and the recommended actions, including blood tests and specialist referrals.",
    "table_summary": "Title: Symptoms in Children and Young People: Lymphadenopathy, Night Sweats, and Pruritus | Summary: This table provides recommendations for children and young people presenting with lymphadenopathy, night sweats, or pruritus, outlining the possible cancers associated with these symptoms (Leukaemia, Non-Hodgkin's lymphoma, Hodgkin's lymphoma) and the recommended actions, including blood tests and specialist referrals."
  },
  {
    "element_id": "page_80_seq_0",
    "page_number": 80,
    "type": "text",
    "raw_text": "Symptom and specific\nPossible cancer Recommendation\nfeatures\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nPruritus with\nassociated symptoms [1.10.7]\nsplenomegaly\nNon-Hodgkin's Separate recommendations have been made for\n(unexplained) in\nlymphoma adults and for children and young people to reflect\nchildren and\nthat there are different referral pathways. In\nyoung people\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment in\nchildren and young people. When considering\nWeight loss with referral, take into account any associated\nNon-Hodgkin's\nlymphadenopathy symptoms [1.10.7] [1.10.9]\nlymphoma or\n(unexplained) in Separate recommendations have been made for\nHodgkin's\nchildren and adults and for children and young people to reflect\n\nThis chunk of the NICE guideline provides recommendations for healthcare professionals on when to suspect and urgently refer children and young people with pruritus and splenomegaly or weight loss and lymphadenopathy, as these symptoms may indicate Non-Hodgkin's or Hodgkin's lymphoma. It emphasizes the need for specialist assessment within 48 hours and consideration of associated symptoms to facilitate timely diagnosis and intervention."
  },
  {
    "element_id": "page_80_seq_0",
    "page_number": 80,
    "type": "text",
    "raw_text": "Hodgkin's\nchildren and adults and for children and young people to reflect\nlymphoma\nyoung people that there are different referral pathways. In\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment. When\nconsidering referral, take into account any\nWeight loss with\nassociated symptoms [1.10.7]\nsplenomegaly\nNon-Hodgkin's Separate recommendations have been made for\n(unexplained) in\nlymphoma adults and for children and young people to reflect\nchildren and\nthat there are different referral pathways. In\nyoung people\npractice young people (aged 16 to 24) may be\nreferred using either pathway depending on their\nage and local arrangements\n\nThis chunk of the NICE guideline focuses on referral recommendations for children and young people with suspected Hodgkin's or Non-Hodgkin's lymphoma, emphasizing the need for a very urgent (within 48 hours) referral for specialist assessment if specific symptoms like unexplained splenomegaly or weight loss are present; it also highlights that the referral pathway for young people (16-24) can vary based on local arrangements. This differentiation acknowledges age-related differences in referral pathways for lymphoma, with the urgency reflecting the potential for rapid disease progression in this age group."
  },
  {
    "element_id": "page_80",
    "page_number": 80,
    "type": "table",
    "raw_text": "Table 1 on Page 80\n\n| Symptom and specific   | Possible cancer   | Recommendation                                      |\n| features               |                   |                                                     |\n|:-----------------------|:------------------|:----------------------------------------------------|\n| Pruritus with          | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| splenomegaly           | lymphoma          | within 48 hours) for specialist assessment. When    |\n| (unexplained) in       |                   | considering referral, take into account any         |\n| children and           |                   | associated symptoms [1.10.7]                        |\n| young people           |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Weight loss with       | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| lymphadenopathy        | lymphoma or       | within 48 hours) for specialist assessment in       |\n| (unexplained) in       | Hodgkin's         | children and young people. When considering         |\n| children and           | lymphoma          | referral, take into account any associated          |\n| young people           |                   | symptoms [1.10.7] [1.10.9]                          |\n|                        |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n| Weight loss with       | Non-Hodgkin's     | Consider a very urgent referral (for an appointment |\n| splenomegaly           | lymphoma          | within 48 hours) for specialist assessment. When    |\n| (unexplained) in       |                   | considering referral, take into account any         |\n| children and           |                   | associated symptoms [1.10.7]                        |\n| young people           |                   | Separate recommendations have been made for         |\n|                        |                   | adults and for children and young people to reflect |\n|                        |                   | that there are different referral pathways. In      |\n|                        |                   | practice young people (aged 16 to 24) may be        |\n|                        |                   | referred using either pathway depending on their    |\n|                        |                   | age and local arrangements                          |\n\nTitle: Symptoms in Children and Young People: Pruritus/Weight Loss with Lymphadenopathy/Splenomegaly | Summary: This table outlines the recommended actions (very urgent referral for specialist assessment) for children and young people presenting with pruritus/weight loss accompanied by unexplained splenomegaly or lymphadenopathy, indicating potential Non-Hodgkin's or Hodgkin's lymphoma, and notes the possibility of differing referral pathways based on age and local arrangements.",
    "table_summary": "Title: Symptoms in Children and Young People: Pruritus/Weight Loss with Lymphadenopathy/Splenomegaly | Summary: This table outlines the recommended actions (very urgent referral for specialist assessment) for children and young people presenting with pruritus/weight loss accompanied by unexplained splenomegaly or lymphadenopathy, indicating potential Non-Hodgkin's or Hodgkin's lymphoma, and notes the possibility of differing referral pathways based on age and local arrangements."
  },
  {
    "element_id": "page_81_seq_0",
    "page_number": 81,
    "type": "text",
    "raw_text": "Ocular examination\nExamination findings and\nPossible cancer Recommendation\nspecific features\nAbsent fundal\nConsider referral for ophthalmological assessment\n('red') reflex in Retinoblastoma\nusing a suspected cancer pathway referral [1.12.2]\nchildren\nParental concern\nPossible\nSymptom and specific features Recommendation\ncancer\nTake into account the insight and knowledge of\nparents and carers when considering making a\nParental or carer insight,\nreferral for suspected cancer in a child or young\nconcern or anxiety about\nChildhood person\nthe child's or young\ncancer Consider referral for children if their parent or\nperson's symptoms\ncarer has persistent concern or anxiety about\n(persistent)\nthe child's symptoms, even if the symptoms are\nmost likely to have a benign cause [1.13.1]\nPrimary care investigations\nPossible\nSymptom and specific features Recommendation\ncancer\nConsider a very urgent referral (for an appointment\nUltrasound scan\nwithin 48 hours) for specialist assessment [1.11.7]\n\nThis section provides specific guidance for healthcare professionals on when to suspect cancer in children based on ocular examinations (specifically the absence of a red reflex), parental concerns, and ultrasound scan findings, emphasizing the need for prompt specialist referral in these cases. It highlights the importance of considering parental instincts and acting swiftly when certain signs are present, even if the likelihood of cancer seems low."
  },
  {
    "element_id": "page_81_seq_0",
    "page_number": 81,
    "type": "text",
    "raw_text": "Ultrasound scan\nwithin 48 hours) for specialist assessment [1.11.7]\nsuggests soft tissue\nSeparate recommendations have been made for\nsarcoma or is Soft\nadults and for children and young people to reflect\nuncertain and clinical tissue\nthat there are different referral pathways. In practice\nconcern persists in sarcoma\nyoung people (aged 16 to 24) may be referred using\nchildren and young\neither pathway depending on their age and local\npeople\narrangements\n\nThis chunk provides guidance on when to refer children and young people for suspected soft tissue sarcoma following an ultrasound scan, emphasizing the urgency of the referral (within 48 hours) and acknowledging the different referral pathways that may exist for this age group. It highlights that even with uncertain ultrasound findings, persistent clinical concern warrants specialist assessment."
  },
  {
    "element_id": "page_81",
    "page_number": 81,
    "type": "table",
    "raw_text": "Table 1 on Page 81\n\n| Examination findings and   | Possible cancer   | Recommendation                                     |\n| specific features          |                   |                                                    |\n|:---------------------------|:------------------|:---------------------------------------------------|\n| Absent fundal              | Retinoblastoma    | Consider referral for ophthalmological assessment  |\n| ('red') reflex in          |                   | using a suspected cancer pathway referral [1.12.2] |\n| children                   |                   |                                                    |\n\nTitle: Retinoblastoma Referral Criteria | Summary: This table specifies the recommendation for referral for ophthalmological assessment using a suspected cancer pathway for children presenting with an absent fundal ('red') reflex, which may indicate retinoblastoma.",
    "table_summary": "Title: Retinoblastoma Referral Criteria | Summary: This table specifies the recommendation for referral for ophthalmological assessment using a suspected cancer pathway for children presenting with an absent fundal ('red') reflex, which may indicate retinoblastoma."
  },
  {
    "element_id": "page_81",
    "page_number": 81,
    "type": "table",
    "raw_text": "Table 2 on Page 81\n\n| Symptom and specific features   | Possible   | Recommendation                                    |\n|                                 | cancer     |                                                   |\n|:--------------------------------|:-----------|:--------------------------------------------------|\n| Parental or carer insight,      | Childhood  | Take into account the insight and knowledge of    |\n| concern or anxiety about        | cancer     | parents and carers when considering making a      |\n| the child's or young            |            | referral for suspected cancer in a child or young |\n| person's symptoms               |            | person                                            |\n| (persistent)                    |            | Consider referral for children if their parent or |\n|                                 |            | carer has persistent concern or anxiety about     |\n|                                 |            | the child's symptoms, even if the symptoms are    |\n|                                 |            | most likely to have a benign cause [1.13.1]       |\n\nTitle: Parental Concern in Children and Young People | Summary: This table outlines recommendations regarding parental or carer concerns about a child's symptoms, advising healthcare professionals to consider these insights when assessing the need for a referral for suspected cancer, even if the symptoms appear benign.",
    "table_summary": "Title: Parental Concern in Children and Young People | Summary: This table outlines recommendations regarding parental or carer concerns about a child's symptoms, advising healthcare professionals to consider these insights when assessing the need for a referral for suspected cancer, even if the symptoms appear benign."
  },
  {
    "element_id": "page_81",
    "page_number": 81,
    "type": "table",
    "raw_text": "Table 3 on Page 81\n\n| Symptom and specific features   | Possible   | Recommendation                                          |\n|                                 | cancer     |                                                         |\n|:--------------------------------|:-----------|:--------------------------------------------------------|\n| Ultrasound scan                 | Soft       | Consider a very urgent referral (for an appointment     |\n| suggests soft tissue            | tissue     | within 48 hours) for specialist assessment [1.11.7]     |\n| sarcoma or is                   | sarcoma    | Separate recommendations have been made for             |\n| uncertain and clinical          |            | adults and for children and young people to reflect     |\n| concern persists in             |            | that there are different referral pathways. In practice |\n| children and young              |            | young people (aged 16 to 24) may be referred using      |\n| people                          |            | either pathway depending on their age and local         |\n|                                 |            | arrangements                                            |\n\nTitle: Ultrasound Scan Findings and Recommendations in Children and Young People | Summary: This table provides the recommendation for children and young people who have ultrasound scan findings suggestive of soft tissue sarcoma, or uncertain findings with persistent clinical concern. It advises considering a very urgent referral to a specialist for assessment within 48 hours, noting different referral pathways for different age groups.",
    "table_summary": "Title: Ultrasound Scan Findings and Recommendations in Children and Young People | Summary: This table provides the recommendation for children and young people who have ultrasound scan findings suggestive of soft tissue sarcoma, or uncertain findings with persistent clinical concern. It advises considering a very urgent referral to a specialist for assessment within 48 hours, noting different referral pathways for different age groups."
  },
  {
    "element_id": "page_82_seq_0",
    "page_number": 82,
    "type": "text",
    "raw_text": "Possible\nSymptom and specific features Recommendation\ncancer\nConsider a very urgent referral (for an appointment\nwithin 48 hours) for specialist assessment [1.11.2]\nX-ray suggests the Separate recommendations have been made for\npossibility of bone Bone adults and for children and young people to reflect\nsarcoma in children sarcoma that there are different referral pathways. In practice\nand young people young people (aged 16 to 24) may be referred using\neither pathway depending on their age and local\narrangements\n\nThis section provides guidance on when to suspect bone sarcoma in children and young people and recommends a very urgent referral for specialist assessment if an X-ray suggests the possibility of bone sarcoma, highlighting the need for prompt action in this age group while acknowledging varied referral pathways for young people based on local arrangements. This recommendation is part of a larger set of recommendations for research on various cancers."
  },
  {
    "element_id": "page_82",
    "page_number": 82,
    "type": "table",
    "raw_text": "Table 1 on Page 82\n\n| Symptom and specific features   | Possible   | Recommendation                                          |\n|                                 | cancer     |                                                         |\n|:--------------------------------|:-----------|:--------------------------------------------------------|\n| X-ray suggests the              | Bone       | Consider a very urgent referral (for an appointment     |\n| possibility of bone             | sarcoma    | within 48 hours) for specialist assessment [1.11.2]     |\n| sarcoma in children             |            | Separate recommendations have been made for             |\n| and young people                |            | adults and for children and young people to reflect     |\n|                                 |            | that there are different referral pathways. In practice |\n|                                 |            | young people (aged 16 to 24) may be referred using      |\n|                                 |            | either pathway depending on their age and local         |\n|                                 |            | arrangements                                            |\n\nTitle: Bone Sarcoma Referral Recommendations for Children and Young People | Summary: This table outlines the NICE guideline recommendation for very urgent referral to a specialist for children and young people when an X-ray suggests the possibility of bone sarcoma, noting that referral pathways may differ for young people aged 16-24.",
    "table_summary": "Title: Bone Sarcoma Referral Recommendations for Children and Young People | Summary: This table outlines the NICE guideline recommendation for very urgent referral to a specialist for children and young people when an X-ray suggests the possibility of bone sarcoma, noting that referral pathways may differ for young people aged 16-24."
  },
  {
    "element_id": "page_83_seq_0",
    "page_number": 83,
    "type": "text",
    "raw_text": "Terms used in this guideline\nChildren\nFrom birth to 15 years.\nChildren and young people\nFrom birth to 24 years.\nConsistent with\nThe finding has characteristics that could be caused by many things, including cancer.\nDirect access\nWhen a test is done and primary care retain clinical responsibility throughout, including\nacting on the result.\nImmediate\nAn acute admission or referral occurring within a few hours, or even more quickly if\nnecessary.\nNon-urgent\nThe timescale generally used for a referral or investigation that is not considered very\nurgent or urgent.\nPersistent\nThe continuation of specified symptoms and/or signs beyond a period that would normally\nbe associated with self-limiting problems. The precise period will vary depending on the\n\nThis chunk defines key terms used throughout the NICE guideline on suspected cancer, ensuring consistent understanding and application of the recommendations by healthcare professionals when assessing and referring patients. Accurate understanding of these terms (like \"urgent\", \"direct access\", \"persistent\") is critical for appropriate and timely management of suspected cancer cases."
  },
  {
    "element_id": "page_84_seq_0",
    "page_number": 84,
    "type": "text",
    "raw_text": "severity of symptoms and associated features, as assessed by the health professional.\nRaises the suspicion of\nA mass or lesion that has an appearance or a feel that makes the healthcare professional\nbelieve cancer is a significant possibility.\nSafety netting\nThe active monitoring in primary care of people who have presented with symptoms. It has\n2 separate aspects:\n• timely review and action after investigations\n• active monitoring of symptoms in people at low risk (but not no risk) of having cancer\nto see if their risk of cancer changes.\nSuspected cancer pathway referral\nPerson to receive a diagnosis or ruling out of cancer within 28 days of being referred\nurgently by their GP for suspected cancer. For further details, see NHS England's webpage\non faster diagnosis of cancer.\nUnexplained\nSymptoms or signs that have not led to a diagnosis being made by the healthcare\nprofessional in primary care after initial assessment (including history, examination and any\n\nThis chunk defines key terms used throughout the guideline, ensuring consistent understanding and application of the recommendations by healthcare professionals, particularly concerning the urgency and management of suspected cancer cases. These definitions clarify the actions needed based on symptom presentation and risk assessment."
  },
  {
    "element_id": "page_84_seq_0",
    "page_number": 84,
    "type": "text",
    "raw_text": "professional in primary care after initial assessment (including history, examination and any\nprimary care investigations).\nUrgent\nTo happen or be done before 2 weeks.\nVery urgent\nTo happen within 48 hours.\n\nThis chunk defines key terms related to the urgency of actions (Urgent, Very Urgent) and a clinical term (Unexplained) used throughout the NICE guideline to ensure consistent interpretation of recommendations regarding cancer referrals and investigations. These definitions provide specific timeframes and clinical context for healthcare professionals to appropriately prioritize and manage suspected cancer cases."
  },
  {
    "element_id": "page_85_seq_0",
    "page_number": 85,
    "type": "text",
    "raw_text": "Young people\nAged 16 to 24 years.\n\nThis definition clarifies that \"young people,\" when used in the guideline, specifically refers to individuals aged 16 to 24 years, which is relevant for applying age-specific recommendations and referral pathways, particularly in sections addressing children and young people. This distinction helps healthcare professionals accurately determine the appropriate course of action based on the patient's age within this range."
  },
  {
    "element_id": "page_86_seq_0",
    "page_number": 86,
    "type": "text",
    "raw_text": "Recommendations for research\nThe guideline committee has made the following recommendations for research.\nKey recommendations for research\n1 Age thresholds in cancer\nLongitudinal studies should be carried out to identify and quantify factors in adults that are\nassociated with development of specific cancers at a younger age than the norm. They\nshould be designed to inform age thresholds in clinical guidance. The primary outcome\nshould be likelihood ratios and positive predictive values for cancer occurring in younger\nage groups.\n2 Primary care testing\nDiagnostic accuracy studies of tests accessible to primary care should be carried out for a\ngiven cancer in symptomatic people. Priority areas for research should include tests for\npeople with cough, non-visible haematuria, suspected prostate cancer, suspected\npancreatic cancer, suspected cancer in childhood and young people and other suspected\nrare cancers. Outcomes of interest are the performance characteristics of the test,\n\nThis section outlines key areas where further research is needed to improve the guideline's effectiveness, specifically focusing on refining age thresholds for cancer risk, improving primary care testing accuracy, and addressing gaps in research for certain cancers and patient experiences. These research recommendations aim to strengthen the evidence base used to inform future updates of the NICE guideline."
  },
  {
    "element_id": "page_86_seq_0",
    "page_number": 86,
    "type": "text",
    "raw_text": "rare cancers. Outcomes of interest are the performance characteristics of the test,\nparticularly sensitivity, specificity and positive and negative predictive values.\n3 Cancers insufficiently researched in primary care\nObservational studies of symptomatic primary care patients should be used to estimate\nthe positive predictive value of different symptoms for specific cancers. Priority areas for\nresearch are those where the evidence base is currently insufficient and should include\nprostate cancer, pancreatic cancer, cancer in childhood and young people and other rare\ncancers. Outcomes of interest are positive predictive values and likelihood ratios for\ncancer.\n4 Patient experience\nQualitative studies are needed to assess the key issues in patient experience and patient\n\nThis chunk, taken from the \"Recommendations for research\" section, highlights the need for further investigation into cancer diagnosis in primary care, specifically focusing on improving testing accuracy and understanding symptom presentation for less-researched cancers, including assessing patient experiences within the diagnostic process. This aims to improve early detection and patient care for these specific cancers."
  },
  {
    "element_id": "page_87_seq_0",
    "page_number": 87,
    "type": "text",
    "raw_text": "information needs in the cancer diagnostic pathway, particularly in the interval between\nfirst presentation to primary care and first appointment in secondary care. Outcomes of\ninterest are patient satisfaction, quality of life and patient perception of the quality of care\nand information.\n5 Prostate-specific antigen testing\nWhat is the diagnostic accuracy of using age-adjusted and fixed prostate-specific antigen\nthresholds for people with symptoms of prostate cancer, including those at high risk of\ndeveloping prostate cancer (such as those with an African family background or a family\nhistory of prostate cancer)?\nFor a short explanation of why the committee made the recommendation for research\nsee the rationale section on prostate-specific antigen testing for prostate cancer.\nFull details of the evidence and the committee's discussion are in evidence review A:\nPSA testing for prostate cancer.\n\nThis chunk outlines two key areas needing further research: understanding patient experiences during cancer diagnosis (specifically the period between primary and secondary care) and determining the diagnostic accuracy of different PSA testing strategies for prostate cancer, particularly in high-risk groups. These research recommendations aim to improve patient care and diagnostic accuracy in the cancer pathway."
  },
  {
    "element_id": "page_88_seq_0",
    "page_number": 88,
    "type": "text",
    "raw_text": "Rationale and impact\nThis section briefly explains why the committee made the recommendation and how it\nmight affect practice.\nProstate-specific antigen testing for prostate\ncancer\nRecommendation 1.6.3\nWhy the committee made the recommendation\nThe evidence on the diagnostic accuracy of fixed and age-specific prostate-specific\nantigen (PSA) thresholds was very uncertain because all of the studies were based on a\npopulation that had already been referred to secondary care. The 2019 guideline\nrecommended referral if PSA levels were above the age-specific reference range. The\ncommittee agreed that referral should be considered based on PSA thresholds, but did not\nmake a stronger recommendation because of the uncertainty in the evidence and the\nlikely low positive predictive value of the PSA test for prevalence estimates based on UK\npopulation data. The committee noted that many prostate cancers are slow growing and\n\nThis chunk explains the rationale behind recommendation 1.6.3, which concerns prostate-specific antigen (PSA) testing for prostate cancer, and how that recommendation is expected to influence clinical practice. It clarifies the committee's decision-making process given the limited evidence and the potential for over-diagnosis, highlighting the importance of patient preferences in referral decisions."
  },
  {
    "element_id": "page_88_seq_0",
    "page_number": 88,
    "type": "text",
    "raw_text": "population data. The committee noted that many prostate cancers are slow growing and\nmight never impact a person's life expectancy. Some people might choose not to be\nreferred to secondary care to avoid invasive investigations and treatment that might not\nbenefit them. Therefore, the committee agreed that a patient-centred approach to referral\nis important, and recommended that the person's preferences and any comorbidities\nshould be taken into account.\nThe committee agreed that more research is needed in this area to better understand the\nmost appropriate thresholds that should prompt referral to secondary care for each age\ngroup. The committee noted that ethnicity and family history are important factors that\naffect the risk of prostate cancer. Therefore, they recommended that the data from\nresearch be stratified by these factors to determine whether different PSA levels should\nprompt referral in these groups. Research in this area may also help to address health\n\nThis section of the guideline explains the rationale behind the committee's recommendation regarding prostate-specific antigen (PSA) testing for prostate cancer referrals, emphasizing a patient-centered approach that considers individual preferences and comorbidities due to the potential for overdiagnosis and overtreatment of slow-growing prostate cancers. The committee also calls for further research, advocating for stratification of data by ethnicity and family history to improve risk assessment and address health inequalities in prostate cancer diagnosis."
  },
  {
    "element_id": "page_88_seq_0",
    "page_number": 88,
    "type": "text",
    "raw_text": "prompt referral in these groups. Research in this area may also help to address health\ninequalities in prostate cancer diagnosis and outcomes in the UK.\nThere was no strong evidence to differentiate between using age-specific or fixed PSA\n\nThis chunk discusses the rationale behind recommending age-specific PSA thresholds for prostate cancer referrals, highlighting the need for further research stratified by ethnicity and family history to improve diagnosis and address health inequalities. It emphasizes that current evidence is insufficient to definitively favor age-specific or fixed PSA thresholds."
  },
  {
    "element_id": "page_89_seq_0",
    "page_number": 89,
    "type": "text",
    "raw_text": "thresholds. The committee also noted that no cost-effectiveness evidence comparing\nage-specific thresholds with fixed thresholds was identified. However, because PSA levels\nincrease naturally with age, the committee agreed a lower fixed PSA threshold would\ndetect more cases of prostate cancer but also lead to unnecessary biopsies and\novertreatment in some age groups. This would also be likely to result in more referrals to\nsecondary care and have a significant impact on NHS resources. The committee therefore\nrecommended the use of age-specific thresholds, which are already established in current\npractice and were recommended in the previous version of the guideline. Because of\nregional variations in practice (particularly in the 50 to 69 age range), the committee\ndecided to define the age-specific PSA thresholds. The committee agreed that the\nthresholds used in the reviewed studies on people with symptoms of possible prostate\n\nThis chunk explains the rationale behind using age-specific PSA thresholds for prostate cancer referrals, balancing the need for detection with the risks of over-investigation and resource strain on the NHS. It highlights the committee's decision to define these thresholds due to regional variations in practice, aiming to standardize care."
  },
  {
    "element_id": "page_89_seq_0",
    "page_number": 89,
    "type": "text",
    "raw_text": "thresholds used in the reviewed studies on people with symptoms of possible prostate\ncancer should be used in the absence of evidence to support alternative values, because\nthese studies were most applicable to the population that the recommendation applies to.\nNo evidence was available specifically for people under 40 or over 79, and so the\ncommittee recommended that clinical judgement is used when deciding whether to refer\npeople in these groups to secondary care.\nHow the recommendation might affect practice\nReferral based on age-specific PSA thresholds is already recommended, so practice\nshould not change significantly. Also, clarifying the age-specific thresholds will help\nstandardise care. Taking into account patient preferences and comorbidities should also\nlead to a more patient-centred approach to referral.\nReturn to recommendation\n\nThis chunk explains the rationale behind using age-specific PSA thresholds for prostate cancer referral, emphasizing that current evidence supports these thresholds for symptomatic individuals, but clinical judgment is needed for those under 40 or over 79 due to lack of specific data. The clarification of these thresholds aims to standardize care and promote a patient-centered approach by considering individual preferences and comorbidities."
  },
  {
    "element_id": "page_90_seq_0",
    "page_number": 90,
    "type": "text",
    "raw_text": "Context\nCancer has an enormous impact, both in terms of the number of people affected by it and\nthe individual impact it has on people with cancer and those close to them. More than\n300,000 new cancers (excluding skin cancers) are diagnosed annually in the UK, across\nover 200 different cancer types. Each of these cancer types has different presenting\nfeatures, though they sometimes overlap. Approximately one-third of the population will\ndevelop a cancer in their lifetime. There is considerable variation in referral and testing for\npossible cancer, which cannot be fully explained by variation in the population.\nThe identification of people with possible cancer usually happens in primary care, because\nmost people first present to a primary care clinician. Therefore, evidence from primary\ncare should inform the identification process and was used as the basis for this guideline.\nThe recommendations were developed using a 'risk threshold', whereby if the risk of\n\nThis chunk provides essential background information, emphasizing the significant impact of cancer in the UK and highlighting that this NICE guideline focuses on improving early cancer identification within primary care settings, where most patients initially present with symptoms. It sets the stage for understanding the guideline's purpose: to standardize and improve cancer referrals and testing."
  },
  {
    "element_id": "page_90_seq_0",
    "page_number": 90,
    "type": "text",
    "raw_text": "The recommendations were developed using a 'risk threshold', whereby if the risk of\nsymptoms being caused by cancer is above a certain level, then action (investigation or\nreferral) is warranted. The positive predictive value (PPV) was used to determine the\nthreshold. In the previous guideline, a disparate range of percentage risks of cancer was\nused to form the recommendations. Few corresponded with a PPV of lower than 5%. The\nguideline development group (GDG) felt that, in order to improve diagnosis of cancer, a\nPPV threshold lower than 5% was preferable. Taking into account the financial and clinical\ncosts of broadening the recommendations, the GDG agreed to use a 3% PPV threshold\nvalue to underpin the recommendations for suspected cancer pathway referrals and\nurgent direct access investigations, such as brain scanning or endoscopy. Certain\nexceptions to a 3% PPV threshold were agreed. Recommendations were made for children\n\nThis chunk explains the methodology used to determine when investigation or referral for suspected cancer is necessary, based on a risk threshold determined by Positive Predictive Value (PPV). A 3% PPV threshold was generally adopted for suspected cancer pathway referrals and urgent investigations, aiming to improve cancer diagnosis while considering costs, with exceptions made for specific situations such as recommendations for children."
  },
  {
    "element_id": "page_90_seq_0",
    "page_number": 90,
    "type": "text",
    "raw_text": "exceptions to a 3% PPV threshold were agreed. Recommendations were made for children\nand young people at below the 3% PPV threshold, although no explicit threshold value was\nset. The threshold was not applied to recommendations relating to tests routinely available\nin primary care (including blood tests such as prostate-specific antigen and imaging such\nas chest X-ray), primary care tests that could be used in place of specialist referral,\nnon-urgent direct access tests and routine referrals for specialist opinion. Further\ninformation about the methods used to underpin the recommendations can be found in the\nfull guideline.\nIt is well recognised that some risk factors increase the chance of a person developing\ncancer in the future, for example, increasing age and a family history of cancer. However,\nrisk factors do not affect the way in which cancer presents. Of the risk factors that were\nreported in the evidence, only smoking (in lung cancer) and age were found to significantly\n\nThis chunk explains that while a 3% Positive Predictive Value (PPV) threshold generally guides recommendations for suspected cancer referrals, exceptions exist for children, certain primary care tests (like blood tests), and routine referrals, acknowledging the unique considerations and risk-benefit balance in these situations. It also clarifies that while general risk factors for cancer exist, the primary guideline recommendations are mostly based on presenting symptoms except in a few specific instances like smoking history for lung cancer."
  },
  {
    "element_id": "page_91_seq_0",
    "page_number": 91,
    "type": "text",
    "raw_text": "influence the chance of symptoms being predictive of cancer. Therefore, these are\nincluded in the recommendations where relevant. For all other risk factors, the\nrecommendations would be the same for people with possible symptoms of cancer,\nirrespective of whether they had a risk factor. However, an exception was made to include\nasbestos exposure in the recommendations because of the high relative risk of\nmesothelioma in people who have been exposed to asbestos.\n\nThis chunk explains that while many risk factors exist for cancer, only smoking and age significantly affect how predictive symptoms are, and are thus included in the guideline's recommendations. Asbestos exposure is an exception due to its strong link to mesothelioma, and is also factored into recommendations."
  },
  {
    "element_id": "page_92_seq_0",
    "page_number": 92,
    "type": "text",
    "raw_text": "Finding more information and committee\ndetails\nTo find NICE guidance on related topics, including guidance in development, see the NICE\ntopic page on cancer.\nFor full details of the evidence and the guideline committee's discussions, see the full\nguideline. You can also find information about how the guideline was developed, including\ndetails of the committee.\nNICE has produced tools and resources to help you put this guideline into practice. For\ngeneral help and advice on putting NICE guidelines into practice, see resources to help\nyou put guidance into practice.\n\nThis section directs readers to additional resources related to cancer diagnosis and treatment, including the full guideline for comprehensive evidence and committee information, as well as practical tools and resources to aid in implementing the guideline's recommendations. It serves as a signpost for those seeking more in-depth understanding or assistance with applying the guideline in practice."
  },
  {
    "element_id": "page_93_seq_0",
    "page_number": 93,
    "type": "text",
    "raw_text": "Update information\nJanuary 2026: We have removed an incorrect recommendation on blood tests for\nmyeloma.\nMay 2025: We amended recommendations 1.2.1 and 1.2.7 to recommend a suspected\ncancer referral for people with symptoms indicating a 3% or more probability of having\noesophageal or stomach cancer (rather than an urgent, direct access referral for an\nendoscopy). We have made these changes following stakeholder feedback. The tables of\nsymptoms have also been updated to reflect these changes.\nApril 2025: We amended the recommendations on blood tests for myeloma in response to\na series of NHS England National cancer programme reviews looking at opportunities for\nearlier diagnosis, including for myeloma. The tables of symptoms and primary care\ninvestigation findings have also been updated to reflect these changes. Amended\nrecommendations are marked [2015, amended 2025].\nOctober 2023: We updated the definition of suspected cancer pathway referral in line with\n\nThis \"Update information\" section provides a chronological record of significant changes made to the NICE guideline document over time, ensuring users are aware of the guideline's evolution and the rationale behind specific revisions, particularly concerning myeloma blood tests, oesophageal and stomach cancer referrals, and the definition of suspected cancer pathway referrals. This is important for healthcare professionals to ensure they are using the most current and accurate recommendations for patient care."
  },
  {
    "element_id": "page_93_seq_0",
    "page_number": 93,
    "type": "text",
    "raw_text": "October 2023: We updated the definition of suspected cancer pathway referral in line with\nNHS England's standard on faster diagnosis of cancer.\nAugust 2023: We updated the recommendations on criteria for faecal testing and referral\nfor suspected colorectal cancer in line with NICE's diagnostics guidance on quantitative\nfaecal immunochemical testing to guide colorectal cancer pathway referral in primary care.\nThe tables of symptoms and primary care investigation findings have been updated to\nreflect these changes. New and amended recommendations are marked [2023] or [2015\namended 2023].\nDecember 2021: We reviewed the evidence on fixed and age-adjusted thresholds for PSA\ntesting and updated recommendation 1.6.3.\nJanuary 2021: We amended the recommendations in the section on colorectal cancer to\ninclude the full list of criteria for faecal testing.\nSeptember 2020: We amended the recommendations in the section on colorectal cancer\n\nThis chunk from the \"Update information\" section details key changes and reviews made to the NICE guideline, specifically focusing on updates to the suspected cancer pathway referral definition, colorectal cancer screening and referral criteria, and prostate-specific antigen (PSA) testing recommendations. These updates are significant as they reflect evolving diagnostic practices, new evidence, and alignment with NHS England's standards for faster cancer diagnosis."
  },
  {
    "element_id": "page_93_seq_0",
    "page_number": 93,
    "type": "text",
    "raw_text": "September 2020: We amended the recommendations in the section on colorectal cancer\nto clarify when to offer faecal testing for colorectal cancer to adults without rectal\nbleeding.\n\nThis chunk describes an update made in September 2020 to the NICE guideline, specifying that the colorectal cancer section was revised to provide clarity on when faecal testing (FIT) should be offered to adults, specifically those *without* rectal bleeding. This update aimed to refine the criteria for identifying individuals at risk of colorectal cancer, potentially leading to more appropriate and timely referrals for further investigation."
  },
  {
    "element_id": "page_94_seq_0",
    "page_number": 94,
    "type": "text",
    "raw_text": "July 2017: Recommendation 1.3.4 was replaced by NICE diagnostics guidance on\nquantitative faecal immunochemical tests to guide referral for colorectal cancer in primary\ncare and other recommendations were amended accordingly. In December 2017, some of\nthe wording in the section on colorectal cancer was clarified, and the tables on abdominal\nand pelvic pain, change in bowel habit and primary care investigations updated in line with\nthis.\nJune 2016: Recommendations in the section on colorectal cancer have been changed to\nsay 'adults' instead of 'people' to more accurately reflect the populations they cover.\nJune 2015: This guideline updates and replaces NICE guideline CG27 (published\nJune 2005).\nRecommendations are marked as [2021], [2020], [2015], [2011], [2011, amended 2020]\nor [2005]:\n• [2021] indicated that the evidence has been reviewed and the recommendation has\nbeen updated in 2021.\n• [2020] indicates that the evidence has been reviewed and the recommendation has\n\nThis chunk provides crucial update information, detailing specific revisions made to the guideline since its initial publication in June 2015, particularly regarding colorectal cancer recommendations, and explains how recommendations are marked to indicate when evidence was last reviewed. It is essential for understanding the guideline's evolution and the currency of specific recommendations."
  },
  {
    "element_id": "page_94_seq_0",
    "page_number": 94,
    "type": "text",
    "raw_text": "• [2020] indicates that the evidence has been reviewed and the recommendation has\nbeen added or updated in 2020.\n• [2011, amended 2020] indicates that the wording has been changed but the evidence\nhas not been reviewed since 2020.\n• [2015], [2005] or [2011] indicates the date that the evidence was last reviewed.\nMinor changes since publication\nMarch 2024: In recommendation 1.12.2 and the table on symptoms in children and young\npeople, we changed absent red reflex to absent fundal ('red') reflex. See the surveillance\nreport for more information.\nOctober 2021: In recommendation 1.12.2 we added a cross-reference to NICE's guideline\non suspected neurological conditions for advice for children who have new-onset squint\nwith an absent fundal 'red' reflex. See the surveillance report for more information. We also\nadded a link to NICE's guideline on babies, children and young people's experience of\nhealthcare in the sections on childhood cancers and symptoms in children and young\npeople.\n\nThis chunk clarifies how to interpret the dates associated with recommendations in the guideline, indicating when the evidence was last reviewed or the recommendation was updated. It also documents minor changes made to the guideline since its initial publication, providing transparency and context for users of the document."
  },
  {
    "element_id": "page_95_seq_0",
    "page_number": 95,
    "type": "text",
    "raw_text": "ISBN: 978-1-4731-8184-7\n\nThis ISBN (International Standard Book Number) is a unique identifier for this specific edition of the NICE guideline document, allowing it to be cataloged and easily found by libraries, healthcare professionals, and the public. It signifies the formal publication and registration of this guideline."
  }
]